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Abstract 
 
Streptococcus pneumoniae is an important respiratory pathogen and a leading cause of community-
acquired pneumonia. As well as invasive disease S. pneumoniae also colonises the nasopharynx. 
Colonisation with S. pneumoniae is nearly universal in infants, dropping to 10% in adulthood. This 
frequent exposure has potential for developing and boosting natural adaptive immune responses.  
However naturally-acquired immune responses that protect against subsequent lung infection with 
S. pneumoniae are not fully understood. This thesis investigates the targets and function of 
naturally-acquired IgG to S. pneumoniae in humans and additionally the mechanisms of protection 
from lung infection following experimental colonisation in mice.  
The target and function of naturally-acquired IgG in human sera and pooled intravenous 
immunoglobulin (IVIG) preparations was assessed. IVIG, pooled from >1000 adult donors provides a 
tool to investigate the natural antibody responses to S. pneumoniae within a population. Data 
indicate that naturally-acquired human IgG predominantly binds to non-capsular antigens on the 
surface of S. pneumoniae and can target surface exposed protein antigens. In vitro assays indicate 
that antibodies to non-capsular targets may be functional, enhancing phagocytosis and killing of S. 
pneumoniae.  In vivo human IgG protected against lung infection. Cellular depletion demonstrated 
that protection within the lung required neutrophils and clearance of S. pneumoniae from the blood 
required macrophages.  
A model of lung infection in the absence of bacteraemia using S. pneumoniae strain EF3030 was 
developed. This model allowed assessment of the immune responses to S. pneumoniae colonisation 
of the nasopharynx that protect against re-infection specifically within the lung. Prior nasal 
colonisation with S. pneumoniae EF3030 was protective against subsequent lung infection. Cellular 
depletion strategies and challenge in antibody-deficient mice demonstrated that protection against 
lung infection required the development of both humoral and cell-mediated immunity. 
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1 Introduction  
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1.1 Introduction to Streptococcus pneumoniae  
1.1.1 Basic microbiology of S. pneumoniae 
 
Streptococcus pneumoniae, also known as the pneumococcus, is a Gram-positive encapsulated 
bacteria, first described in 1881 as a pathogenic diploccoci.  It can be identified microbiologically on 
the basis of showing alpha-haemolysis on blood agar plates, optochin resistance and bile solubility 
(Garcia-Suarez Mdel et al., 2006). S. pneumoniae usually exists as a diplococcus, forming pairs of 
lancet-shaped cocci, but is also capable of forming small chains. It is a facultative anaerobe growing 
best in 5% CO2, at 37 C, in broth or as colonies on blood agar.  
As a Gram-positive bacteria S. pneumoniae has a single cytoplasmic membrane surrounded by a 
peptidoglycan cell wall, common to all serotypes. A number of Gram-positive bacteria including S. 
pneumoniae synthesise a large polysaccharide capsule that surrounds and is attached covalently to 
the cell wall. The pneumococcal capsular polysaccharide (CPS) was first described as a soluble 
carbohydrate in cultures of S. pneumoniae (Dochez and Avery, 1917, Heidelberger and Avery, 1923). 
It was subsequently determined that different S. pneumoniae isolates varied in the structure of 
polysaccharide they produced (Heidelberger et al., 1925). Distinct capsular polysaccharide structures 
form the basis of the 93 known serotypes of S. pneumoniae (Gladstone et al., 2011, Bentley et al., 
2006).  
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1.1.2 S. pneumoniae infection    
1.1.2.1 Colonisation  
 
S. pneumoniae, along with a number of other potential bacterial pathogens including Staphylococcus 
aureus and Haemophilus influenzae asymptomatically colonises the nasopharynx in healthy 
individuals. The acquisition and clearance of colonisation is a dynamic process and S. pneumoniae is 
transmitted via aerosol droplet spread from other colonised individuals (Hartzell et al., 2003). 
Nasopharyngeal colonisation with S. pneumoniae is almost universal in infants; in a longitudinal 
study in the UK mean carriage (colonisation) rates were highest between 0-2 years of life (52% of 
individuals colonised at any one time), with carriage occurring more than once in 86% of children in 
this age group (Hussain et al., 2005). The average duration of the first episode of colonisation has 
been estimated at 63 days (Turner et al., 2012).  Carriage prevalence reduces with age, with mean 
carriage rates dropping to below 10% in those over 18 years old (Hussain et al., 2005). Although 
largely asymptomatic in itself, it has been suggested that nasopharyngeal carriage is a necessary pre-
requisite for the development of invasive disease (Bogaert et al., 2004). Carriage of S. pneumoniae in 
the nasopharynx leads to a prolonged interaction with the immune system of the host. This 
interaction is likely to influence the adaptive immune response that assists prevention of future 
invasive pneumococcal disease (Cohen et al., 2011, McCool et al., 2002).   
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1.1.2.2 Symptomatic disease 
 
Although most S. pneumoniae infection episodes involve colonisation of the nasopharynx, S. 
pneumoniae is also one of the most important human bacterial pathogens, responsible for up to 1.6 
million deaths annually worldwide, including 1 million child deaths (Levine et al., 2006). S. 
pneumoniae infection can manifest as a number of different diseases (Figure 1.1). Aspiration of S. 
pneumoniae colonising the nasopharynx into the lungs may result in pneumonia. In the UK S. 
pneumoniae is the leading cause of community acquired pneumonia, with an annual incidence 
estimated at 36.5 per 100,000 people (Bewick et al., 2012). S. pneumoniae is also a leading cause of 
meningitis, an infection of the meninges surrounding the brain, and bacteraemia, the presence of 
bacteria in the blood. Both bacteraemia and meningitis have a case fatality rate of approximately 
25% in adults (Ludwig et al., 2012). Bacteraemia is a relatively common complication of S. 
pneumoniae pneumonia, occurring in approximately 20% of cases admitted to hospital. Pneumonia 
has an overall mortality of around 5 to 10%, but is much commoner than septicaemia and meningitis 
so accounts for the highest burden of pneumococcal disease, and worldwide approximately 90% of 
deaths as a result of S. pneumoniae infection are due to pneumonia (O'Brien et al., 2009, Fitzwater 
et al., 2012). As well as severe invasive disease, S. pneumoniae is also a common cause of middle ear 
infection and is the most frequent bacteria isolated from middle ear fluid of individuals suffering 
acute otitis media (Jacobs et al., 1998, Sommerfleck et al., 2012). In addition to primary disease, S. 
pneumoniae is an important cause of secondary bacterial infection following influenza infection. It is 
estimated that secondary infection with S. pneumoniae may be present in up to 40% of patients with 
influenza (Wang et al., 2011). The presence of S. pneumoniae in influenza patients is associated with 
increased mortality (Palacios et al., 2009), and in murine models previous Influenza infection 
exacerbated the severity of subsequent infection with S. pneumoniae (Li et al., 2012). 
The incidence of invasive pneumococcal disease is highest at the extremes of age, with significantly 
higher rates of disease in individuals under 2 or over 65 years of age (van der Poll and Opal, 2009).  
19 
 
Individuals with acquired immune deficiencies, including HIV infection, also have an increased risk of 
invasive pneumococcal disease, and S. pneumoniae is the leading cause of bacterial respiratory 
infection in adults and children with HIV (Janoff et al., 1992). There is also an increased incidence of 
invasive pneumococcal infection in individuals with chronic lung disease for example in patients 
diagnosed with Chronic obstructive pulmonary disease (COPD) (Chidiac, 2012).  
 
 
              
 
 
Figure 1.1: Types of disease caused by S. pneumoniae. 
Some of the common clinical manifestations of S. pneumoniae disease following nasopharyngeal 
colonisation and the potential interactions between each disease type (Bogaert et al., 2004). 
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1.1.2.3 S. pneumoniae serotypes and disease  
 
The prevalence of different pneumococcal serotypes varies widely, as does their ability to cause 
disease (Brueggemann et al., 2004). Between 2008 and 2010 the most common serotypes of S. 
pneumoniae detected in patients suffering community acquired pneumonia in a UK hospital were 
serotypes 14, 8 and 1 (Bewick et al., 2012).  
For individual serotypes the incidence of invasive disease relative to the number of colonisation 
events has been estimated for the most prevalent serotypes. These ratios can be expressed as a 
serotype-specific ‘attack rate’, calculated from the incidence of invasive pneumococcal disease per 
100,000 acquisitions for each serotype. This attack rate is a measure of a serotypes potential to 
cause invasive disease, often described as serotype ‘invasiveness’. In a UK study, highly invasive 
serotypes (>20 cases of invasive disease per 100,000 acquisitions) included 4, 14, 7F, 9V, and 18C 
(Sleeman et al., 2006). There is an inverse relationship between both carriage duration or prevalence 
and invasiveness for each serotype (Sleeman et al., 2006, Brueggemann et al., 2004); serotypes with 
a low attack rate appear to stably colonise the nasopharynx for longer durations, in comparison to 
highly invasive serotypes which colonise for relatively short periods of time.  Recent epidemiological 
observations in the UK indicate that with increasing age an increase in serotype-specific ‘attack rate’ 
occurs, across all serotypes. This age-related increase seems to be more pronounced in less-invasive 
compared to highly-invasive serotypes (Bewick et al., 2012). As well as relative invasiveness, 
pneumococcal serotypes also vary in the type and severity of invasive disease they cause. Serotypes 
1 and 5 are more commonly found in complicated pneumonias in children (Hausdorff, 2007). 
Serotypes 1 and 14 are more often isolated from the blood than serotypes 3, 19 and 23, which in 
turn are isolated more frequently from the cerebrospinal fluid (Hausdorff et al., 2000a).  
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1.1.2.4 Treatment of S. pneumoniae infection 
 
Prior to the discovery of penicillin, serum therapy was the main treatment for invasive 
pneumococcal disease.  Serum therapy involved the transfer to patients of type-specific serum, 
often from  horses or rabbits vaccinated with pneumococcal polysaccharide (Goodner and Horsfall, 
1937). Such therapy was reported to reduce death rates, and protect against bacteraemia in patients 
presenting with pneumococcal pneumonia (Bullowa and Wilcox, 1936), and also prevented 
bacteraemia in animal models of disease (Bull, 1915c). The toxicity of serum therapy and the 
emergence of effective antibiotics led to its abandonment. Currently β-lactam antibiotics are the 
first-line in the treatment of invasive pneumococcal disease (Feldman and Anderson, 2011). 
However S. pneumoniae has developed resistance to many major classes of antibiotics, including β-
lactams, macrolides and fluoroquinolones (Feldman and Anderson, 2011). Although the incidence of 
resistance varies widely with geography, it is estimated that overall 15-30% of S. pneumoniae 
isolates worldwide are multi-drug resistant (resistant to 3 or more classes of antibiotics) (Lynch and 
Zhanel, 2009). Though currently antibiotic resistance may not be a major clinical problem, the 
potential lack of available treatment options due to increasing antibiotic resistance could have major 
consequences for the future case-fatality rate of S. pneumoniae infections. Increasing antibiotic 
resistance has led to the suggestion that antibody based therapies may have a role to play in future 
treatment of S. pneumoniae infections (Casadevall et al., 2004, Casadevall and Scharff, 1995).   
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1.1.3 Global serotype distribution  
 
The global distribution of pneumococcal serotypes is not uniform. Serotypes responsible for both 
carriage and invasive disease vary with location. Serotypes 19F and 23F were the most common 
serotypes isolated from nasal washings in a longitudinal study of Thai children (Turner et al., 2012).  
In comparison the most common serotypes isolated form nasal washings of Italian children, over a 
similar time period, were 10A and 10F (Ansaldi et al., 2012).The S. pneumoniae serotypes 
responsible for invasive disease also vary depending on location. The most common serotypes 
responsible for invasive pneumococcal disease in Africa are serotypes 1, 5 and 6A whereas in Europe 
and North America serotypes 14 and 6B appear more commonly as causes of invasive disease 
(Figure 1.2) (Mehr and Wood, 2012, Donkor et al., 2013). In Latin America serotype 14 is dominant 
with 50% of isolates responsible for acute otitis media in Argentinian patients in 2009 being serotype 
14, whereas in the USA serotype 14 was detected in approximately 10% of isolates, over the same 
time period (Rodgers et al., 2009). Differences in global serotype distribution are reflected in 
different coverage rates of the 13-valent pneumococcal vaccine, which is lower in Africa than Europe 
or North America (Figure 1.2). Vaccine introduction itself may reduce the circulation of certain 
serotypes within a population (Fitzwater et al., 2012); therefore uneven vaccine uptake may 
contribute to global variations in serotype prevalence 
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Estimated prevalence of invasive pneumococcal disease in different geographical areas, for the 13 
serotypes included in the 13-valent conjugate vaccine, prior to the introduction of PCV-7 into 
national immunisation programmes. Bars indicate the mean percentage of different serotypes and 
line indicates the cumulative mean (McIntosh and Reinert, 2011). 
Europe 
Africa 
North America 
Figure 1.2: Global distribution of S. pneumoniae serotypes.  
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1.2 S. pneumoniae surface envelope and genetics 
1.2.1 S. pneumoniae capsule 
 
Based on the relatedness of their capsular polysaccharide structure the 93 serotypes of S. 
pneumoniae can be categorised into 46 serogroups. The pneumococcal capsule is a virulence factor 
that aids pneumococcal survival in the host, and unencapsulated S. pneumoniae do not cause 
invasive infections in animal models of disease (Watson and Musher, 1990).  The capsule may aid 
virulence via a number of mechanisms. Firstly, the presence of a polysaccharide capsule can inhibit 
phagocytosis by neutrophils (Hyams et al., 2010a).The composition of different polysaccharide 
serotypes also affects their susceptibility to neutrophil mediated phagocytosis. Highly encapsulated 
serotypes such as 19F and 23F display increased resistance to neutrophil mediated phagocytosis, 
which has been linked to a higher carriage prevalence (Weinberger et al., 2009, Hyams et al., 2010c). 
The capsule may also help S. pneumoniae evade host defence mechanisms by masking immunogenic 
surface molecules (Alugupalli and Gerstein, 2005). For example, the ability of pneumococcal surface 
protein C (PspC) to bind factor H, a negative regulator of the complement pathway is affected by 
capsular serotype (Yuste et al., 2010) and there is a positive correlation between serotype-
invasiveness and factor H binding (Hyams et al., 2013). The binding of antibodies to pneumococcal 
surface protein A (PspA) may also be affected by capsular serotype (Abeyta et al., 2003). 
Investigations using capsular-switched isogenic strains of S. pneumoniae have indicated that the 
capsule may alter the surface-exposure of the pneumococcal proteins CbpA and PsrP, which are 
adhesins,  thus affecting virulence (Sanchez et al., 2011). The metabolic demand of synthesising 
different pneumococcal polysaccharides varies between serotypes, and this may affect the ability of 
S. pneumoniae strains to colonise the nasopharynx (Hathaway et al., 2012). 
As well as serotype variation the degree of capsular polysaccharide expression by a particular strain 
can vary, causing phase variation. Transparent phase variants have lower levels of capsular 
polysaccharide (Kim and Weiser, 1998) , exercise increased adherence to host cells and can more 
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easily colonise the nasopharynx (Weiser et al., 1994). Opaque variants on the other hand display 
higher levels of capsular polysaccharide and exhibit greater resistance to phagocytosis, but 
decreased adherence to host cells.  
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Figure 1.3: Basic structure of S. pneumoniae cell surface. 
Basic schematic of S. pneumoniae surface structure including the lipid cell membrane, peptidoglycan 
cell wall, polysaccharide capsule and three classes of surface protein (Jedrzejas, 2004).  
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27 
 
1.2.2 S. pneumoniae cell wall  
 
In common with other Gram-positive bacteria S. pneumoniae has a peptidoglycan cell wall that is 
essential for maintaining the structural integrity of the cell (Figure 1.3). Peptidoglycan in the S. 
pneumoniae cell wall is composed of chains of the glycan N-acetylmuramic acid and N-acetyl-D-
glucosamine (Bui et al., 2012), cross-linked by short peptides (Navarre and Schneewind, 1999). The 
cell wall of S. pneumoniae also contains accessory structures including teichoic acid and lipoteichoic 
acid (Navarre and Schneewind, 1999). Teichoic acids are covalently bound to cross-linked 
peptidoglycan via a phosphodiester bond. Lipoteichoic acids are anchored to the lipid cell membrane 
(Figure 1.3). Both teichoic acid lipoteichoic acids contain phosphorylcholine residues, to which one 
class of pneumococcal surface proteins (choline binding proteins) can bind. Peptidoglycan associated 
teichoic and lipoteichoic acids make up the pneumococcal cell wall polysaccharide (CWPS) antigen 
(Lu et al., 2009).     
1.2.3 S. pneumoniae surface proteins 
 
Surface proteins of S. pneumoniae are important for its interaction with its environment and 
therefore contribute to disease pathogenesis. Surface exposed proteins may also be targets for 
opsonizing antibody. Detection of genes with common motifs, suggestive of surface localisation, 
indicates that 4% of the pneumococcal genome may code for proteins that are surface located 
(Wizemann et al., 2001). A number of mechanisms of localisation and attachment of proteins to the 
bacterial surface have been described (Bergmann and Hammerschmidt, 2006). Table 1.1   shows an 
overview of some important surface proteins, grouped by their mechanism of attachment to the 
bacterial surface. 
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Table 1.1: Summary of some of the well-characterised surface proteins of S. pneumoniae grouped according to their mechanism of attachment to the 
bacterial surface (Bergmann and Hammerschmidt, 2006, Kadioglu et al., 2008).  
   
Lipoproteins   Roles 
PpmA Putative proteinase maturation protein 
A  
Adherence to epithelial cells 
SlrA Streptococcal lipoprotein rotamase A  Modulates virulence factors 
PsaA Pneumococcal surface adhesin A  Adhesion to host cells, Manganese transport 
PiaA Pneumococcal iron acquisition A Iron transport 
PiuA Pneumococcal iron uptake A Iron transport 
Choline binding proteins   
PspA Pneumococcal surface adhesin A  Binds apolactoferrin, Inhibits complement deposition 
PspC Pneumococcal surface protein C  Binds complement factor H, Role in adhesion to host -tissue 
CbpD Choline binding protein D  Role in competence-induced cell lysis, responds to CSP 
CbpE Choline binding protein E  Phosphorylcholine esterase, removes phosphorylcholine from cell wall 
LytA Autolysin A Cell wall hydrolysis role in autolysis 
LPxTG proteins   
NanA Neuraminidase Cleavage of terminal sialic acid residues on host cell glycolipids and 
glycoproteins 
IgA1ase IgA1 protease  Cleaves IgA1 
PrtA  Serine protease 
HtrA High-temperature requirement A Heat-shock induced serine proteases, resistance to oxidative stress 
Hyal Hyaluronidase Breakdown of host extracellular matrix  
Non-classical    
PhtD Pneumococcal histidine triad protein D   Zinc binding protein 
PhtE Pneumococcal histidine triad protein E Metal binding protein, adherence to host tissue  
PilusA Pneumococcal pilus Adhesion to host cells 
PavA Pneumococcal adhesion and virulence A Binds fibronectin 
Eno Enolase Binds to plasminogen, promotes degradation of extracellular matrix 
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1.2.3.1 Choline binding proteins 
 
The choline binding protein PspA was first identified as a protein that lacked the features of 
streptococcal LPxTG proteins, but instead bound to choline residues on cell wall lipoteichoic acid via 
its C-terminal region (Yother and Briles, 1992). The release of PspA from the bacterial surface can be 
induced by either incubation of bacteria in high concentrations of choline, or deletion of the C-
terminal region (Yother and Briles, 1992).This mechanism of attachment is shared by a number of 
other pneumococcal surface proteins, all sharing a common C-terminal choline binding domain, 
consisting of a repeating 20 amino acid sequence (Wren, 1991). The common C-terminal domain of 
these proteins binds choline residues attached to pneumococcal cell wall teichoic and lipoteichoic 
acid, resulting in their non-covalent attachment to the cell surface (Figure 1.3). Other well 
characterised CBPs of S. pneumoniae include autolysin (LytA) (Garcia 1986) and pneumococcal 
surface protein C (PspC) (Rosenow et al., 1997).  
1.2.3.2 LPxTG motif proteins  
 
Surface proteins with an LPxTG amino acid signal sequence represent a class of proteins common to 
Gram-positive cocci (Fischetti et al., 1990). The presence of an LPxTG signal sequence at the C-
terminus targets these proteins to the bacterial cell surface (Navarre and Schneewind, 1999).  This 
signal sequence is cleaved by sortase, a transpeptidase, and the resultant cleaved proteins are then 
covalently attached via sortases to peptidoglycan of the pneumococcal cell wall (Mitchell and 
Mitchell, 2010). Genome analysis indicates the presence of 19 LPxTG anchored surface proteins in 
the TIGR4 strain of S. pneumoniae (Bergmann and Hammerschmidt, 2006). Some pneumococci 
express pili, long appendages involved in adhesion that extend beyond the capsule (Barocchi et al., 
2006). The pneumococcal pilus is attached to the cell surface via a LPxTG signal sequence  (Lofling et 
al., 2011). 
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1.2.3.3 Lipoproteins 
 
Cell surface lipoproteins are covalently linked to phospholipids of the pneumococcal cell membrane 
(Figure 1.3). This mechanism of attachment to the cell surface is conserved among bacteria (Sutcliffe 
and Harrington, 2002). Lipoproteins are initially secreted as prolipoproteins, following secretion they 
are covalently attached to the membrane phospholipid diacylglyceryl via the enzyme diacylglyceryl 
transferase (Lgt) (Tokunaga et al., 1982). Following attachment to the phospholipid membrane, the 
N-terminal signal peptide is cleaved by the enzyme lipoprotein signal peptidase (Lsp), forming the 
mature lipoprotein. Some lipoproteins form important components of transmembrane ABC 
transporters, these include the iron-uptake transporters Piu, Pit and Pia (Brown et al., 2001) and the 
manganese uptake transporter PsaA (Dintilhac et al., 1997). Other lipoproteins are not components 
of ABC transporters, for example, PpmA is an adhesin involved in pneumococcal adherence to host 
tissues (Gor et al., 2005). 
1.2.3.4 Non-classical surface proteins  
 
There are a number of pneumococcal surface proteins that fall outside any of the three categories 
already described, and are attached to the cell surface by other novel and often poorly understood 
mechanisms that would not be detected by genome analysis. These proteins can be collectively 
grouped into ‘non-classical’ surface proteins and include, for example, the pneumococcal histadine 
triad (Pht) family of proteins (Adamou et al., 2001). As their name suggests the Pht proteins contain 
a repeated histadine triad motif and have been demonstrated as surface located by flow-cytometry. 
A pneumococcal serine rich repeat protein (PsrP) has also been described (Rose et al., 2008). This 
protein is a member of a family of serine rich repeat proteins (SRRP) found in numerous pathogenic 
bacteria and has a role in adhesion to host tissue and the development of invasive disease (Sanchez 
et al., 2010). Additional S. pneumoniae proteins have transmembrane insertions, which mean they 
are partially expressed on the cell surface. For example the pneumococcal serine/threonine kinase 
(Stk-P) has a transmembrane region anchoring it to the cell surface (Echenique et al., 2004).  
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1.3 Genetic diversity of S. pneumoniae  
1.3.1 Genome structure 
 
S. pneumoniae contains a single circular chromosome estimated at between 2,240 to 2,270 kilobase 
pairs (KBP) in length (Gasc et al., 1991). The first pneumococcal genome to be sequenced was the 
serotype 4 strain TIGR4, which contains approximately 2200 open reading frames (ORFs) (Tettelin et 
al., 2001). Subsequently the genomes of other pneumococcal strains have been sequenced, all 
containing approximately 2000 ORFs (Barocchi et al., 2007). Significant genomic diversity between 
strains of S. pneumoniae exists on a number of levels.  
1.3.1.1 Transformation 
 
S. pneumoniae is naturally competent. Competence refers to the ability of an organism to undergo 
genetic transformation, incorporating DNA into its genome via homologous recombination. 
Induction of competence in S. pneumoniae is controlled by the concentration of a secreted peptide 
competence stimulating peptide (CSP) (Steinmoen et al., 2002). The induction of a competent state 
is dependent upon the concentration of CSP, this allows populations of S. pneumoniae to respond to 
their own density, a process known as quorum sensing.  
Colonisation of the nasopharynx provides a site for the exchange of genetic information between 
bacteria (Leung et al., 2011). This exchange allows adaptation to environmental pressures, for 
example, the development of anti-microbial resistance (Zhu and Lau, 2011), or the acquisition of 
genes involved in virulence (Brown et al., 2001). Investigating the evolution over time of the PMEN1 
serotype 23F strain of pneumococcus has allowed the identification of recombination ‘hot spots’, 
where horizontal gene transfer events were detected at increased frequency. Recombination 
‘hotspot’ loci include genes encoding the pneumococcal surface proteins PspA, PspC PsrP and 
capsule biosynthesis. Selective pressures may have led to the removal or alteration of genes 
encoding the pneumococcal proteins PspA and PsrP in this isolate (Croucher et al., 2011). All the 
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genes required for type-specific polysaccharide production are located together in genetic ‘cassette’ 
(Dillard and Yother, 1994). This facilitates capsule switching during transformation.  Sequence typing 
indicates that S. pneumoniae of the same sequence type may have different capsular polysaccharide 
serotypes, probably as a result of capsule switching. Capsule switching has been demonstrated in 
response to the introduction of the pneumococcal conjugate vaccine, where serotype 19A isolates 
have emerged from a previously 23F expressing lineage (Croucher et al., 2011).  
1.3.2 Sequence type 
 
As well as by capsular serotype, S. pneumoniae may also be categorised based on its genetic 
sequence type. Multi-locus sequence typing (MLST) classifies S. pneumoniae based on the sequence 
of seven ‘core’ housekeeping gene fragments (Hanage et al., 2005), therefore allowing grouping into 
‘sequence type’. It has been demonstrated that a number of isolates responsible for invasive disease 
from different countries were of the same sequence type, but not necessarily the same serotype 
(Coffey et al., 1998). These isolates are probably from the same clone and have different capsular 
polysaccharides due to horizontal transfer of genes encoding the capsule. S. pneumoniae strains of 
different sequence type may therefore have distinct virulence phenotypes independent of 
differences in their capsular polysaccharide (Sjostrom et al., 2006). More recently it has been 
demonstrated that the isolates responsible for invasive disease in west Africa are more likely to be 
clonal (of the same sequence type) than the those identified as common in carriage (Donkor et al., 
2013).   
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1.3.3 Regions of difference  
 
As well as global differences in their genomes, genomic variation of S. pneumoniae can also occur at 
specific sites. Studies of the pneumococcal pathogenicity island (PPI-1) were amongst the first to 
indicate genetic variation at a particular site. PPI-1 is a collection of genes involved in virulence, the 
3’ region of which is highly variable between different strains. Some variations in PPI-1 have been 
associated with alterations in the virulence of S. pneumoniae (Brown et al., 2001, Harvey et al., 
2011). Later further S. pneumoniae genes were shown to vary substantially between strains and 
termed ‘regions of diversity’ (van der Poll and Opal, 2009).  Some regions of diversity are involved in 
virulence and can distinguish between invasive and non-invasive strains. Comparison of the genome 
sequence of highly invasive, compared to a non-invasive isolates of S. pneumoniae has identified 8 
regions of the genome specific only to highly invasive isolates, these include variable regions of the 
PPI-1, ABC transporters and metabolic enzymes (Harvey et al., 2011).  
Along with regions of diversity, single genes are present or absent in different strains. Overall 
analysis of seventeen pneumococcal genomes indicated that less than 50% of genes were conserved 
between all 17 pneumococcal strains examined (Hiller et al., 2007). This diversity has led to the 
‘supra-genome’ hypothesis being applied to S. pneumoniae, which states that all the genes available 
to a species exist in a hypothetical pool, with every strain deriving and contributing genes to this 
pool (Hiller et al., 2007). 
Genetic diversity means that certain pneumococcal proteins that may be protective antigens are not 
present in all serotypes. For example significant differences in the expression of the pneumococcal 
adhesin PsrP have been demonstrated between serotypes (Munoz-Almagro et al., 2010), and the 
pneumococcal pili are also only present on certain pneumococcal serotypes (Basset et al., 2007b). 
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1.3.4 Allelic variation 
  
Whilst many pneumococcal surface proteins are structurally conserved between serotypes and 
strains, some of these proteins display allelic variance, providing an additional level of genetic 
variation between strains. For example, the gene sequence for the choline binding protein PspC  is 
highly variable between strains, and based on sequence identity it has been classed into 11 different 
groups (Iannelli et al., 2002). Antibodies to one allele of PspC do not necessarily cross react with 
other alleles; mice immunised with recombinant PspC from a type 3 strain (HB565) were protected 
against homologous challenge, partially protected against infection with a serotype 2 S. pneumoniae 
(D39), but not protected against challenge with a serotype 4 strain (Ricci et al., 2011). These 
differences in protection were linked to the level of variation in the amino acid sequence of PspC 
between strains.  PspA is also structurally variable between serotypes, alleles of PspA are divided 
into two main families and further into different clades (Hollingshead et al., 2000). The development 
of antibodies to PspA may be family specific (Melin et al., 2008), and although antibodies raised 
against one PspA family can cross-react with PspA from both families (Nabors et al., 2000), the level 
of cross-reactivity varies between families (Nabors et al., 2000). Similar to PspC, comparisons have 
been made of the ability of polyclonal mouse sera raised against PspA fragments from different 
clades to bind to PspA, with the cross-reactivity of anti-PspA antibodies related to the level of 
similarity of PspA between strains (Darrieux et al., 2008). In contrast lipoproteins (for example, PsaA, 
PiuA and PiaA) are highly conserved between pneumococcal serotypes (Sampson et al., 1997, Jomaa 
et al., 2005), and antibodies raised against the lipoproteins Piu/Pia from S. pneumoniae D39 
(serotype 2), mediated increased phagocytosis of a number of other S. pneumoniae serotypes 
(Jomaa et al., 2005). 
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1.3.4.1 Gene expression  
 
Pneumococcal gene expression is a dynamic process. Analysis of gene expression by microarray 
indicated that expression of a number of genes can be altered when S. pneumoniae are exposed to 
altered environments, which may affect virulence (Orihuela et al., 2004). 17 out of 20 of the genes 
classified as ‘virulence genes’ were differentially expressed when exposed to different physiological 
niches (blood, cerebrospinal fluid, and cultured epithelial cells). Changes included, for example, 
enhanced expression of the pneumococcal surface protein PspC in the presence of cultured 
epithelial cells. An increased expression of PspA was observed in all three physiological 
environments and enhanced expression of the pneumococcal surface protein PhtD was 
demonstrated in CSF. Investigation of gene expression by RT-PCR confirmed alterations in gene 
expression in different organ compartments in vivo. In addition, PspC was more abundantly 
expressed in S. pneumoniae  isolates from the nasopharynx than the lungs and blood of mice 72hrs 
post intranasal (IN) infection with the D39 strain (LeMessurier et al., 2006). Microarray studies have 
also shown pronounced differences in gene expression between S. pneumoniae strains when 
exposed to the same physiological conditions (Ogunniyi et al., 2012). 
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1.4 Immunity to S. pneumoniae  
 
1.4.1 Immunodeficiency and S. pneumoniae  
 
There are a number of primary immune deficiencies that may result in reduced or absent 
immunoglobulin production. These diseases include X-linked agammaglobunemia, caused by a 
defect in B-cell differentiation and common variable immune deficiency (CVID), a heterogeneous 
group of primary immune deficiencies all associated with deficient immunoglobulin production. 
Patients with primary immunoglobulin deficiencies display increased susceptibility to a number of 
infections, including an increased incidence of pneumonia (Oksenhendler et al., 2008). S. 
pneumoniae and H. influenzae are the most common causative agents of pneumonia in these 
patients (Rosen et al., 1995). The incidence of respiratory tract infection in immunoglobulin deficient 
patients can be partially reversed by intravenous immunoglobulin (IVIG) replacement therapy 
(Quinti et al., 2011). IVIG is pooled, purified immunoglobulin (IgG) from over a thousand donors, 
administered intravenously (IV) (Schwab and Nimmerjahn, 2013). The ‘trough’ concentration of IgG 
in patients’ blood between infusions of IVIG has been used to assess treatment efficacy and some 
studies have indicated that higher trough levels of IVIG may be protective against pneumonia 
(Orange et al., 2010). It has also been noted that IVIG therapy may reduce the deterioration in 
pulmonary function in patients with CVID (measured by FEV1) (de Gracia et al., 2004), presumably 
due to prevention of recurrent lung infection. The increased incidence of pneumococcal lung 
infection in immunoglobulin deficient patients, and its partial reversal following replacement 
therapy with pooled IgG, suggests an important role for IgG in natural immunity to lung infection 
with S. pneumoniae.  
As well as antibody deficiencies, other immune deficiencies are associated with increased 
susceptibility to infection with S. pneumoniae. Patients with deficiencies in the classical pathway of 
complement activation have increased incidence of pneumococcal septicaemia, meningitis and 
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bacterial pneumonia (Jonsson et al., 2005). Phagocytosis of S. pneumoniae was reduced when 
opsonised in the sera of patients with a classical complement defect, compared to healthy controls 
(Yuste et al., 2008). Patients with cellular immune deficiencies are also more susceptible to 
pneumococcal disease, and the incidence of invasive S. pneumoniae  may be up to 30 times higher in 
HIV positive patients compared to healthy controls (Chidiac, 2012). Impaired CD4+ T-cell responses 
to S. pneumoniae have been demonstrated in Malawian adults with HIV (Glennie et al., 2011).  
Asplenic patients have compromised immunity associated with increased susceptibility to infection, 
in particular sepsis, with encapsulated bacteria such as S. pneumoniae. It is estimated that 50-90% 
overwhelming infections post-splenectomy are down to S. pneumoniae (Davidson and Wall, 2001, 
Waghorn, 2001). In animal models of bacteraemia, experimental splenectomy significantly reduced 
the clearance of S. pneumoniae from the blood (Shinefield et al., 1966, Okinaga et al., 1981).   
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1.4.2 Innate Immunity to S. pneumoniae  
 
1.4.2.1 Host-recognition of S. pneumoniae  
 
The host response to invading bacteria requires cells to identify the bacterial pathogen. This is 
mediated by pattern recognition receptors (PRRs) on host cells, which recognise conserved pathogen 
associated molecular patterns (PAMPs). Toll-like receptors (TLRs) are one well-described family of 
intra and extra-cellular pattern recognition receptors and a number of TLR’s may recognise different 
components of S. pneumoniae.  TLR2 recognises lipoteichoic acid and lipoproteins of Gram-positive 
bacteria including S. pneumoniae (Mogensen et al., 2006). TLR2 KO mice displayed impaired 
clearance of pneumococcal colonisation (van Rossum et al., 2005). In addition TLR4 recognises the 
pneumococcal toxin pneumolysin, and TLR9 recognises unmethylated CpG motifs on bacterial DNA 
(Paterson and Orihuela, 2010).  Another family of PRRs are the NOD-like receptors (NLRs) which 
identify PAMPs within the cell cytosol. NOD-2 recognises peptidoglycan, and detects internalised S. 
pneumoniae (Opitz et al., 2004). Certain NLRs can form intracellular signalling complexes called 
inflammasomes, which can be activated by the pneumococcal toxin pneumolysin (McNeela et al., 
2010). Other PRRs that may detect S. pneumoniae include scavenger receptors and SIGN-R1 on 
macrophages. The scavenger receptor MARCO is required for maximal TLR2 and NOD2 signalling, in 
response to colonisation with S. pneumoniae in mice (Dorrington et al., 2013). SIGN-R1 recognises 
the pneumococcal polysaccharide capsule (Paterson and Orihuela, 2010).    
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1.4.2.2 Role of complement in immunity to S. pneumoniae 
 
The complement system consists of a series of plasma and cell surface proteins involved in the 
opsonisation and killing of pathogens. Complement is an important component of innate immunity 
to S. pneumoniae, and individuals with an inherited deficiency in the central complement 
component C3, or the classical pathway component C2 are highly susceptible to pneumococcal 
infection (Paterson and Orihuela, 2010, Jonsson et al., 2005). There are three main pathways of 
complement activation, classical, lectin and alternative. The classical pathway is initiated by the 
binding of immunoglobulin, or acute phase proteins such as C reactive protein (CRP) and serum 
amyloid P (SAP) to phosphorylcholine of the pneumococcal cell wall (Casal and Tarrago, 2003). The 
lectin pathway is initiated by the binding of mannose binding lectin (MBL) to mannose on the 
pathogen surface (Eisen, 2010). The alternative pathway involves the deposition of complement 
component C3 directly on the bacterial surface.  In murine models of disease the classical pathway 
has been shown to be the dominant complement pathway in innate immunity to S. pneumoniae. 
(Brown et al., 2002b). The importance of complement in immunity to S. pneumoniae is highlighted 
by the complement-evasion strategies it employs. These include the binding of the complement 
regulator factor H by PspC (Yuste et al., 2010) and inhibition of complement deposition by the 
capsular polysaccharide (Hyams et al., 2010a).The pneumococcal surface protein PspA also inhibits 
complement activity by competing with CRP for binding to phosphocoholine residues on bacterial 
surface (Mukerji et al., 2012).  Opsonisation of S. pneumoniae by complement leads to phagocytosis 
and assists bacterial clearance. Complement is essential for effective clearance of S. pneumoniae 
from the blood (Yuste et al., 2005).  Studies of type 3 pneumococcus have shown that a number of 
complement proteins are present in the lungs of animals challenged with S. pneumoniae  (Coonrod 
and Yoneda, 1981), and complement depletion resulted in increased CFU in the lungs, in animal 
models of S. pneumoniae pneumonia (Yuste et al., 2005). 
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1.4.2.3 Innate immunity to colonisation with S. pneumoniae 
 
The primary clearance of S. pneumoniae from the nasopharynx depends upon neutrophils and 
macrophages (van Rossum et al., 2005, Zhang et al., 2009). In murine models of colonisation, 
neutrophils were recruited to the lumen of the nasopharynx and depletion of neutrophils resulted in 
normally asymptomatic colonisation becoming invasive (Matthias et al., 2008). Neutrophils may also 
facilitate the delivery of pneumococcal antigen to lymphoid tissue (Matthias et al., 2008). However  
alone neutrophils may not be sufficient to clear primary S. pneumoniae colonisation, as the decline 
in bacterial numbers in the nasopharynx of colonised mice failed to correlate with neutrophil influx 
(Matthias et al., 2008). Instead it appears clearance of primary colonisation depends upon the 
recruitment of monocytes and macrophages as depletion of these cells reduced pneumococcal 
clearance from the nasopharynx (Zhang et al., 2009). Neutrophils on the other hand appear to be 
important in the clearance of S. pneumoniae from the nasopharynx following secondary challenge, in 
previously colonised mice. Clearance of S. pneumoniae may be influenced by the presence of other 
bacterial species co-colonising the nasopharynx. In comparison to inoculation with S. pneumoniae 
alone, mixed inoculation of both H. influenzae and S. pneumoniae into the nasopharynx of mice 
resulted in a rapid clearance of S. pneumoniae, associated with a greater influx of neutrophils 
(Lysenko et al., 2005).    
1.4.2.4 Innate immunity to lung infection with S. pneumoniae 
 
The first line of immunity to S. pneumoniae reaching the lungs is the respiratory epithelium. S. 
pneumoniae may be cleared from the airways by the mucociliary clearance system of respiratory 
epithelial cells (Pittet et al., 2010). Epithelial cells secrete surfactant proteins which are capable of 
binding to and agglutinating pneumococci and appear to contribute to host defence (Jounblat et al., 
2005). Epithelial cells also secrete numerous anti-microbial peptides such as α and β-defensins and 
cathelecidin in response to bacterial infection (Schaller-Bals et al., 2002), which may also contribute 
to the clearance of S. pneumoniae from the lungs.   
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Alveolar macrophages are resident phagocytic cells of the lungs, and make up the majority (<95%) of 
cells in bronchoalveolar lavage fluid (BALF) under normal conditions (Gordon and Read, 2002). 
Bacterial inoculum into the lung are usually efficiently cleared by alveolar macrophages (Marriott 
and Dockrell, 2007). This clearance occurs without the recruitment of inflammatory cells and release 
of inflammatory mediators. However, if the resident alveolar macrophages are unable to initially 
clear this inoculum, inflammation associated with a recruitment of neutrophils occurs. Alveolar 
macrophages release inflammatory mediators including tumour necrosis factor alpha (TNF-α), 
interleukin-6 (IL-6) and interleukin-1 (IL-1). These cytokines can stimulate an inflammatory response. 
For example, IL-1β and TNF-α release by macrophages facilitates the release of the neutrophil 
attracting chemokine CXCL8 (IL-8) from epithelial cells (Standiford et al., 1990, Sun et al., 2007). 
Neutrophils are usually the first cells recruited following bacterial inoculum into the lungs (Yamada 
et al., 2011, Dallaire et al., 2001), where they control S. pneumoniae numbers by phagocytosis 
(Hyams et al., 2010a). In murine models of  pneumonia neutrophil influx appeared to peak by 12hrs 
post-infection with S. pneumoniae (Kadioglu et al., 2000).      
Neutrophil recruitment is promoted by chemokines released in response to infection. Neutrophils 
express two CXCR receptors (CXCR1 and CXCR2) which respond to CXC chemokines, resulting in 
neutrophil migration. CXCR1 responds to CXCL6 (granulocyte chemotactic protein-2) and CXCL8 (IL-
8) (Stillie et al., 2009). Additionally CXCR2 responds to a range of other chemokines including CXCL1 
(GRO-α), CXCL2 (GRO-β) and CXCL3 (GRO-γ).The CXC chemokine IL-8 appears to be particularly 
important in the migration of neutrophils into the lung following bacterial infection. Patients with 
bacterial pneumonia have been shown to have increased lung concentrations of IL-8 (Baggiolini et 
al., 1994), and antibody neutralisation of KC (Keratinocyte chemoattractant, CXCL1), considered the 
murine functional homologue of IL-8 (Singer and Sansonetti, 2004), reduces neutrophil influx in 
response to experimental bacterial pneumonia in mice (Craig et al., 2009). Bacterial products 
themselves may mediate neutrophil chemotaxis directly. N-formyl-peptides released by bacteria 
bind to formyl peptide receptors (FPRs) on neutrophils (Gauthier et al., 2007). Inhibition of FPRs by 
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cyclosporine H reduced neutrophil numbers in the alveolar space of mice 6hrs following high dose 
challenge with S. pneumoniae (Gauthier et al., 2007).  Neutrophils are recruited into the alveoli of 
infected lungs via the integrins MAC-1 and α4β1 (Kadioglu et al., 2011b).  
Phagocytosis of S. pneumoniae by neutrophils is enhanced by opsonisation with complement and 
Immunoglobulins. IgG bound to the surface of S. pneumoniae may enhance phagocytosis directly, by 
interaction with FCγ receptors, or indirectly by facilitating complement deposition (Mold et al., 
2002). Complement bound to S. pneumoniae is recognised by complement receptors on the surface 
of neutrophils (Williams et al., 2003). Once internalised, there are a number of mechanisms by which 
neutrophils can kill bacteria. Neutrophils can produce reactive oxygen species (ROS), including 
hydrogen peroxide and hydroxyl radicals via the enzyme NADPH oxidase (Segal, 2005). Neutrophils 
also contain anti-microbial peptides within cytoplasmic granules. In vitro experiments have indicated 
that human neutrophils kill S. pneumoniae primarily via antimicrobial serine proteases, rather than 
the generation of ROS (Standish and Weiser, 2009) as inhibition of theses peptides reduced 
intracellular killing of S. pneumoniae, but inhibition of NADPH oxidase did not.  
Neutrophil recruitment appears to be crucial to the resolution of pneumococcal pneumonia (Calbo 
and Garau, 2010), and a robust Influx of neutrophils into the lungs may clear S. pneumoniae; 
however excessive neutrophil influx may contribute to inflammation and lung damage characteristic 
of pneumonia (Dockrell et al., 2012). Antibody-depletion of neutrophils led to enhanced bacterial 
numbers in the alveolar space 24-hours post IN infection with S. pneumoniae (Sun and Metzger, 
2008). However the physical migration of neutrophils into the alveolar space may enhance bacterial 
invasion into the blood (Marks et al., 2007), and antibody depletion of neutrophils protected mice 
from bacteraemia post-challenge with a serotype 8 S. pneumoniae (Marks et al., 2007).    
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1.4.2.5 Innate immunity to S. pneumoniae bacteraemia  
 
As already discussed CRP binding to phosphorylcholine enhances the deposition of complement 
component C3 on the surface of S. pneumoniae (Horowitz et al., 1987), and is important for the 
clearance of S. pneumoniae from the blood, transfer of human CRP protected mice from 
experimental pneumococcal bacteraemia (Horowitz et al., 1987). The acute phase protein serum 
amyloid P (SAP) also improves complement deposition on the surface of S. pneumoniae and 
enhances its clearance from the blood (Yuste et al., 2007). Natural poly-reactive IgM is also 
important for the innate clearance of S. pneumoniae from the blood (Brown et al., 2002b, Baxendale 
et al., 2008). IgM produced in the absence of antigenic stimulation is considered natural IgM.  A 
particular subset of B-cells, B1a are responsible for the production of germ-line encoded poly-
specific natural antibody, primarily IgM (Baumgarth, 2011). Natural IgM is capable of binding to a 
range of pneumococcal polysaccharide serotypes and passive transfer of natural IgM protected mice 
in a model of pneumococcal sepsis (Baxendale et al., 2008). IgM appears to target bacteria in the 
blood to the marginal zone of the spleen, for removal (Zandvoort and Timens, 2002). The spleen is 
important for the removal of S. pneumoniae from the blood, splenectomised mice have impaired 
clearance of pneumococcal bacteraemia (Shinefield et al., 1966), and in humans S. pneumoniae is 
responsible for more than 50% of overwhelming infections post-splenectomy (Davidson and Wall, 
2001). Tracking radiolabelled bacteria following in vivo infection indicated that S. pneumoniae in the 
bloodstream is primarily cleared by phagocytic cells of the liver and spleen (Brown et al., 1983). 
Macrophages located in the marginal zone of the spleen express the C-type lectin SIGN-R1 which 
binds to pneumococcal capsular polysaccharide and therefore promotes phagocytosis and clearance 
of S. pneumoniae from the blood (Kang et al., 2004).                      
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1.4.3 Natural adaptive immune response to S. pneumoniae  
1.4.3.1 Development of humoral immunity  
 
A decrease in the incidence of pneumococcal disease with increasing age in children, following a 
period of high colonisation incidence, indicates the development of adaptive immunity. As 
previously discussed, individuals with acquired defects in humoral immunity are at greater risk of S. 
pneumoniae infection (Oksenhendler et al., 2008), demonstrating an important role for antibody in 
naturally-acquired immunity to S. pneumoniae. Purified capsular polysaccharide is an effective 
serotype-specific vaccine against S. pneumoniae through induction of anti-capsular polysaccharide 
antibody, and anti-polysaccharide immune serum can passively protect against serotype-specific 
pneumococcal disease (Casadevall and Scharff, 1994). It has therefore been assumed that the main 
mechanism of naturally-acquired immunity to S. pneumoniae is via the generation of antibodies to 
the pneumococcal polysaccharide (Musher et al., 1993). Longitudinal observational studies have 
indicated that nasopharyngeal colonisation does result in the development of anti-capsular 
antibodies (Goldblatt et al., 2005), and there is some epidemiological evidence this causes serotype-
specific immunity for at least some capsular serotypes (Weinberger et al., 2008). However, whilst 
anti-capsular antibodies may play a role in adaptive immunity there is also epidemiological evidence 
to suggest that other mechanisms are important in the development of naturally-acquired immunity 
to S. pneumoniae. A parallel reduction in the incidence of invasive disease occurs across all serotypes 
with increasing age in children (Figure 1.4) (Lipsitch et al., 2005) , which suggests the development of 
a common rather than serotype-specific mechanism of immunity. Furthermore, the age over which 
the reduction in invasive disease occurs does not necessarily coincide with the time at which an 
increase in anti-capsular antibodies is observed (Lipsitch et al., 2005). Longitudinal studies of S. 
pneumoniae colonisation in children have demonstrated that individuals acquire IgG to a number of 
S. pneumoniae protein antigens following periods of colonisation with S. pneumoniae (Prevaes et al., 
2012). Data from murine models of experimental colonisation suggest that colonisation with S. 
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pneumoniae induces high titres of IgG to S. pneumoniae, including antibody to specific 
pneumococcal protein antigens (Richards et al., 2010, Cohen et al., 2011).   
 
 
 
 
Figure 1.4: Incidence of invasive S. pneumoniae by age.  
Specific incidence of invasive S. pneumoniae disease per 100,000 person years in the United States 
by serogroup (in children of increasing age). ‘NVG’ indicates those serotypes not included in the 7-
valent vaccine combined (Lipsitch et al., 2005).   
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1.4.3.2 Role of IgM/IgA 
  
In addition to IgG, IgA and IgM may have some role in adaptive immunity to S. pneumoniae. IgM is 
also produced by B-cells in response to pathogens, and experimental infection with S. pneumoniae 
serotype 3 induced the production of anti-phosphorylcholine IgM in mice (Koppel et al., 2005). 
Following experimental colonisation of mice small rises in S. pneumoniae-specific IgM have been 
demonstrated (Cohen et al., 2012), associated with the development of IgM to the capsular 
polysaccharide. IgA is found in abundance at mucosal surfaces. There are two subclasses of IgA, IgA1 
and IgA2, the predominant subclass in the human airway is IgA1 (Kadioglu et al., 2008). Secretory IgA 
(sIgA) is formed of dimers of IgA1 or IgA2 connected by a J-chain. sIgA  is secreted across epithelial 
cells by the action of the polymeric Ig receptor (pIgR) (Pabst, 2012). IgA may have a role in protective 
immunity to S. pneumoniae, secretory IgA was produced following IN vaccination with the 
pneumococcal surface protein PspA. IgA was required for protection in this model as IgA deficient 
mice were not protected (Fukuyama et al., 2010) .  S. pneumoniae expresses an enzyme, IgA1ase, 
capable of cleaving human IgA1, therefore preventing opsonisation by IgA1in the nasopharynx (Wani 
et al., 1996).  The vast majority of patients with specific IgA deficiencies do not appear to have any 
clinical manifestations (Pabst, 2012). However, recent a study has suggested that individuals with a 
selective IgA deficiency may have an increased incidence of respiratory tract infection (Jorgensen et 
al., 2013). 
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1.4.3.3 Antigen targets for naturally-acquired antibody 
 
Experimental colonisation in mice can result in both the development of anti-CPS IgM and IgG 
against protein targets (Richards et al., 2010, Cohen et al., 2011), though the dominant antibody 
responses following murine colonisation appear to be against protein rather than polysaccharide 
antigens (Cohen et al., 2011). Reduced CFU of S. pneumoniae in the nasopharynx of previously 
colonised mice correlated with both anti-CPS IgM and IgG against the surface protein PspA (Richards 
et al., 2010). Importantly in mouse models of nasopharyngeal carriage experimental carriage with 
one serotype was protective against subsequent invasive disease caused by another serotype 
(Richards et al., 2010, Roche and Weiser, 2010), suggesting the development of serotype 
independent immunity. In experimental human colonisation models, protection from acquisition of 
S. pneumoniae was associated with pre-existing IgG to the pneumococcal surface protein PspA, but 
not with serotype specific anti-CPS antibody (McCool et al., 2002). Humans experimentally colonised 
with S. pneumoniae developed both serum IgG against the capsular polysaccharide and IgG against a 
number of pneumococcal surface proteins (Ferreira et al., 2013). Sera from these individuals, when 
passively transferred to mice was protective against challenge with a different serotype of S. 
pneumoniae (Ferreira et al., 2013). In unvaccinated human serum the concentration of IgG to the 
capsular polysaccharide does not necessarily correlate with binding of IgG to different S. 
pneumoniae serotypes (Hyams et al., 2011) (Figure 1.5), suggesting antigens other than the capsular 
polysaccharide may be important targets of naturally-acquired IgG. The S. pneumoniae capsule may 
also mask targets of IgG binding to sub-capsular antigens (Hyams et al., 2010a). 
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Figure 1.5: IgG binding to different S. pneumoniae serotypes.  
IgG binding to different S. pneumoniae clinical isolates following incubation in pooled human sera,  
and the concentration of capsular specific IgG  (μg/ml) in that sera (Hyams et al., 2011). 
 
Low levels of IgG to the pneumococcal surface proteins PhtD, PhtE, and Ply have been demonstrated 
in children prone to pneumococcal otitis media (Sharma et al., 2012). This was associated with a 
lower percentage of memory B-cells in otitis-prone children recognising these pneumococcal surface 
antigens (Sharma et al., 2012). Higher antibody levels to a range of pneumococcal proteins (NanA, 
PpmA, PsaA, SlrA, SP0189, and SP1003) correlated  with reduced risk of respiratory tract infection in 
14 month old children (Lebon et al., 2011) and to a reduced risk of otitis media (Kaur et al., 2011).  
Higher antibody responses to the pneumococcal proteins CbpA and pneumolysin (salivary and serum 
IgG) have also been demonstrated in children who are culture negative compared to those colonised 
with S. pneumoniae (Zhang et al., 2006b). However, recent epidemiological studies observing serum 
IgG responses to a range of pneumococcal proteins suggested that although nasopharyngeal 
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colonisation may elicit antibodies to a range of pneumococcal proteins, levels of IgG to 
pneumococcal surface proteins were not associated with a reduced risk of subsequent carriage in a 
population of children (Prevaes et al., 2012). Murine models indicate that whilst antibodies to 
pneumococcal protein antigens correlated with protection from future colonisation, they are not 
required for this protection (Trzcinski et al., 2005), and in mice acquired immunity to colonisation 
depends upon cellular responses, in particular the development of Th17 responses,  and antibody 
may be redundant for protection (Zhang et al., 2009).   
1.4.3.4 Mechanisms of antibody mediated protection  
 
1.4.3.4.1 Antibodies to S. pneumoniae CPS 
 
There are a number of mechanisms by which antibodies may protect against S. pneumoniae 
infection. Binding of antibodies to the polysaccharide capsule may facilitate complement deposition 
on the bacterial surface, enhancing phagocytosis (Brown et al., 1982), and capsular polysaccharide-
specific antibody can also facilitate phagocytosis by directly interacting with FC receptors on the 
surface of phagocytes, enhancing phagocytosis (Gordon et al., 2000). Antibody targeting the 
pneumococcal capsular polysaccharide may also protect by agglutination. For a number of years it 
has been known that factors in sera can lead to the agglutination of bacteria in vivo and the 
protective capacities of serotype specific anti-pneumococcal sera have been correlated with its 
capacity to cause pneumococcal agglutination (Bull, 1915c, Bull, 1915a). Serotype-specific anti-
capsular IgG can induce pneumococcal agglutination in vitro (Dalia and Weiser, 2011). Agglutination 
results in pneumococci more sensitive to complement deposition and complement dependent 
phagocytic killing correlates with the degree of antibody-mediated pneumococcal agglutination. A 
novel mechanism of protection by antibodies to the S. pneumoniae capsular polysaccharide has 
been described; binding of polysaccharide specific antibodies increased the transformation 
frequency of cultures of S. pneumoniae, resulting in competence induced bacterial killing (Yano et 
al., 2011).     
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1.4.3.4.2 Antibodies to S. pneumoniae proteins  
 
Antibodies to specific protein targets of S. pneumoniae can passively protect against invasive 
disease. Monoclonal antibodies to PspA mediate protection following IV or IP challenge with S. 
pneumoniae (Briles et al., 1989) and monoclonal antibodies raised against protease-sensitive 
antigens of S. pneumoniae protected mice from invasive disease (McDaniel et al., 1984). 
Immunisation of mice with recombinant pneumococcal proteins induces specific antibody responses 
(Jomaa et al., 2005, Green et al., 2005). Sera from mice immunised with a number of different S. 
pneumoniae surface proteins mediates enhanced opsonophagocytosis of S. pneumoniae in vitro 
(Jomaa et al., 2005, Harfouche et al., 2012).  Passive transfer of sera containing antibodies to a range 
of pneumococcal proteins induced by colonisation protected mice from invasive S. pneumoniae 
challenge (Cohen et al., 2011). Subcutaneous immunisation with purified S. pneumoniae PspA and 
PdB (a detoxified derivative of pneumolysin) protected against infection with an S. pneumoniae 19F 
strain (EF3030) that remained within lungs, and protection was associated with the induction of IgG 
against these protein antigens (Briles et al., 2003). Sera form older human subjects has reduced 
antibody  titres to both the S. pneumoniae capsular polysaccharide and the S. pneumoniae protein 
antigens CbpA, LytC, PhtD (Simell et al., 2008), and aged sera displays reduced opsonophagocytosis 
of S. pneumoniae in vitro (Simell et al., 2011). Plasma from diabetic patients may be deficient in anti-
PspA antibodies, compared to controls, and  sera from these patients demonstrated impaired 
phagocytosis of a ST14 S. pneumoniae associated with reduced complement deposition (Mathews et 
al., 2012). Antibodies may also neutralise the function of S. pneumoniae virulence proteins. 
Antibodies to the pneumococcal cytotoxin pneumolysin may inhibit its function and are protective in 
models of pneumococcal lung infection (Salha et al., 2012, Briles et al., 2003). Antibodies to the 
pneumococcal proteins PhtD, PhtE PcpA and PsaA can block the adherence of S. pneumoniae to 
epithelial cells in vitro (Khan and Pichichero, 2012, Khan et al., 2012, Romero-Steiner et al., 2003).   
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1.4.4 Development of cellular immunity to S. pneumoniae  
 
1.4.4.1 CD4+ T-cells  
 
Antigen specific T-cells have a role to play in adaptive immunity to S. pneumoniae. CD4+ ‘T-helper’ 
cells can differentiate into a number of subsets (Th1, Th2, Th17, iTregs), defined by the range of 
cytokines they produce (Zhu et al., 2010). Differentiation of T-cells into distinct lineages involves the 
up-regulation of specific ‘master regulators’ of transcription, with the transcription factors T-bet, 
GATA3, RORyt and FOXP3 being expressed by Th1, Th2, Th17 and iTregs respectively (Zhu et al., 
2010).  Th1 cells are characterised by the expression of IFN-γ. Peripheral blood mononuclear cells 
(PBMCs) from isolated from humans are capable of producing IFN-γ following stimulation with 
pneumococcal antigen (Mureithi et al., 2009), and human monocytes promoted Th1 responses by 
CD4 cells (IFN-γ production) in response to stimulation with live pneumococci in vitro (Olliver et al., 
2011). However, IFN-γ receptor KO mice or mice treated with an IFN-γ neutralising antibody were 
better able to control pneumococcal infection than WT mice (Rijneveld et al., 2002) , suggesting that 
IFN-γ is not necessarily protective during S. pneumoniae pneumonia. Furthermore, IFN-γ production 
is responsible for the inhibition of host defence during secondary bacterial pneumonia following 
influenza infection (Sun and Metzger, 2008) .   
Th2 cells are important for directing B-cell responses to pathogens. This can occur through physical 
contact, for example, through CD40-CD40L interactions (Moens et al., 2008) and via the production 
of Th2 cytokines (IL-4, IL-5, IL-13) (Mosmann et al., 1986). T-cell help improves B-cell activation, 
increasing the affinity of immunoglobulin via the processes of somatic hyper-mutation and class 
switching. B-cell production of antibodies against the pneumococcal proteins PspC and Ply, is 
dependent upon the presence of CD4+ T-cells in vitro (Zhang et al., 2006a).  
Th17 CD4+ T-cells are defined by the production of IL-17 and IL-22, IL-23 has a role in the 
differentiation of T-cells into a Th17 phenotype (Rudner et al., 2007). Th17 cells are important in 
52 
 
mucosal host defence against extracellular pathogens, including S. pneumoniae. In murine models of 
colonisation acquired immunity to colonisation depended upon the development of Th17 cells 
(Zhang et al., 2009). IL-17 is able to act on epithelial cells, activating the production of CXC cytokines 
involved in neutrophil recruitment. IL-17 can stimulate the production of IL-8 (CXCL8) in cultures of 
human bronchial epithelial cells (Laan et al., 1999), and treatment with recombinant IL-17 induced a 
neutrophil influx into the airways of rats (Laan et al., 1999). IL-17 may also act on epithelial cells 
directly to increase the production of antimicrobial peptides, for example IL-17 can augment the 
production of β-defensin in cultured human airway epithelial cells (Kao et al., 2004).  IL-17 may also 
directly stimulate killing of S. pneumoniae by alveolar macrophages (Wright et al., 2013).   
Regulatory T-cells (Tregs) are characterised by the production of the inhibitory cytokines IL-10 and 
TGF-β, and have an immunosuppressive function (Vignali et al., 2008). The increased susceptibility to 
S. pneumoniae infection in the CBA/Ca mouse strain compared to BALB/c is due to reduced numbers 
of TGF-β expressing Tregs (Neill et al., 2012). Inhibition of TGF-β impaired the ability of BALB/c mice 
to resist IN infection with S. pneumoniae, whereas adoptive transfer of Tregs prolonged the survival 
of previously susceptible CBA/Ca mice (Neill et al., 2012), indicating an important role for these cells 
in protection from S. pneumoniae infection. Conversely however, IL-10 may abrogate immune 
responses that can protect against S. pneumoniae infection, and IN administration of recombinant 
IL-10 resulted in increased lung bacterial counts 40hrs following S. pneumoniae challenge in C57/BL6 
mice (van der Poll et al., 1996).  
CD4+ T-cells may contribute to the pathogenesis of invasive pneumococcal disease. MHC II deficient 
mice, displaying reduced numbers of CD4+ T-cells showed increased survival following IN infection 
with S. pneumoniae D39, associated with a reduced inflammatory response (Lemessurier et al., 
2010).  Inhibition of T-cell function with cyclosporine or antibody depletion produced a similar 
protective effect in this model (Lemessurier et al., 2010). 
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1.4.4.2 Role of γδ T-cells 
 
T-cells expressing γδ T-cell receptors (γδ T-cells), may have a role in protection from lung infection 
with S. pneumoniae. Following S. pneumoniae infection in mice numbers of γδ T-cells increase in the 
lungs (Kirby et al., 2007). γδ T-cells expressing the T-cell receptor variable gene segment Vγ4+ are 
enriched within the lung. TCR-Vγ4 KO mice display increased susceptibility to S. pneumoniae 
infection and reduced inflammatory responses, including a reduced neutrophil influx in response to 
challenge (Nakasone et al., 2007). Additionally, TCR-y KO mice displayed reduced levels of IL-17 
following primary S. pneumoniae infection (Ma et al., 2010).  
1.4.4.3 Role of CD8+ T-cells 
 
CD8+ cytotoxic T-cells are thought to be important in immunity to intracellular pathogens. CD8+ cells 
may also have a role in protection from S. pneumoniae infection. CD8 KO mice are more susceptible 
to primary infection with ST3 S. pneumoniae than their WT controls (Weber et al., 2011). However it 
is not clear if CD8+ T-cells have any role in the development of adaptive immunity to S. pneumoniae 
infection.  
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1.4.4.4 Cellular immunity to carriage 
 
Acquired immunity to pneumococcal carriage in mice is dependent upon IL-17 expressing CD4+ T-
cells (Th17) (Zhang et al., 2009, Lu et al., 2008). CD4+ cell depletion or IL-17A neutralisation 
prevented pneumococcal clearance in mouse models of carriage (Zhang et al., 2009). Protection 
from colonisation was associated with enhanced neutrophil recruitment in previously colonised 
mice. Neutrophil depletion abrogated the protective effect of previous colonisation, and IL-17A 
depletion reduced neutrophil recruitment into the nasopharynx. (Zhang et al., 2009).  Importantly 
acquired protection from colonisation still occurred in antibody deficient mice (McCool and Weiser, 
2004, Basset et al., 2007a), indicating that cellular rather than humoral immunity may be the 
predominant mechanism mediating acquired immunity to colonisation in murine models. In humans 
stimulation of PBMCs and adenoidal mononuclear cells in vitro with the S. pneumoniae antigens 
pneumolysin and CbpA led to proliferation of CD4+ T-cells and the release of IFN-γ and TNF-α (Zhang 
et al., 2007). CD4+ T-cell proliferation and cytokine release was higher in mononuclear cells from 
children without detectable nasopharyngeal carriage of S. pneumoniae, than those who were culture 
positive for S. pneumoniae (Zhang et al., 2007), suggesting a potentially protective role for these 
responses against carriage. Th17 type cytokine responses were not investigated in this study 
however polymorphisms in the IL-17A gene have separately been associated with higher levels of S. 
pneumoniae carriage in patients with bronchiolitis (Chen et al., 2010).  
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1.4.4.5 Cellular immunity to invasive S. pneumoniae  
 
In murine models of disease, experimentally colonised mice were protected from subsequent lung 
infection (Cohen et al., 2011, Richards et al., 2010). As previously discussed, this protection has been 
shown to depend  on the development of antibody responses and does not require CD4+ cells at the 
time of challenge (Cohen et al., 2011).  However, these models use S. pneumoniae D39, which 
rapidly invades into the blood, and does not necessarily allow an assessment of the protective 
immune responses specifically within the lung, which may involve the development of cellular 
immunity. T-cells accumulate in the lung following S. pneumoniae challenge in mice, and the entry of 
T-cells corresponded temporally with reduced bacterial numbers in the lungs post-infection 
(Kadioglu et al., 2000). Experimentally colonised mice have increased numbers of CD4+ cells and IL-
17 in their lungs following S. pneumoniae challenge (Richards et al., 2010, Cohen et al., 2011). Mice 
deficient in IL-23 production displayed increased susceptibility to S. pneumoniae challenge (Kim et 
al., 2013). Isolated lung mononuclear cells from mice deficient in IL-23 demonstrated reduced IL-17A 
and IFN-γ responses to heat killed S. pneumoniae upon stimulation ex vivo (Kim et al., 2013). 
Furthermore, morphine treated mice displayed increased susceptibility to S. pneumoniae lung 
infection which could be partially reversed by administration of recombinant IL-17 (Ma et al., 2010). 
Overexpression of IL-17 in the lung also resulted in enhanced neutrophil recruitment and improved 
bacterial clearance from the lung following Klebsiella pneumoniae challenge in mice (Ye et al., 2001).  
In models of experimental human carriage, experimental colonisation with S. pneumoniae 6B led to  
increased numbers of CD4+ T- cells expressing IL-17-A and TNF-α in BALF from colonised subjects 
(Wright et al., 2013). Additionally, the percentage of CD4+ T-cells expressing IL-17A or TNF-α when 
stimulated with pneumococci ex vivo, was increased in cells from BALF or blood of colonised 
individuals when compared to non-colonised controls (Wright et al., 2013).  In humans hospitalised 
with pneumococcal pneumonia higher numbers of IL-17A+ and IL-22A+ CD4 T-cells have been 
detected in lavage samples, compared to healthy controls (Paats et al., 2013), suggesting a role for 
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these cells in the immune responses to S. pneumoniae pneumonia.  These data indicate that Th17 
cells may have a role to play in protective immunity to S. pneumoniae within the lung. 
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1.5 Vaccines  
1.5.1 Serum therapy for S. pneumoniae 
 
In the late 19th century it was demonstrated that the serum from rabbits immunised with heat killed 
S. pneumoniae protected against subsequent infection with S. pneumoniae (Watson et al., 1993). 
Following this much work focussed on the development immune serum as a therapy for 
pneumococcal disease (Bull, 1915b, Young and Huntoon, 1926). A number of different preparation 
methods for anti-S. pneumoniae immune sera have been reported (Young and Huntoon, 1926, 
Bullowa and Wilcox, 1936), most involving the inoculation of live or dead pneumococci or 
pneumococcal polysaccharide into and animal, and collection of sera after the development of a 
humoral immune response. Treatment with immune sera resulted in the agglutination of S. 
pneumoniae both in vitro and in the blood of rabbits experimentally infected with S. pneumoniae 
(Bull, 1915a, Bull, 1915c). Such agglutination reactions were reported to only occur following 
treatment with type-specific (homologous) sera, failing to occur with heterologous sera raised 
against different S. pneumoniae serotypes. ‘Clumping’ of pneumococci in the sputum of pneumonia 
patients following serum therapy is reported to be related to their ability to recover from infection  
(Frisch, 1939). Serotype-specific pneumococcal antiserum was previously used in the treatment of 
lobar pneumonia. Treatment with immune sera reduced death rate of patients suffering from lobar 
pneumonia (Kyes, 1918), reduced the spread of S. pneumoniae within the lungs (Armstrong and 
Johnson, 1932), and improved survival of patients with bacteraemic pneumococcal pneumonia 
(Figure 1.6). Passive protection against S. pneumoniae with type-specific immune serum highlights 
the ability of antibodies against the pneumococcal polysaccharide capsule to protect against invasive 
disease. Demonstration that anti-CPS antibodies were induced following the administration of 
purified pneumococcal polysaccharide led to the development of purified polysaccharides as 
vaccines. (Felton et al., 1941, Finland and Ruegsegger, 1935). However due to the widespread use of 
antibiotics against S. pneumoniae it was not until the late 1970’s, following the work of R. Austrian, 
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that the first  polyvalent purified polysaccharide vaccines for S. pneumoniae were developed and 
licensed for widespread use (Austrian, 1977).  
 
 
Figure 1.6: Survival following antibiotic treatment and serum therapy for S. pneumoniae infection.  
Results from a 10-year study assessing survival of hospitalised patients with bacteraemic 
pneumococcal pneumonia treated with either; penicillin, pneumococcal antisera or untreated 
(Austrian and Gold, 1964). 
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1.5.2 Current vaccines  
 
There are currently two types of vaccine that offer protection against invasive pneumococcal 
disease; both are based on the polysaccharide capsule. A pneumococcal polysaccharide vaccine 
(PPV) consisting of the purified capsular polysaccharide of 23 serotypes has been in use since 1983. 
PPV is immunogenic and protective in immunocompetent adults (Cornu et al., 2001). Vaccines based 
on purified polysaccharides rely on the development of antibodies from B-cells without T-cell help 
(Defrance et al., 2011). Infants lack the ability to make T-independent antibody responses; therefore 
PPS is poorly immunogenic in this age group (Barrett, 1985). This lack of immunogenicity led to the 
development of pneumococcal conjugate vaccines (PCV). Pneumococcal conjugate vaccines consist 
of pneumococcal polysaccharide conjugated to a protein carrier. The first pneumococcal conjugate 
vaccine to be licensed for use in Europe, in 2001, was PCV-7 (Pebody et al., 2005). This vaccine 
consists of purified polysaccharide from 7 serotypes conjugated to a diphtheria toxoid carrier 
protein (Murray and Jackson, 2002). Conjugation to a carrier protein facilitates T-cell-B-cell 
interactions and subsequently the development of T-dependent antibodies against the capsular 
polysaccharide. Pneumococcal conjugate vaccines are immunogenic and protective in children 
against the serotypes included in the vaccine (Dominguez et al., 2011). 
Despite the success of both PPV and PCV in preventing pneumococcal disease, both vaccines have a 
number of limitations. Polysaccharide vaccines only protect against included serotypes. At the time 
of introduction PCV protected against serotypes responsible for up to 80% of invasive pneumococcal 
disease in the USA (Hausdorff et al., 2000b). However variation in the geographical distribution of 
serotypes means that the protection afforded by PCV-7 is not globally uniform, and the vaccine 
coverage is low in areas with a high burden of pneumococcal disease (Gordon et al., 2003). Another 
limitation of the current vaccines is the phenomenon of ‘serotype replacement’ (Guevara et al., 
2009), this term is used to describe the increase in the prevalence of non-vaccine serotypes 
following vaccine introduction. To help overcome the limitations of dissimilar serotype distribution 
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and serotype replacement, newer conjugate formulations containing polysaccharide of up to 13 
serotypes have been developed (Reinert et al., 2010). However, serotype replacement may also 
occur with serotypes not contained within these new vaccine formulations (Flasche et al., 2011). 
Pneumonia accounts for the highest burden of pneumococcal disease in adults, however PPV used in 
this age group is poorly protective against pneumonia without bacteraemia (Jackson et al., 2003, 
Dear et al., 2003).  As well as limitations in efficacy and serotype coverage, the cost of developing 
conjugate vaccines is high, limiting their use in developing countries. The limitations associated with 
capsular polysaccharide based vaccination have stimulated the investigation for vaccine strategies 
that may protect against all serotypes of S. pneumoniae. 
1.5.3 Prospective vaccines  
 
A number of new approaches to vaccination against S. pneumoniae have been considered, these 
include; killed whole cell, live recombinant and protein-subunit vaccines (Ferreira et al., 2011). Killed 
unencapsulated S. pneumoniae delivered IN is protective against invasive challenge with 
encapsulated S. pneumoniae in animal models (Malley et al., 2001). Attenuated Salmonella based 
vaccines expressing the pneumococcal protein PspA produce a serum antibody response and 
protected against pneumococcal challenge in mice (Kang et al., 2002).  Pneumococcal proteins or 
protein epitopes that are highly conserved across serotypes offer the possibility of developing cross-
protective vaccines. Since the protective immune response to S. pneumoniae is at least partly 
dependent upon the clearance of opsonised bacteria (Bogaert et al., 2004), the search for protein 
antigens has focussed on the identification of surface proteins, conserved across all pneumococcal 
serotypes. Antibodies to conserved surface antigens would be expected to opsonise all S. 
pneumoniae strains and thereby induce broadly protective responses.  Numerous pneumococcal 
proteins have been identified as possible vaccine candidates and shown to be protective in mouse 
models of disease. Antigens in development include, but are not limited to; the choline binding 
protein PspA, lipoproteins PsaA and Piu/Pia, histadine triad protein PhtD, detoxified pneumolysin 
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and the cell wall metabolism and cell signalling proteins PcsB and StkP (Ferreira et al., 2011). Phase I 
safety and immunogenicity trials in humans have demonstrated that the protein vaccine candidates 
PhtD and PlyD (a detoxified pneumolysin derivative) are safe and induce specific-IgG responses 
(Seiberling et al., 2012, Kamtchoua et al., 2012).  Although phase I trials are underway, none of these 
vaccine candidates have yet demonstrated protection against pneumococcal disease in humans. 
As well as vaccines aimed at developing protective antibody responses, vaccines capable of 
stimulating protective cellular responses to S. pneumoniae (in-particular Th17 responses) are also 
being developed. Screening an expression library of pneumococcal proteins has identified a number 
of antigens capable of inducing CD4+ T-cell dependent IL-17 responses that protected mice from 
experimental colonisation, and induced IL-17 production in isolated human in CD4+ T-cells (Moffitt 
et al., 2011). This approach has allowed the identification of a number of pneumococcal T-cell 
antigens (Moffitt et al., 2011). Interestingly the major S. pneumoniae protein antigens recognised by 
Th17 cells appear to differ from the major antigens associated with humoral immunity (Cohen et al., 
2011, Roche and Weiser, 2010, Richards et al., 2010).  
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1.6 Murine models of S. pneumoniae colonisation and lung infection 
 
Inoculation of S. pneumoniae into the nares of mice under light anaesthesia in a small volume (10μl) 
can result in nasopharyngeal colonisation without lung infection or bacteraemia (Wu et al., 1997, 
Cohen et al., 2011). In this model bacteria were not detectable in BALF of colonised mice 2 or 11 
days post-challenge with S. pneumoniae D39  (Cohen et al., 2011). Nasal colonisation with S. 
pneumoniae D39 in CBA/Ca can be cleared by 21 days post-inoculation (Cohen et al., 2011). IN 
inoculation of 1x105 CFU S. pneumoniae D39 into MF1 mice resulted in stable nasopharyngeal 
colonisation, detectable for up to 28 days post-inoculation (Richards et al., 2010). MF1 mice 
colonised with an isogenic pneumolysin deficient mutant of D39 (PLN-A) clear bacteria from the 
nasopharynx after 14 days (Richards et al., 2010). Both WT D39 and a D39 PLN-A strain induced 
polysaccharide-specific IgM responses and IgG to PspA, in the sera of colonised mice. Mice colonised 
with D39 PLN-A were protected against a subsequent IN lung infection with 1x106 CFU WT D39, 28 
days after initial colonisation (Richards et al., 2010). Mice colonised with WT D39 were protected 
from subsequent IN infection with 1x107 CFU of D39 (Cohen et al., 2011). In this challenge model S. 
pneumoniae was detectable in the blood by 9hrs post-infection, and previous colonisation 
completely protected against bacteraemia. Previously colonised mice also displayed reduced CFU in 
the lungs post-challenge with S. pneumoniae D39, although this effect was more modest. 
Importantly protection in this model of disease depended upon the development of antibody, as no 
protection was seen in B-cell deficient (μMT) mice (Cohen et al., 2011). An unencapsulated mutant 
of S. pneumoniae TIGR4 was detectable in the nares of mice 9 days following experimental 
colonisation and resulted in the development of S. pneumoniae specific antibody responses (Roche 
et al., 2007). Colonisation with an unencapsulated mutant of S. pneumoniae TIGR4 improved survival 
following subsequent IN infection with serotype 6A S. pneumoniae (Roche et al., 2007). In another 
model of lung infection, sera from humans experimentally colonised with S. pneumoniae 6B 
passively protected mice from IN challenge with 1x106 CFU of S. pneumoniae D39 (Ferreira et al., 
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2013). In this model bacterial numbers were significantly reduced in the blood of mice treated with 
sera from colonised individuals, with a more modest effect on bacterial numbers in the lungs. A 
number of different bacteria can inhabit the upper respiratory tract, and the nasopharyngeal 
microbiome may have an effect on immune responses to S. pneumoniae colonisation. For example,  
it has been demonstrated that Haemophilus influenzae can outcompete S. pneumonie within the 
murine nasopharynx (Lysenko et al., 2005). Additionally the nasopharynx of children colonised with 
S. pneumoniae is often co-colonised with Staphylococcus aureus, to which individuals develop 
antibody responses (Lebon et al., 2011). 
As previously discussed, current understanding of the mechanisms of protection from S. pneumoniae 
lung infection following colonisation are based on challenge with strains that rapidly invade into the 
blood following IN administration. S. pneumoniae D39 is detectable in the blood 9hrs following IN 
challenge with 1x107 CFU(Cohen et al., 2011). Due to this rapid invasion it is not easy to interrogate 
the immune responses that may protect specifically within the lung, independent of protection from 
bacteraemia. A number of strains of S. pneumoniae have been used in murine models of primary S. 
pneumoniae lung infection (Chiavolini et al., 2008). The relative invasiveness of strains following IN 
infection may vary depending on both strain background and capsular serotype (Kelly et al., 1994). S. 
pneumoniae EF3030 does not invade into the blood following IN challenge. Infection of CBA/N mice 
with 1x106.8 CFU of S. pneumoniae EF3030 (serotype 19F) resulted in established pneumococcal 
disease within the lung (Briles et al., 2003). Bacteria were detectable in the lungs and BALF of mice 5 
days following EF3030 challenge, but no bacteria are recovered from the blood. In this model of 
disease immunisation with purified pneumococcal proteins (PspA and PdB) induced an IgG response 
and protected against EF3030 lung challenge. Protection from lung infection in this model therefore 
appears to be as a result of direct protection within the lung, rather than indirectly thorough 
protection against bacteraemia.  Intratracheal infection of BALB/c mice with 3x107 CFU of S. 
pneumoniae EF3030 similarly led to established pneumococcal disease within the lung, with bacteria 
detectable 3 days following challenge and 60% mortality at this time point (Winter et al., 2007). It 
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may therefore be possible to use EF3030 as a model of non-invasive pneumonia, to interrogate the 
mechanisms of protective immunity in the lung following colonisation. Mice challenged IN with 
1x107 CFU EF3030 had detectable bacteria in nasal washes at least 20 days following challenge 
(Briles et al., 2003), and IN inoculation of CBA/N mice with 1x107 CFU of a serotype 19 strain of S. 
pneumoniae (L82013), resulted in colonisation that is detectable in the nares 7 days post-challenge 
(Wu et al., 1997). Therefore as well as causing non-invasive lung infection EF3030 may also be used 
to experimentally colonise mice. 
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1.7 Summary 
 
S. pneumoniae exists both as an asymptomatic commensal colonising the nasopharynx and as a 
cause of severe invasive disease. Nasopharyngeal colonisation with S. pneumoniae leads to a 
prolonged interaction with the immune system of the host. This interaction is likely to be important 
for the development of natural immunity that may protect the host from subsequent invasive 
disease. However, the mechanisms of naturally-acquired immunity to S. pneumoniae are not fully 
defined. Pooled human intravenous immunoglobulin (pooled IgG) preparations used to treat 
individuals with hypogammaglobunemia can partially reverse the risk of respiratory tract infections, 
suggesting an important role for IgG in protection from S. pneumoniae lung infection. However the 
target antigens of naturally-acquired IgG and the mechanisms by which it may protect against S. 
pneumoniae infection are not well described.  
There are some data that suggest individuals may acquire antibodies to either capsular 
polysaccharide or surface proteins of S. pneumoniae following nasopharyngeal colonisation. 
Epidemiological data demonstrate a parallel decrease in the incidence of invasive disease with 
increasing age in children across all S. pneumoniae serotypes. This suggests the development of a 
common rather than serotype-specific mechanism of immunity, contradicting the assumption that 
naturally-acquired immunity to S. pneumoniae is dependent upon the development of serotype-
specific antibody to the pneumococcal capsular polysaccharide. Further, murine models of 
colonisation indicate that the development of antibody to non-capsular targets may be important in 
protection from future invasive disease.  
There is therefore a need to understand the major targets of naturally-acquired IgG against S. 
pneumoniae in humans, and to investigate the relative importance of naturally-acquired antibody to 
the capsular polysaccharide or non-capsular targets in protection from invasive S. pneumoniae 
infection. Investigating the S. pneumoniae antibody targets in human sera may be important for the 
rational design of vaccines aimed at preventing lung infection with S. pneumoniae. Additionally, 
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insights into the mechanisms of naturally-acquired immunity to S. pneumoniae may help in 
understanding the increased risk of S. pneumoniae infection in certain patient groups. 
The anti-S. pneumoniae antibody repertoire in healthy adults will reflect the antibodies acquired 
during colonisation with S. pneumoniae. Similarly IVIG pooled from >1000 adult donors will reflect 
the naturally-acquired antibody responses within a population that may be protective against S. 
pneumoniae lung infection. Understanding the functionally important S. pneumoniae target antigens 
for IVIG and the mechanisms by which IgG may protect against lung infection will provide new 
insight into the natural development of protective immunity against S. pneumoniae lung infection. 
Additionally, exploring the major antigen targets in pooled and individual sera from different 
geographical locations would allow the effects of location and associated changes in pneumococcal 
ecology on the development of humoral immunity to S. pneumoniae to be investigated. 
In addition to the development of humoral immunity, colonisation with S. pneumoniae also induces 
a cell-mediated immune response, and cell-mediated Th17 responses are required for protection 
from re-colonisation. Models of lung infection following colonisation have used highly invasive 
strains of S. pneumoniae that rapidly progress to bacteraemia. In these models antibodies provide 
protection from the rapid onset of sepsis. However the mechanisms of acquired immunity that 
protect against S. pneumoniae infection within the lung in the absence of bacteraemia are not 
clearly defined. Developing a model of S. pneumoniae colonisation and lung challenge, with an S. 
pneumoniae serotype that does not invade into the blood would allow assessment the mechanisms 
of acquired immunity following colonisation which may be protective against S. pneumoniae 
pneumonia specifically within the lung. Non-bacteraemic pneumonia represents the largest burden 
of pneumococcal disease. It is therefore important to understand the mechanisms of naturally-
acquired immunity, in order to better develop vaccines that may protect against S. pneumoniae 
within the lung.   
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1.8 Aims of thesis  
 
1.8.1 General aim 
 
The aim of this thesis is to understand the naturally-acquired adaptive immune responses to S. 
pneumoniae, and to determine the mechanisms by which these immune responses are protective 
against S. pneumoniae lung infection.   
 
1.8.2 Specific aims 
 
1. To assess the immunodominant S. pneumoniae antigens targeted by naturally-acquired IgG in 
adult human sera and IVIG products.  
2. To assess the targets of naturally-acquired IgG across different populations and against different 
strains of S. pneumoniae.  
3. To investigate the functionally important antigen targets of naturally-acquired human IgG 
against S. pneumoniae. 
4. To determine the mechanism(s) by which naturally-acquired human IgG can protect against S. 
pneumoniae lung infection in a mouse model. 
5. To develop a murine model of non-bacteraemic pneumonia and colonisation. 
6. To assess the effect of prior colonisation on immune responses to non- bacteraemic lung 
infection with S. pneumoniae.  
7. To determine the mechanisms by which S. pneumoniae colonisation may protect against S. 
pneumoniae challenge within the lung.  
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2 Methods  
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2.1 Sources of sera and intravenous immunoglobulin  
2.1.1 Sera samples   
 
A number of different sources of sera were used in the experiments described.  Firstly, sera were 
obtained from the whole blood of healthy volunteers within the Centre for Inflammation and Tissue 
Repair at UCL who had not been vaccinated against S. pneumoniae. Whole blood (15ml) was allowed 
to coagulate for 1hr at room temperature, followed by centrifugation (4800rpm, 10min). The top 
layer of sera was removed and stored at -80 C until use.  
Sera, both pooled and individual were also obtained from a Malawian population through 
collaboration with Dr Stephen Gordon at the Liverpool School Tropical Medicine (LSTM). Sera were 
pooled from 20 HIV negative donors aged between 19 and 49 (mean: 29yrs, 16 male 4 female). 
Individual sera were obtained from 6 HIV negative donors aged between 21 and 36 (mean: 29yrs, 3 
male 3 female).  
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2.1.2 Intravenous immunoglobulin preparations 
 
 Five different commercially available IVIG preparations were used in this thesis and are summarised 
in Table 2.2. The IgG concentration in each of the products was calculated by nephelometry at the 
clinical pathology laboratory, Great Ormond Street Hospital. The distribution of IgG subclasses was 
available from the product data sheets.  Intratect from Biotest was used for in vivo experiments and 
functional studies, unless otherwise stated. The concentration of capsular polysaccharide specific 
IgG in Intratect was measured by multiplexed ELISA at Papworth Hospital, Cambridge (Table 2.1).The 
safety and efficacy in of Intratect in patients has been described previously (Kreuz et al., 2010).  
Table 2.1: Concentration of anti-polysaccharide IgG in IVIG (Intratect) used for in vitro and in vivo 
experiments in this thesis, measured by multiplexed ELISA.  
Serotype 1 4 5 6B 7F 9V 14 18C 19F 23F 
ng/ml  
IgG 
22.3 10.4 23.4 57.5 33.1 25.4 132.7 36.4 41 40.2 
 Manufacturer IgG g/L Sub-class distribution Geographical 
region sourced 
from 
Intratect  Biotest 46.6 IgG1    57%,           IgG2    37%,            
IgG3    3% ,           IgG4    3% 
Germany, 
Austria, 
Switzerland 
Pentaglobin  Biotest 41.2 IgG1     63%,         IgG2     26%,         
IgG3     4%,           IgG4      7% 
 
USA 
Vigam  BPL 51.2 IgG1      64%,            IgG2      29%,             
IgG3        6%,              IgG4        1% 
 
USA 
Gammaplex  BPL 43 IgG1       62%,       IgG2       31%,       
IgG3        6%,         IgG4        1% 
 
USA 
Flebogammadif  Grifols 58.1 IgG1      66.6%,     IgG2        28.5%,    
IgG3         2.7%,     IgG4          2.2% 
Germany 
Table 2.2: Summary of pooled IgG products (IVIG) used in this thesis, including the concentration of 
IgG in each and the population from which each product was sourced. 
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2.2 S. pneumoniae culture 
2.2.1 Bacterial strains and growth conditions   
 
S. pneumoniae was grown in Todd-Hewitt medium (THY, Oxoid, UK) containing 5% yeast extract, and 
on Colombia blood agar plates containing 5% defibrinated horse blood (TCS Biosciences, UK) at 37 C 
5% CO2. Growth in medium was assessed by measuring the Optical Density (OD) at 580
nm with a 
spectrophotometer (Amersham Pharmacia). Bacterial stocks were grown to mid-log phase (OD580nm 
0.4-0.5) before freezing in 10% glycerol at -80 C. Table 2.3 summarises the bacterial strains used 
throughout this thesis. S. pneumoniae TIGR4 is a well characterised laboratory strain of S. 
pneumoniae  that has previously been used in models of invasive lung infection and colonisation 
(Cohen et al., 2013). This strain was therefore used for in vivo and in vitro experiments to assess the 
role of antibody in protection from S. pneumoniae infection. The S. pneumoniae 19F strain EF3030 
does not progress quickly to bacteraemia (Briles et al., 2003) and was consequently used in 
experiments assessing protection against non-invasive pneumonia. EF3030 was a kind gift from 
Professor David Briles (University of Alabama), the S. mitis strains were kind gifts from Dr Fernanda 
Peterson (University of Oslo). S. pneumoniae mutant strains were selected based on their resistance 
to the relevant antibiotic (Table 2.3). Before each experiment antibiotic resistant strains were grown 
on blood agar plates containing Erythromycin (0.2µg/ml), Kanamycin (500µg/ml) or Chloramphenicol 
(4 µg/ml), as appropriate.  The absence of capsular polysaccharide from unencapsulated strains was 
confirmed by their morphology as ‘pinprick’ colonies on blood agar. 
2.2.2 Fluorescent labelling of S. pneumoniae   
 
S. pneumoniae was grown to OD 580 0.6-0.7 in 15mls THY followed by washing in bicarbonate buffer 
(0.1M NaHCO3), and re-suspension in 1ml bicarbonate buffer. 50µl 6-carboxyfluorescein succinimidyl 
ester (FAM-SE, Molecular Probes)  solution (10mg/ml in DMSO) was added to the suspension, before 
incubation for 1hr at 37 C,  5% CO2.The suspension was then washed in phosphate buffered saline 
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(PBS) until no free dye remained in the supernatant. Labelled stocks were frozen at -80  C in PBS + 
10% glycerol.  
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 Strain Serotype Mutation Phenotype Antibiotic 
resistance 
References 
S. pneumoniae  wild-
type strains 
TIGR4 4     
 D39 2     
 EF3030 19F    (Briles et al., 2003) 
 23F 23F     
 0100093 ST3      
S. pneumoniae mutants  D39ΔPspC 2 pspC Deletion of surface protein PspC  Erythromycin (Yuste et al., 2010) 
 D39ΔPspA  pspA Deletion of surface protein PspA Erythromycin  
 ST3ΔPpmA 2 ppmA Deletion of surface protein PpmA Trimethoprim  
 D39Δlgt 2 lgt Deletion of lipoproteins Chloramphenicol (Cohen et al., 2012) 
 D39ΔPhtD 2 phtD Deletion of surface protein PhtD   
 D39ΔPly 2   Erythromycin  
 D39ΔPiaA 2 piaA  Chloramphenicol (Brown et al., 2002a) 
 TIGR4Δcps 
(P1672) 
4 cps locus Unencapsulated Kanamycin (Trzcinski et al., 
2003) 
 D39ΔD 2 cpsD Unencapsulated Erythromycin (Morona et al., 2004) 
 ST3Δcps 3 cps locus Unencapsulated Kanamycin  
 23FΔcps 23F cps locus Unencapsulated Kanamycin  
 TIGR4Δpab 4 pabB deletion of PABA synthase Kanamycin (Chimalapati et al., 
2011) 
S. mitis strains S. mitis       
 S. mitisΔcps   cps locus Unencapsulated Kanamycin (Rukke et al., 2012) 
 S.mitisT4cps  cps locus S. mitis expressing capsule from S. 
pneumoniae TIGR4  
Kanamycin (Rukke et al., 2012) 
Table 2.3: Summary of the bacterial strains used throughout this thesis. 
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2.3 Serological assays 
2.3.1 Whole cell ELISA   
 
S. pneumoniae was inoculated into 20ml THY and grown until OD580 0.4-5. Bacteria were then 
washed twice in PBS and re-suspended (in PBS) to an OD580 of 1.0. 50µl of bacterial suspension was 
added per well to a 96-well plate (Maxisorb, Nunc) and left to coat overnight at 4 C. Plates were 
washed 4 times (to remove unbound bacteria) with 200µl wash buffer (PBS+ 0.05% tween). 100µl 
blocking buffer (PBS+0.05% tween+ 1% BSA) was then added per well, plates were incubated for 1hr 
at 37 C.  Test sera or pooled Immunoglobulins were serially diluted in dilution buffer (PBS+0.05% 
tween+ 1% BSA) and added to wells in duplicates (50µl per dilution); plates were then incubated for 
two hours at room temperature. After this incubation plates were washed 4 times and secondary 
antibody diluted 1:10,000 (Table 2.4) was added in dilution buffer (100µl per well). The plate was 
then incubated for two hours at room temperature before being washed 4 times in 200µl wash 
buffer. For alkaline phosphatase (AP) conjugated secondary antibodies substrate para-
nitrophenylphosphate (pNPP) (Sigma) was prepared in substrate buffer (1mg/ml), 100µl substrate 
was added per well. The plates were then incubated in the dark for 20min, after which 100µl 3N 
sodium hydroxide (NaOH) was added to each well to terminate the reaction. The absorbance was 
read at 405nm, subtracting readings at 630nm (Versamax). For Horseradish Peroxidase (HRP) 
conjugated secondary antibodies 100µl TMB substrate was added per well and the reaction stopped 
by the addition of 1M hydrochloric acid (HCL). The absorbance was read at 450nm subtracting 
readings at 550nm. For some experiments serial dilutions of sample were analysed and ELISA titre 
calculated. ELISA titre represents the theoretical sample dilution that would result in an OD of 0.1. 
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Antibody Conjugate Manufacturer 
Anti-human IgG HRP Biosource Int.  
Anti-mouse IgG AP Sigma 
Anti-mouse IgM AP Sigma 
Anti-mouse IgA AP Sigma 
 
Table 2.4: Antibodies used in whole cell ELISAs, including the conjugate and the manufacturer. 
 
2.3.2 Competition ELISA (Cell Wall Polysaccharide) 
 
Cell Wall Polysaccharide (CWPS) competition ELISAs were performed with pooled sera (1:800) or 
IVIG (1:10,000) diluted in ELISA dilution buffer and incubated for 30 min at 37 C in purified CWPS 
(Staten’s Serum Institut), CPS (Staten’s Serum Institut) or whole cell lysate (S. pneumoniae T4), at the 
following concentrations; 100, 10, 1, 0.1 and 0.01 µg/ml. A whole cell ELISA against S. pneumoniae 
TIGR4 (as described above) was then developed with the pre-incubated sera.   
2.3.3 Competition ELISA (protease-treated lysates) 
 
20µl of S. pneumoniae TIGR4 whole cell lysate (1500 µg/ml) was treated with the addition of 10µl 
trypsin (2.5mg/ml, Gibco, Invitrogen). As controls 20µl T4 lysate was treated with 10µl PBS and 20µl 
PBS treated with 10µl trypsin. Lysates were incubated overnight, before the addition of 10µl 25X 
complete protease inhibitor (Roche). Pooled sera were diluted to a final concentration of 1:3000 in 
ELISA dilution buffer. Lysate (or trypsin-treated PBS) was added to pooled sera in serial 10-fold 
dilutions from 1x10-4 to 1x102µg/ml. A whole cell ELISA of IgG binding to T4 was then performed (as 
described above).     
2.3.4 Purified protein ELISA   
 
Purified PspC (TIGR 4), SP1633 and SP1651 were a kind gift from Professor Tim Mitchell, University 
of Birmingham.  Pneumococcal proteins were diluted to 5µg/ml in coating buffer (3.03gNa2CO3, 
6.0g NaHCO3 in IL ddH2O); 50µl protein suspension was added per well to 96-well microtitre plate 
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(Maxisorb, NUNC).  Plates were coated overnight at 4 C , then washed  4 times with 200µl wash 
buffer (PBS+ 0.05% tween) per well. Plates were then blocked with 100µl blocking buffer for 1hr at 
37 C. Test sera was serially diluted in dilution buffer (PBS+0.05% tween+ 1% BSA), and added to 
wells in duplicates (50µl per dilution) before  incubation for 2hrs at room temperature. Plates were 
then washed 4 times and secondary antibody (anti-human IgG-alkaline phosphatase conjugate or 
anti-human IgM-alkaline phosphatase conjugate -1:10,000) added in dilution buffer, followed by 
incubation for two hours at room temperature. After incubation plates were washed 4 times in 
200µl of wash buffer. Substrate (pNPP) was prepared in substrate buffer to 1mg/ml, 100µl substrate 
was added per well. The plate was then incubated in the dark for 20min, after which 100µl NaOH 
(3N) was added to each well to terminate the reaction. The absorbance was read at 405nm, 
subtracting reading at 630nm (Versamax).  
2.3.5 Preparing whole cell lysates of S. pneumoniae 
 
S. pneumoniae was grown to mid-log phase in THY, 6mls of culture were pelleted by centrifugation 
at 13,000 rpm for 5min. Bacterial pellets were washed twice in PBS and re-suspended in 400µl PBS. 
Bacterial suspensions were sonicated on ice at output level 2, 50% cycle, for 2mins (probe sonicator, 
Branson S250). Samples were centrifuged for 5min at 13,000rpm to remove cell debris and the 
clarified supernatant recovered. The protein concentration of lysates was measured with the 
bicinchoninic acid (BCA) assay (Thermo Scientific, US). Briefly, 100µl BCA working solution was added 
to 5µg lysate in duplicates, absorbance at 562nm was measured (Versamax plate reader) and 
compared to a bovine serum albumin (BSA) standard prepared in PBS. Lysates were normalised to a 
total protein concentration of 1mg/ml. 
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2.3.6 Immunoblotting  
 
10µl lysate was added to 2.5µl loading dye (10% 1M DTT + 1X Laemelli buffer: 3.125 ml 1M tris HCl, 
1g Sodium dodecyl sulphate (SDS), 2ml glycerol, bromophenol blue (trace), made up to 10ml ddH2O).  
Samples were heated to 95 C for 5min before loading into polyacrylamide gels (10%). Proteins were 
separated by SDS-PAGE at 120mv for 2hrs (Novex mini-cell, Invitrogen, USA).The protein was then 
transferred onto a nitrocellulose membrane (GE healthcare) by semi-dry blotting at 20 mv for 1hr 
(Invitrogen, USA). Nitrocellulose membranes were blocked overnight in TBS + 0.1% tween (TBST) + 
5% milk powder. Nitrocellulose membranes were probed with; human serum (1:1000), IVIG (1:3300) 
in 5mls TBST+ 5% milk for 1hr rolling incubation at room temperature, followed by three washes in 
TBST for 15min each. Membranes were then probed with the secondary antibody; anti-Human IgG-
HRP conjugate (1:5000), diluted in TBST+5% milk, for 1hr at room temperature. Blots were 
developed with HRP substrate (GE healthcare) and imaged in the dark using hyperfilm (GE 
healthcare).    
2.3.7 Multiplex binding assay (Luminex)  
 
Multiplex (Luminex) bead assay of pneumococcal proteins. 18 recombinant pneumococcal proteins 
from a range of strain backgrounds were conjugated to seroMAP beads (Table 2.5). The coupling 
reaction has been described previously (Verkaik et al., 2009). In brief, 25µg of each recombinant 
protein was covalently attached to 5x106 microspheres (xMAP). The Luminex panel was then 
validated by comparing binding on a singleplex basis to multiplexed binding. For relative 
quantification of antibody levels in serum samples, mixtures of equal numbers of each bead type 
were made (1.1µl of each bead per well), in a final volume of 55µl per well (diluted in PBS+1% BSA). 
Assays were performed in 96 well plates. Human serum samples were diluted 1:1000 in PBS+1% 
BSA. Murine sera and BALF samples were diluted 1:100 and 1:1 respectively.  50µl bead mix was 
added per well, followed by 50µl diluted serum. Plates were then covered and incubated at room 
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temperature for 35min shaking at 800rpm. The buffer was then aspirated by suction, after which 
beads were washed twice (PBS+1% BSA). After washing beads were re-suspended in 50µl buffer. 
50µl secondary antibody (anti-human or anti-mouse IgG, conjugated to PE, 1:50) was then added per 
well. Plates were incubated for 35min at room temperature, shaking at 800rpm. Following 
incubation the buffer was aspirated from wells and beads were washed once (PBS+1%BSA) prior to 
reading. The fluorescence of each antigen-couple bead was measured using a Bio-Plex machine (Bio-
Rad).  
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Pneumococcal protein  Location Notes   Strain 
PhtD Pneumococcal histadine triad 
protein D   
CW Zinc binding protein  TIGR4 
PspC Pneumococcal surface protein C  CW Binds factor H  TIGR4 
Ply Pneumolysin  EX Number of roles in virulence 
(adhesion and lysis of host 
immune cells) 
TIGR4 
PsaA Pneumococcal surface adhesin A  M Component of the ABC 
transport system, which is 
involved in resistance to 
oxidative stress and transport 
of Mn2+ 
TIGR4 
PspA Pneumococcal surface protein A CW Inhibition of complement 
deposition binding of 
apolactoferrin 
TIGR4 
Hyal Hyaluronidase  CW Breaks down ECM 
components  
TIGR4 
PhtE Pneumococcal histadine triad 
protein E 
CW Metal binding protein  TIGR4 
PpmA Putative proteinase maturation 
protein A  
M Role in colonisation, 
adherence to epithelial cells.  
D39 
SP0189 Hypothetical protein     TIGR4 
IgA1ase IgA1 protease  CW Cleaves human IgA1  TIGR4 
CbpD Choline binding protein D  CW Competence induced cell lysis 
(fratricide) 
TIGR4 
SP1633  I Response regulator  TIGR4 
NanA Neuraminidase  CW Biofilm formation, 
endothelial invasion 
TIGR4 
SlrA Streptococcal lipoprotein 
rotamase A  
M Modulates biological function 
of virulence factors  
D39 
Eno Enolase  CW Binds to plasminogen  D39 
SP1651  I Thiol peroxidase  TIGR4 
SP0376  I Response regulator  TIGR4 
PilusA Pneumococcal pilus   Role in adhesion  TIGR4 
 
Table 2.5: Pneumococcal proteins conjugated to xMAP beads for Luminex assay, including the strain 
of S. pneumoniae from which each purified protein was isolated and their cellular location (CW=cell 
wall, EX=extracellular, M=membrane, I=intracellular,  (Lebon et al., 2011). 
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2.4 S. pneumoniae growth and agglutination 
2.4.1 S. pneumoniae growth assay 
 
1x106 CFU of S. pneumoniae were inoculated into Todd-Hewitt medium (THY, Oxoid, UK) containing 
5% yeast extract (Oxoid, UK). Growth of S. pneumoniae was assessed by measuing the OD580 of 
cultures incubated at 37 C 5% CO2 over an 8 hour period, using a spectrophotometer. Growth in the 
presence of 10% IVIG  (Intratect, 40mg/ml IgG) or PBS was assessed. Following 8 hour growth, 
cultures were methanol-fixed on to polylysine slides (VWR), and stained with rapid romanowsky 
staining (Diff-Quick). Stained S. pneumoniae were immaged with a light microscope (Olympus, BX40) 
using Qcapture pro software.   
2.4.2 S. pneumoniae agglutination assay 
 
To directly assess agglutination, FAM-SE labelled S. pneumoniae were diluted in PBS to a 
concentration of 1x106 CFU/ml and incubated at 37°C for 1 hr with 0%, 1%, 5%, 10%, IVIG (Intratect) 
in a volume of 100µl. Following incubation bacteria were fixed by the addtion of 100µl neutral 
buffered formallin. Bacteria were identified as a fluorescent (FL-1) positive population by flow-
cytometrey and particle size was asessed as a change in forward-scatter (FSC). Analysis of cells was 
performed on a FACSCalibur flow-cytometer using CellQuest and FlowJo software (BD Bioscience, 
UK).  
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2.5 Surface targets of IgG 
 
2.5.1 IgG deposition on surface of S. pneumoniae 
 
IgG binding to the surface of S. pneumoniae was assessed by flow-cytometry. 5x105 CFU of S. 
pneumoniae were washed in PBS and incubated with varying concentrations of IVIG diluted in PBS, 
at room temperature for 30min. Bacteria were then washed twice in PBS and incubated with anti-
human IgG secondary antibody (1:200), conjugated to PE (Sigma-Aldrich) at 4 C for 20mins. Finally 
bacteria were washed twice in PBS to remove unbound secondary antibody and fixed in 4% PFA. 
FACS analysis of bacterial cells was performed on the FACSCalibur, CellQuest and FlowJo software 
(BD Bioscience, UK). Gating of bacteria was based on FSC and SSC, and fluorescent controls 
incubated with no primary antibody.   
2.5.2 Protease shaving of S. pneumoniae 
 
 S. pneumoniae TIGR4Δpab (1x107 CFU) were washed in PBS and re-suspended in 500µl PBS with or 
without 100μg/ml of pronase (Roche). Bacteria were incubated for 20min at 37 C, shaking at 
150rpm. Following incubation 20µl of complete-mini protease inhibitor (25X, Roche) was added to 
each tube. Bacteria were then washed twice in PBS and re-suspended in PBS+10% glycerol. IgG 
binding to pronase treated TIGR4Δpab incubated in 1% IVIG or 10% polyclonal anti-type 4 rabbit 
serum (Staten’s Serum Institute, Pool A) was assessed as described above.   
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2.5.3 Absorption of IVIG (depletion of CPS-specific IgG) 
 
S. mitis expressing a TIGR4 capsule (S. mitisT4cps) was grown to OD580 0.4 washed in PBS and re-
suspended to OD 1.0 in PBS. 4mls of suspension was pelleted by centrifugation and re-suspended in 
1.8mls of IVIG (Intratect). The suspension was incubated for 1hr at 37 C, shaking at 100rpm. 
Following incubation the bacteria were removed by centrifugation and IVIG recovered. This was 
repeated once. Mock absorbed IVIG was prepared by following the absorption steps without the 
addition of bacteria.   
83 
 
2.6 Phagocytosis and killing assays 
2.6.1 Culture of murine macrophages  
 
RAW 264.7 macrophages were grown in Roswell Park Memorial Institute medium (RPMI, Invitrogen 
UK) supplemented with L-glutamine, Pen-strep (Invitrogen) and fetal calf serum (FCS, Lonza) (RPMI 
+++). Cells were passaged at 80% confluence. Cells were passaged by washing in PBS, followed by 
gentle scraping to re-suspend the cells. The cell suspension was then centrifuged (300xg, 5min), and 
the pellet re-suspended in RPMI+++ and transferred to a cell culture flask (T175) in a final volume of 
25ml.    
2.6.2 Macrophage opsonophagocytosis assay  
 
RAW 264.7 cells were harvested by gentle scraping, then centrifuged at 300xg for 5mins and re-
suspended in RPMI without supplements (RPMI---). Cells were counted with trypan blue on a 
haemocytometer and diluted to 5x105cells/ml in RPMI (---). 400µl of the cell suspension was added 
per well to a 24 well plate, followed by 200µl RPMI --- per well. Cells were incubated for 1-3hrs at 
37 C, 5% CO2 to allow adherence.  1.4x10
7 FAM-SE labelled bacteria were opsonised with 25%  
pooled sera, 10% IVIG, or RPMI alone in a final volume of 400µl RPMI ---, for 30min at 37 C. 
Opsonised bacteria were then suspended in 1.4 ml RPMI (final volume) and 200µl added to each well 
as required (MOI 10). After addition of FAM-SE labelled bacteria, plates were centrifuged at 
1800rpm for 3mins before incubation at 37 C in 5% CO2. After 45mins the medium was removed 
and cells were washed twice in PBS. 300µl trypsin was then added per well, and plates incubated for 
7 min at 37 C. The cells were re-suspended by gentle scraping. 50µl FBS added to quench the 
trypsin, then 100µl 3% paraformaldehyde (PFA) added to each well to fix the cells. The plates were 
kept in the dark at 4 C before analysis using a FACSCalibur, and CellQuest and Flowjo software (BD 
Bioscience, UK). Gates were based on dot plots of uninfected controls. Fluorescence was detected in 
FL-1 and mean fluorescent intensity (MFI) of macrophages used as a measure of bacterial uptake.  
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2.6.3 Neutrophil Isolation 
 
Granulocytes were isolated from heparinised whole blood by dual layer Histopaque separation using 
Histopaque 1077 and 1119 (Sigma-Aldrich, UK). Briefly, 3ml histopaque 1077 was carefully layered 
on top of 3ml histopaque 1119 in a 15ml centrifuge tube. 6ml heparinised whole blood was carefully 
layered on top. Tubes were then centrifuged (25min 700xg, brakes off). The granulocytes were 
recovered from a layer above the red cell-debris, washed twice in PBS to remove platelets, and re-
suspended in RPMI ---. Cell numbers were counted on a standard haemocytometer following trypan 
blue staining to exclude dead cells.  
2.6.4 Neutrophil phagocytosis assays 
 
Isolated human neutrophils were washed in PBS and re-suspended in Hanks buffered salt solution 
with calcium and magnesium to a concentration of 1x106cells/ml, 100μl of this suspension was 
added to wells of a 96-well plate. FAM-SE labelled S. pneumoniae were opsonised for 30min at 37 C 
in different concentrations of IVIG. 2x106CFU of FAM-SE labelled S. pneumoniae were added per 
well, in a volume of 25μl (MOI 20). Neutrophils were co-incubated with bacteria for 30min at 37 C 
then fixed by the addition of 100μl PFA. Cells were analysed on a FACSCalibur, CellQuest and Flowjo 
software (BD Bioscience, UK), as described above for macrophage phagocytosis assays.  
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2.6.5 Neutrophil killing assays  
 
S. pneumoniae were opsonised in PBS with and without 10% IVIG, for 30min at 37 C, shaking at 
150rpm. 400 CFU were added per well to a 96 well plate, followed by the addition of 1x105 
neutrophils in 100µl of Hanks buffered salt solution (HBSS) with calcium and magnesium. The plates 
were incubated for 45mins at 37 C, 150rpm. After 45mins well contents were diluted and plated 
onto blood agar plates for CFU enumeration, after overnight incubation at 37 C and 5% CO2. 
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2.7 In vivo experiments 
2.7.1 Animals 
 
All in vivo experiments were performed in mice at the biological services unit, UCL. For adoptive 
transfer experiments (presented in chapter 5) for which no mutant mice were required, experiments 
were performed on outbred CD1 mice. For experiments assessing the protective immune response 
to colonisation (presented in chapter 6), experiments were performed on inbred C57/BL6 mice, to 
match the genetic background of antibody deficient (μMT) mice.   
Table 2.6 gives an overview of the different mouse strains used throughout this thesis. 
Table 2.6: Strains and suppliers of mice used for in vivo experiments throughout this thesis. 
 
2.7.2 Murine pneumonia challenge model  
 
C57/BL6 or CD1 mice were anesthetised with aerosolised halothane (Vet-Tech) (4%) and challenged 
via IN installation of S. pneumoniae, suspended in 50μl of PBS.  At designated time points post-
infection mice were anaesthetised with pentobarbitol and culled by severing the femoral artery. 
Blood was collected into heparinised tubes (Sigma-Aldrich) to prevent clotting. In some experiments 
blood was also collected into non-heparinised tubes and allowed to clot, to obtain sera by 
centrifugation for 5min at 13,000 rpm. To perform bronchoalveolar lavages (BAL) an incision in the 
diaphragm was made to allow lung expansion, followed by a small (1mm) incision in the trachea, 
Strain  Age (weeks) Source/Supplier Short Description 
CD1 6-8 Harlan Outbred  
C57/BL6 6-8 Harlan  Inbred  
μMT (C57/BL6)  8-10 Provided by Dr Clare Notley 
UCL. (JAX ) 
μMT mice contain a 
mutation in the IgM 
heavy chain; 
therefore do not 
produce mature B-
Cells or antibody.  
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into which a 20-gauge cannula was passed. 1ml PBS was injected through the cannula and aspirated 
repeatedly for a total of three times. Lungs or spleens were harvested into 500μl of sterile PBS and 
homogenised by passing through a 40µM filter in 3mls PBS. CFU in lung homogenates, BALF and 
blood were counted by serial dilution in PBS and plating on blood agar plates. Total cell numbers in 
BALF were enumerated with a standard haemocytometer after trypan blue staining (Sigma-Aldrich). 
100µl BALF was spun on to polysine microscope slides (Shandon Cytopsin) and stained by rapid 
Romanowsky staining (Diff-quick, Thermo Scientific), for differential cell counts under a light 
microscope (Zeiss).  Supernatants of lung homogenates, BALF and sera were stored at -80οC for 
cytokine measurement.     
2.7.3 Murine colonisation model 
 
C57/BL6 or CD1 mice were anesthetised with aerosolised isoflurane (4%) (MiniRad) and challenged 
via IN instillation of S. pneumoniae suspended in 10μl of PBS.  At designated time points post-
infection the nares were washed with 400µl PBS. S. pneumoniae CFU in nasal washings were 
enumerated by plating onto blood agar, and blood agar containing optochin (100μg/ml, Sigma-
Aldrich). S. pneumoniae was discriminated from other bacteria that may colonise the murine 
nasopharynx by alpha-haemolysis and optochin sensitivity.   
2.7.4 Pre-colonisation and pneumonia challenge  
 
Mice were colonised with 1x107 CFU S. pneumoniae or PBS as control. 30 days following colonisation 
mice were challenged with 1x107 CFU as described. At designated time points post-infection lungs, 
BALF, blood and sera were collected as described.  
2.7.5 IVIG treatment model 
 
Mice were pre-treated with IVIG prior to pneumonia challenge. 13mg IVIG (Intratect) was 
administered as two separate IP injections, 3hrs prior to and immediately before pneumonia 
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challenge or colonisation. Human IgG concentration in the sera, BALF and nasal washings of treated 
mice was quantified by ELISA (Cambridge Bioscience).  
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2.7.6 Passive transfer of immune sera 
 
CD1 mice were vaccinated by IP administration of 5x104 CFU of S. pneumoniae TIGR4Δpab, in a 
volume of 100µl. Mice were re-vaccinated after a week. 28 days following the first vaccination mice 
were culled with a lethal dose of pentobarbitol and blood collected from the femoral artery to 
obtain sera for measuring antibody responses. Immune serum from mice vaccinated with 
TIGR4Δpab was transferred into naïve CD1 mice by IP injection. 400µl of sera was administered as 
two separate IP inoculations 6hrs apart. 24hrs following transfer mice BALF was collected, nasal 
washes performed and serum collected.   
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2.7.7 Cellular and cytokine depletion  
 
To deplete ly6G+ neutrophils, 600µg anti-ly6G mAb (1A8, BioxCell) was administered by IP injection 
24hrs prior to challenge in a volume of 200µl. Neutrophil depletion was confirmed by counting cells 
in the BALF following challenge. To deplete CD4+ T-cells cells 250µg anti-CD4 mAb (GK 1.5, BioxCell) 
was administered by IP injection 48 and 24hrs prior to challenge. CD4+ T-cell depletion was 
confirmed by flow-cytometry as a reduction in CD4+ cells or a reduction in CD3+ CD8- cells in the 
spleens and lungs of mice. Depletion of splenic macrophages was achieved by  IV administration of 
100µl 5mg/ml liposomal clodronate (or PBS liposomes) as described previously (van Rooijen and van 
Nieuwmegen, 1984). Macrophage depletion was confirmed using flow-cytometry as a reduction in 
F4/80+ splenocytes. IL-17 was neutralised by IP administration of 100μg of anti-mouse IL-17A 
(BioXcell) 24hrs and immediately prior to challenge.  
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2.7.8 ELISAs on murine tissue 
 
The concentration of IL-17 in samples was measured using a Quantikine ELISA kit (R&D systems). 
50µl of sample or standard, diluted in 50µl assay diluent was added to wells pre-coated with capture 
antibody. Samples were incubated for 2hrs at room temperature, before wells were washed 4 times 
with wash buffer (PBS+0.01% tween). 100µl detection antibody, conjugated to HRP, was added to 
each well and incubated for 2hrs at room temperature. Plates were washed 4 times in washing 
buffer before the addition of TMB substrate. After 15min the reaction was stopped by the addition 
of Hydrochloric acid.  The colour change in each well was assessed by reading the OD at 450nm, with 
wavelength correction set at 550nm (Versamax). The cytokine concentration in samples was 
calculated from a standard curve plotting OD against standards of known concentration. 
Concentrations of TNF-α and IL-10 were assessed using a Duo Set ELISA (R&D systems). 96-well 
plates (Nunc, Maxisorb) were coated overnight with capture antibody. Wells were washed and 
blocked in PBS+1% BSA. After washing 100µl sample or and standard was added per well and the 
assay performed as described above for the Quantikine ELISA. IL-23 was measured using a CytoSet 
ELISA (Invitrogen), and KC using a KC ELISA set (Insight Biotechnology) following the same procedure.  
Albumin concentration was assessed using a murine albumin ELISA kit (Bethyl Laboratories). 96-well 
plates were coated overnight with capture antibody. Due to the sensitivity of the ELISA samples 
were diluted 1:10,000. 100µl of sample or standard was added per well and the assay performed as 
described above. The concentration of total human or mouse IgG in samples was also assessed by 
ELISA. Briefly, 96-well plates were coated overnight with the relevant capture antibody. Samples 
were diluted 1:100. 100µl of sample or standard was added per well and the assay performed as 
described above.  
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2.7.9 Histology of murine lung tissue 
 
Lungs from mice were collected into 4% PFA, in PBS and left to fix for 4hrs. Lungs were then 
incubated overnight in 15% sucrose then transferred to 70% ethanol for storage at 4 C until 
processing. Lungs were processed in paraffin wax overnight using an automated tissue-processor 
(Leica). Samples were then embedded into paraffin blocks. 3μm lung sections were prepared on a 
rotary microtome (Shandon), and mounted on to glass slides. Slides were stained with haematoxylin 
and eosin using a Tissue-Tek automated stainer (Sakura), then overlaid with a glass coverslip. Slides 
were imaged using a NanoZoomer digital pathology system (Hammatsu).   
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2.8 Analysis of murine cells by flow-cytometry 
2.8.1 Cell preparation and staining 
 
Murine lungs and spleens were collected into ice cold PBS and single cell preparations prepared by 
homogenisation though a 40μM filter. Red blood cells were lysed by re-suspension of cells in 5mls 
red blood cell lysis buffer for 5mins (Santa-Cruz Biotechnology). Cells were then washed in PBS and 
re-suspended in 1ml PBS. Cell numbers were determined by crystal violet staining and counting on a 
standard haemocytometer. 1x106 cells were added per wells to a 96-well plate. Plates were spun at 
1400rpm for 2min, to pellet and cells re-suspended in 50µl PBS+ 1% BSA. 50µl of specific antibodies 
(Table 2.7) diluted 1:50 in PBS+1% BSA were added to each well. For multiple antibody staining 
single stained controls and ‘fluorescent minus one’ (FMO) controls were included. Plates were 
incubated for 20min at 4C, and then washed twice in 200µl PBS, and the cells re-suspended in 100µl 
of 4% PFA. Plates were kept in the dark at 4C before analysis by flow-cytometry.         
2.8.2 Flow-cytometry lymphocytes (lungs) 
 
Lung or spleen cells were analysed on a FACSCalibur (BD) flow-cytometer, using CellQuest 
acquisition software and analysed using FlowJo software. At least 10,000 lymphocytes were acquired 
per sample on the basis of size (FSC) and granularity (SSC). Lymphocyte populations were identified 
by staining for CD4, CD8 and CD3 (Table 2.7). Gates were based on FMO controls of samples stained 
with all antibodies excluding the target of interest. Single stained controls were used to set 
compensation gates. Total lymphocyte numbers were calculated based on the percentage of each 
subset as a proportion of all cells in each sample.  
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2.8.3 Flow-cytometry macrophages (Spleen) 
 
Splenocytes were analysed on a FACSCalibur (BD) flow-cytometer, using CellQuest acquisition 
software and FlowJo analysis software. At least 10,000 individual cells were acquired per sample. 
Macrophages were identified by staining for F4/80 and gates based on unstained controls. Total 
macrophage numbers were calculated based on the percentage of F4/80 positive cells as a 
proportion of all splenocytes in each sample.    
 
 
Antibody Fluorochrome Supplier Clone FL channel 
Anti-mCD4 FITC BD Bioscience RM 4-5 1 
Anti-mCD3 PE E Bioscience 145-2c11 2 
Anti-mCD8 PerCP BD Bioscience 53-6.7 3 
Anti-F4/80 PE Caltag MF 48000 4 1 
 
Table 2.7: Antibodies used in this thesis for phenotyping of cells by flow-cytometry. 
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2.9 Statistics 
 
Data were presented as group means +/- standard deviation (SD). Student’s T-test was used to 
compare the mean of two groups, or analysis of variance (ANOVA) for comparison between multiple 
groups, with Bonferonni post-test to compare selected groups. Parametric tests were used for in 
vivo experiments due to their greater sensitivity; this reduces the number of animals required for 
experimentation which is preferred for ethical and practical reasons. For depletion studies, where 
the absence of a difference indicates a biological effect the greater sensitivity of parametric tests is 
also favourable, as any true differences between groups should be identified. F-tests were 
performed to assess if the slope of linear regression lines were statistically different from 0. All 
statistical tests were performed using Graph Pad Prism statistical software.  
 
2.10 Ethics 
 
All sera samples from individuals at the Centre for Respiratory Research at UCL were obtained with 
ethical consent from UCL Research Ethics Committee (Ref: 3076/001). All Malawian sera and 
bronchoalveolar lavage samples were obtained with ethical consent from Liverpool School of 
Tropical Medicine (Ref: 00.54) and the University of Malawi (Ref: P.99/00/102). All animal 
experiments were approved by the UCL Biological Services Ethical Committee and the Home Office 
(UK) under project licence (PPL70/6510).    
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Results  
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3 Results (1): Serology  
 
Nasopharyngeal colonisation with S. pneumoniae is an immunising event that results in a host 
antibody (IgG) response. However, there remains some controversy over which S. pneumoniae 
antigens are dominant targets for this naturally-acquired IgG. Host and bacterial variation may also 
alter which antigens are dominant in different individuals and across populations. A number of in 
vitro assays were therefore performed to assess the dominant antigen targets recognised by IgG in 
different sources of adult human sera and pooled IVIG products.   
3.1.1 IgG to whole S. pneumoniae and purified capsular polysaccharide  
 
To assess the levels of IgG in sera from different Malawian individuals to whole pneumococci, a 
whole cell ELISA of IgG binding to 4 different strains of S. pneumoniae (ST4, ST14, ST9V, and ST1) was 
used. All sera contained detectable levels of IgG to each strain of S. pneumoniae with some variation 
in the extent of binding to different strains (Figure 3.1). There was also some variation in the extent 
of IgG binding to each S. pneumoniae strain between sera from different individuals (Figure 3.1). For 
example, sera ‘B’ demonstrated considerably greater binding to S. pneumoniae TIGR4, whereas sera 
‘F’ displayed the greatest binding to S. pneumoniae ST9V.    
The concentration of serotype-specific IgG to different pneumococcal polysaccharides in these 
individual Malawian sera was determined by multiplexed ELISA. Results indicated varying levels of 
IgG to a range of pneumococcal polysaccharides and between sera from different individuals for 
each specific serotype (Figure 3.1). Overall the highest responses were to type-14 polysaccharide.    
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A 
 
 
B
 
 
Figure 3.1: IgG binding in different human sera. 
(A) Whole cell ELISA IgG binding titre to S. pneumoniae serotypes 4, 14, 9V and 1 in individual 
Malawian sera (A-F) (B) Concentration of IgG to 13 different S. pneumoniae polysaccharide types in 
different individual Malawian sera, as assessed by multiplexed ELISA. (Bars represent mean, error 
bars represent SD). Multiplexed polysaccharide ELISAs were kindly performed at the Institute of 
Child Health, UCL by Polly Burbidge. Results in figure A are representative of two independent 
experiments, antibody quantification presented in figure B was performed once, in duplicate.  
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3.1.2 Correlation of anti-CPS IgG concentration and whole cell ELISA titre 
 
Different individual Malawian sera varied both in their binding to different S. pneumoniae serotypes 
by ELISA and their concentration of serotype-specific anti-capsular polysaccharide (CPS) antibody. 
Linear regression was performed to correlate serotype-specific anti-CPS IgG levels in different 
individual sera to the level of IgG binding to different S. pneumoniae serotypes (as determined by 
ELISA). This allowed assessment as to whether the concentration of serotype specific anti-capsular 
IgG in individual sera was the dominant determinant of IgG binding (Figure 3.2). Levels of anti-
serotype 4 CPS IgG failed to correlate with binding of individual sera to whole type-4 pneumococci 
(Figure 3.2), this persisted for IgG to anti-serotype14 or anti-serotype 9V polysaccharide. In contrast 
levels of IgG to the type-1 polysaccharide did correlate with IgG binding to whole ST1 pneumococci 
(Figure 3.2). These data suggest that with the exception of ST1, levels of IgG to specific capsular 
polysaccharides do not accurately predict the ability of IgG in different individual sera to bind to S. 
pneumoniae, by whole cell ELISA.  
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Figure 3.2: Correlation of anti-polysaccharide IgG with IgG binding to whole S. pneumoniae.  
(A-D)Whole cell ELISA IgG binding titre to S. pneumoniae serotypes 14, 1, 4 and 9V, compared with 
specific anti-capsular IgG concentrations in individual Malawian sera by linear regression. ELISA titres 
are representative of two independent experiments. 
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3.1.3 IgG binding to TIGR4Δcps (ELISA) 
 
Since levels of anti-CPS IgG broadly failed to correlate with IgG binding to whole pneumococci, the 
ability of different individual sera to bind to S. pneumoniae TIGR4 lacking the polysaccharide capsule 
(TIGR4Δcps) was investigated to assess if individual adult sera contained IgG to non-capsular 
antigens. In the absence of the polysaccharide capsule binding of IgG in different individual human 
sera to S. pneumoniae was maintained (Figure 3.3), demonstrating that IgG to the capsular 
polysaccharide of S. pneumoniae was not necessarily required for IgG binding to whole 
pneumococci, at least if assessed by whole cell ELISA.  
 
 
 
Figure 3.3: IgG binding to TIGR4Δcps.  
Whole cell ELISA IgG binding titre to S. pneumoniae TIGR4 and TIGR4Δcps in different individual 
Malawian sera. (Columns represent mean, error bars represent SD). Results are representative of 
two independent experiments.     
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3.1.4 Correlation of whole cell ELISA and anti-CWPS IgG concentration 
 
Another antigen of S. pneumoniae that may be an important target for IgG binding is the cell wall 
polysaccharide (CWPS). However, the concentration of IgG to the pneumococcal CWPS (measured 
by ELISA) in individual sera, failed to correlate with IgG binding of each serum to S. pneumoniae 
TIGR4 by whole cell ELISA (Figure 3.4). This indicates that anti-CWPS IgG in not a major determinant 
of naturally-acquired human IgG in human sera binding to S. pneumoniae, by ELSA.  
 
 
 
 
Figure 3.4: Correlation of anti-CWPS IgG and binding to whole S. pneumoniae 
Whole cell ELISA IgG binding titre to S. pneumoniae TIGR4 compared with anti-CWPS IgG binding 
titre, in individual Malawian sera compared by linear regression. Results are representative of two 
independent experiments. 
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3.1.5 Competition ELISAs 
 
Pooled sera and IVIG contain IgG representative of the population from which they are pooled. To 
directly assess the targets of IgG binding to S. pneumonia, in pooled adult sera and IVIG competition 
ELISAs were performed. This involved pre-incubation of IVIG or pooled sera in different 
pneumococcal antigens including; capsular polysaccharide, cell wall polysaccharide and whole cell 
lysates of S. pneumoniae. Pre-incubation of pooled sera with increasing concentrations of CWPS, 
failed to reduce binding of IgG to S. pneumoniae TIGR4, as measured by ELISA (Figure 3.5). Similarly 
incubation of IVIG in increasing concentrations of CWPS or purified type-4 or 19F polysaccharide 
failed to inhibit binding to S. pneumoniae TIGR4 and a serotype 19F strain respectively. In 
comparison binding was inhibited by pre-incubation of sera or IVIG in whole cell lysates of the 
respective serotype (TIGR4 or ST19F) (Figure 3.5). These data indicate that the CWPS or capsular 
polysaccharide of S. pneumoniae is not necessarily important for the observed binding of IgG in 
human sera or IVIG to whole pneumococci, as measured by ELISA.     
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Figure 3.5: Competition ELISAs IgG binding to S. pneumoniae.  
(A) IgG binding in pooled human sera to S. pneumoniae TIGR4 following pre-incubation in increasing 
concentrations of S. pneumoniae lysate or purified S. pneumoniae CWPS. (B) IgG binding in IVIG 
(Intratect) to S. pneumoniae TIGR4 following pre-incubation in increasing concentrations of whole S. 
pneumoniae lysate, purified S. pneumoniae CWPS or type-4CPS. (C) IVIG binding to S. pneumoniae 
19F following pre-incubation in whole cell lysate or type-19F CPS. (***= P < 0.001 representative of 
two way ANOVAs comparing change in OD following incubation in whole lysate versus CPS or CWPS, 
error bars represent SD). Results are representative of two independent experiments. 
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To investigate if IgG to pneumococcal proteins could be responsible for the observed binding to S. 
pneumoniae by whole cell ELISA, competition ELISAs were repeated. Pooled sera and IVIG were pre-
incubated in either whole cell lysates of S. pneumoniae TIGR4 or lysates treated with trypsin to 
digest pneumococcal proteins. Pre-incubation of sera or IVIG in whole cell lysates reduced IgG 
binding to TIGR4. Prior trypsin treatment of these lysates partially diminished this effect (Figure 3.6), 
though didn’t fully restore IgG binding  
Overall these whole cell ELISA data suggest that protein targets, rather than anti-CWPS IgG or anti-
CPS specific IgG, are at least partially responsible for IgG binding to S. pneumoniae in adult human 
sera and IVIG.  
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Figure 3.6: Competition ELISAs protease treated lysate.  
(A) IgG binding in IVIG (Intratect) to S. pneumoniae TIGR4, by whole cell ELISA, following pre-
incubation in different concentrations of whole S. pneumoniae lysates, with and without pre-
treatment of lysates with trypsin. (B) IgG binding in pooled sera to S. pneumoniae TIGR4, by whole 
cell ELISA, following pre-incubation in different concentrations of whole S. pneumoniae lysates, with 
and without pre-treatment of lysates with trypsin. (P values represent two-way ANOVAs with 
Bonferonni post-test to compare columns, error bars represent SD). Results are representative of 
two independent experiments. 
 
  
1.0 10.0 100.0
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
Lysate+trypsin
Lysate+PBS
Trypsin+PBS
P < 0.001 P < 0.001
[Lysates] (ug/ml)
A
n
ti
-T
IG
R
4
 I
g
G
O
D
 4
0
5
-6
3
0
1.0 10.0 100.0
0.0
0.1
0.2
0.3
0.4
P < 0.001
Lysate+trypsin
Lysate+ PBS
Trypsin+ PBS
P < 0.05
[Lysates] (ug/ml)
A
n
ti
-T
IG
R
4
 I
g
G
O
D
 4
0
5
-6
3
0
A 
B 
107 
 
3.1.6 Luminex assay  
 
The above data indicated that non-capsular antigens, including pneumococcal proteins are likely to 
be major targets for naturally-acquired IgG binding to S. pneumoniae. To assess the range of anti-
protein IgG targets in human sera and pooled immunoglobulin preparations, multiplex (Luminex) 
bead assays were performed. This involved simultaneous detection of antibody binding to 
recombinant pneumococcal proteins coated on to fluorescent (xMAP) beads. Binding was quantified 
by an increase in fluorescence, using an anti-human IgG secondary conjugated to PE. Importantly, 
this allowed a semi-quantitative analysis of antibody levels to a range of pneumococcal proteins in 
different sources of sera and IVIG. 
To confirm that the Luminex assay allowed a quantitative assessment of antibody binding, and to 
determine appropriate dilutions for subsequent assays, IgG binding in serially-diluted IVIG was 
assessed (Figure 3.7).  Binding of IgG to all proteins was concentration dependent, with a reduction 
in fluorescence intensity at increasing dilutions of IVIG (Figure 3.7). A dilution of 1:1000 represented 
a point with a large dynamic range of IgG binding to different purified proteins; this dilution (1:1000) 
was therefore used in subsequent experiments.  
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Figure 3.7: Dilution series of IgG binding to pneumococcal proteins.  
MFI of anti-human IgG binding to xMAP beads coated with different purified pneumococcal proteins, 
following incubation in increasing dilutions of IVIG (Intratect). The dashed line indicates the dilution 
(1:1000) used in subsequent assays.     
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The Luminex assay was used to assess the major protein antigen targets for IgG in different pooled 
IVIG preparations. Levels of IgG to pneumococcal protein antigens, in different sources of IVIG, 
appeared to show a consistent pattern of responses (Figure 3.8), with high levels of anti-PhtD and 
anti-PspC antibodies, intermediate responses to the proteins PspA, PsaA and Ply, slightly inferior 
responses to PpmA, PhtE, Hyal and Sp0189 and low or absent responses to all other proteins.  
The targets of anti-protein IgG in individual human sera, both from Malawi and the UK, were also 
assessed by Luminex. A similar general pattern of dominance was seen to the results for IVIG (Table 
3.1) with strong responses to PhtD, PspC, PspA, PsaA and PpmA. However there was significant 
variation in the level of IgG to certain pneumococcal protein antigens between sera from different 
individuals (Figure 3.8).  For example, sera ‘B’ and ‘F’ from Malawian individuals demonstrated 
markedly higher binding to PspC than the remaining 4 individual Malawian sera, and sera ‘B’ and ‘C’ 
had poorer responses to purified PsaA (Figure 3.8). 
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Figure 3.8: IgG binding to purified pneumococcal proteins.   
(A) Stacked bars representing MFI of IgG in five different IVIG preparations binding to purified S. 
pneumoniae proteins conjugated to fluorescent (xMAP) beads (Luminex).  (B) MFI of IgG in 6 
different individual sera (Malawi) binding to purified S. pneumoniae proteins (Luminex). (Error bars 
represent SD).  Results in Figure A and B are representative of one experiment, performed in 
duplicate. 
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        UK      Malawi    
 A B C D  A B C D E F 
PhtD 3 2 1 5  3 2 1 2 2 3 
PspC 6 3 4 1  1 1 2 3 3 2 
PspA 4 1 2 4  7 6 4 4 4 5 
PsaA 2 5 9 3  2 10 6 1 1 1 
Ply 8 4 3 7  6 5 3 5 5 4 
PpmA 1 7 10 2  5 3 13 7 7 6 
PhtE 7 8 6 6  4 4 5 8 8 8 
Hyal 5 10 5 11  9 8 7 6 6 7 
SP0189 11 11 8 12  12 11 8 13 13 10 
IgA1ase 14 6 7 9  8 7 11 9 9 9 
CbpD 9 9 13 8  11 9 14 10 10 13 
Eno 15 15 15 15  16 15 16 15 15 15 
SP1633 10 12 11 13  13 13 10 14 14 11 
SlrA 16 17 16 10  14 14 9 16 17 14 
NanA 12 13 12 14  10 12 12 11 12 12 
SP1651 16 17 14 17  18 17 17 18 18 18 
SP0376 13 16 16 16  17 18 15 17 16 17 
PilusA 16 14 16 17  15 16 18 12 11 16           
 
Table 3.1: Rank of IgG binding (MFI) to different purified protein antigens of S. pneumoniae (measured by Luminex) in individual sera from the UK or 
Malawi. The same ranking score was assigned if differences between proteins were less than blank controls.  
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3.1.7 Luminex assay validation  
 
To determine if the Luminex assay was reliable for the quantification of antibody responses to 
different pneumococcal proteins, antibody levels in individual Malawian sera to two of the purified 
pneumococcal proteins included on the Luminex panel (PspC, PsaA) were also assessed by ELISA. 
ELISA titres were then compared against MFI (Luminex) values for these proteins by linear regression 
(Figure 3.9). A strong correlation was seen between the two methods; where individual sera had a 
high MFI to PspC or PsaA by Luminex they also had a relatively high ELISA titre to that same protein 
(Figure 3.9). IgG binding in Malawian sera to the purified proteins SP1633 and SP1651 to which no 
antibody binding was detected by Luminex, was also assessed by ELISA, again low or absent IgG 
binding was detected to these proteins (Figure 3.9). In comparison IgG levels to PspC against which 
high responses were detected by Luminex, were also relatively high by ELISA (Figure 3.9). In addition 
to individual sera IgG binding in different IVIG preparations was also assessed by ELISA, and binding 
to PspC was higher than to PhtE when measured by both ELISA and Luminex (Figure 3.9). These data 
confirm that the Luminex assay appears as reliable as ELISAs for the quantification of antibody 
responses to different S. pneumoniae protein antigens.   
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Figure 3.9: Validation of Luminex assay.  
(A) Linear regression of IgG in different individual sera binding to purified PspC by ELISA (titre) 
compared to Luminex (MFI). (B) Linear regression of IgG in different individual sera binding to 
purified PsaA by ELISA (titre) compared to Luminex (MFI) (C). ELISA titre of IgG binding to purified 
pneumococcal proteins PspC, SP1633, SP1651 in different individual sera (Malawi). (D) Comparison 
of IgG binding in different IVIG products to purified PhtE and PspC by ELISA (OD 405-630) and 
Luminex (MFI). (P values represent F-test assessing difference of slope compared to zero, error bars 
represent SD).  Luminex and ELISA quantification was performed once, in duplicate. 
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3.1.8 Correlation between IgG to protein antigens and whole cell ELISA titre  
 
The Luminex assay provided a quantitative assessment of antibody responses to protein antigens in 
different individual sera. This allowed comparison between the quantity of IgG to pneumococcal 
protein antigens in different individual sera and IgG binding to whole S. pneumoniae as measured by 
whole cell ELISA. The IgG responses to all proteins on the Luminex system were summed for each 
individual Malawian serum sample; the cumulative anti-protein IgG response was then compared by 
linear regression to IgG binding to S. pneumoniae (as previously assessed by whole cell ELISA, Figure 
3.1). There was a good correlation between IgG levels to these pneumococcal proteins in a particular 
individuals sera and the level of IgG binding to S. pneumoniae TIGR4, ST14 and ST1 (Figure 3.10). 
ST9V demonstrated a similar trend, but this was not significant (Figure 3.10).  
These correlations could be due to differences in total IgG concentration between sera samples, 
rather than levels of pneumococcal-specific IgG. However, there was no correlation between 
Luminex measurements of IgG binding to S. pneumoniae protein antigens and total IgG 
concentration as measured by ELISA (Figure 3.10). Additionally, IgG binding to S. pneumoniae 
protein antigens did not correlate with binding to another streptococcus species S. pyogenes (Figure 
3.10).  
These data indicate that the quantity of IgG to specific   S. pneumoniae protein antigens may be 
important in determining IgG binding to whole S. pneumoniae, as measured by whole cell ELISA. 
Therefore S. pneumoniae proteins could be major targets of naturally-acquired IgG.  
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Figure 3.10: Correlation of anti-protein IgG with IgG binding to whole S. pneumoniae.  
(A-D) Linear regression of IgG binding to different serotypes of S. pneumoniae by whole cell ELISA 
compared to anti-protein IgG concentration in different individual sera (as assessed by Luminex). (E) 
Linear regression of total IgG concentration in each individual sera (quantified by ELISA) compared to 
cumulative anti-protein IgG (as assessed by Luminex). (F) Linear regression of IgG binding to S. 
pyogenes by whole cell ELISA compared to cumulative anti-protein IgG concentration in different 
individual sera (as assessed by Luminex). (P values represent F-test assessing difference of slope 
compared to zero). ELISA titres are representative of two independent experiments. 
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3.1.9 IgG protein targets in different geographical sources of sera and IVIG 
 
To determine if antibodies from distinct populations recognise a similar range of S. pneumoniae 
protein antigens, the range of pneumococcal protein targets for IgG binding in pooled sera or IVIG 
from 3 geographically distinct locations (Europe, USA, and Malawi) were compared. This was 
achieved by comparing the MFI for each protein obtained from the multiplex binding assays by 
linear regression (Figure3.11).  
There was a very strong correlation in the order of anti-protein antibody responses in IgG pooled 
from three populations (Figure3.11) with consistently high responses to PhtD, PspC and PsaA. 
Slightly more variation in the order of anti-protein antibody responses was seen when comparing 
pooled sera from Malawi, to IVIG products sourced from Europe or USA. This may be due to the 
greater number of donors that make up IVIG (N=>1000) which could reduce the variability of 
responses to protein antigens, compared to pooled Malawian sera, which was pooled from relatively 
few donors (N=20). 
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Figure3.11: IgG targets in different sources of pooled immunoglobulin.  
(A) Linear regression of IgG binding (MFI) to different purified S. pneumoniae protein antigens in IVIG 
pooled from a European population compared to IVIG pooled from USA. (B)  Linear regression of IgG 
binding (MFI) to different purified S. pneumoniae protein antigens in IVIG pooled from Europe or 
pooled Malawian sera (pooled from 20 donors). Luminex assays were performed once, in duplicate. 
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3.1.10 Identification of IgG protein targets by Western blot   
 
The Luminex assay assesses antibody responses to a pre-selected panel of protein antigens. 
Therefore Western blotting was used for an overall assessment of the potential number of protein 
targets for IgG in different sources of sera and IVIG. Probing lysates of the S. pneumoniae D39 strain 
with IVIG indicated responses to a number of different protein targets, identified as bands on 
immunoblots (Figure 3.12). Probing mutants S. pneumoniae D39 lacking known surface proteins 
allowed the identification of some of these protein targets, including PiaA, PspA, PspC and PhtD 
(Figure 3.12). Importantly (where included on the panel) the targets identified by Western blotting 
were also previously identified as immunodominant targets of IgG binding by Luminex.  
Immunoblots against lysates of different S. pneumoniae serotypes demonstrated a consistent 
pattern when probed with IVIG (Figure 3.12), though responses to certain protein were absent in 
some strains. This suggests, with some exceptions, the major protein targets of IVIG are generally 
conserved between strains of S. pneumoniae.  Immunoblots of S. pneumoniae TIGR4 probed with 
pooled IgG from different geographical locations (Europe, USA, and Malawi) demonstrated a similar 
pattern of responses (Figure 3.12). This supports data from the Luminex assay, indicating that IgG 
pooled from these different geographical locations recognises a consistent pattern of dominant 
pneumococcal protein antigens. 
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Figure 3.12: Targets of IgG in pooled sera binding by immunoblotting. 
(A) Immunoblots of deletion mutants of S. pneumoniae D39 lacking known surface proteins 
(indicated above lanes) probed with IVIG (Intratect). Red boxes highlight absent bands at correct 
molecular weight for deleted protein. (B)  Immunoblots of whole cell lysates of different S. 
pneumoniae serotypes probed with IVIG (red boxes indicate absent bands in certain serotypes). (C) 
Immunoblots of S. pneumoniae TIGR4 probed with different pooled sera (indicated above lanes). 
Western blots are representative of two independent experiments. 
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3.1.11 Pattern of IgG responses in individual sera by Western blot 
 
To comprehensively assess the range of protein antibody targets in different individual sera, 
immunoblots of lysates of S. pneumoniae D39 and TIGR4 were probed with sera from 6 individuals 
(from the UK). The pattern of responses was then compared.  There were broadly similar patterns of 
bands between different individual sera, probed against the same lysates (Figure 3.13), indicating 
that the dominant IgG responses to protein antigens were relatively consistent across different 
individual sera. However, for both D39 and TIGR4 there was some variation between individuals, 
with Western blots of sera from certain individuals having reduced intensity of bands at particular 
protein sizes. For example, against S. pneumoniae D39 sera ‘A’ and ‘B’ had low responses to a band 
at approximately 70KDa, and sera ‘C’ and ‘F’ had low responses to a band at approximately 35KDa in 
S. pneumoniae TIGR4. These data support the Luminex data for different individual sera, where the 
pattern of antigen dominance was broadly similar between all individuals, but selected sera 
demonstrated low or absent IgG responses to certain S. pneumoniae protein antigens.  
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Figure 3.13: Targets of IgG binding in individual sera by immunoblotting. 
(A) Immunoblots of whole cell lysates of S. pneumoniae D39 probed with different sera from UK 
individuals, developed with anti-human IgG. (B) Immunoblots of whole cell lysates of S. pneumoniae 
TIGR4 probed with different individual human sera, developed with anti-human IgG (Red boxes 
highlight areas of variation between individual sera).  Western blots are representative of two 
independent experiments. 
 
A 
B 
KDa 
KDa 
D39 
TIGR4 
122 
 
3.1.12 Anti-S. pneumoniae IgG in human lavage samples 
 
Adult human sera contain IgG to whole S. pneumoniae, as well as to a range of pneumococcal 
surface proteins. To determine if anti-pneumococcal IgG is present within the lung of adult humans, 
IgG binding in BALF from different Malawian individuals was investigated. BALF was obtained from 
volunteers in Malawi through collaboration with Dr Stephen Gordon (Liverpool School of Tropical 
Medicine). IgG binding to whole S. pneumoniae was assessed by whole cell ELISA. Due to limitations 
with sample quantity, titres were not calculated; instead ELISA data is represented as an OD. BALF 
samples contained IgG binding to whole S. pneumoniae TIGR4 by ELISA, with variation in the amount 
of anti-pneumococcal IgG binding between different individuals (Figure 3.14). The highest responses 
were comparable to pooled sera from the same population diluted 1:1000. However, as the process 
of collecting lavage fluid involves considerable dilution of the epithelial lining fluid, it is difficult to 
directly estimate the concentration of anti-pneumococcal IgG within the human lung.   
Due to limited quantities of the multiplex beads Luminex assays were not performed on these 
samples, however BALF IgG levels to the purified pneumococcal proteins PspC and PhtE was 
assessed by ELISA. BALF fluid contained detectable IgG to each of these proteins (Figure 3.14). 
Binding of IgG to whole S. pneumoniae by ELISA correlated with levels of IgG to either PspC or PhtE 
in different lavage samples.  There was no significant correlation between total IgG concentration in 
BALF and binding to S. pneumoniaeTIGR4 by whole cell ELISA (Figure 3.14). These data demonstrate 
that human BALF contains IgG to S. pneumoniae including to purified pneumococcal proteins, and 
the concentration of IgG to specific antigens may determine the binding of IgG in BALF to whole S. 
pneumoniae. The concentration of IgG to pneumococcal capsular polysaccharide was not assessed in 
these BALF samples.  
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Figure 3.14: Anti-S. pneumoniae IgG in human bronchoalveolar lavage fluid.  
(A) IgG binding in different BALF samples from 10 Malawian individuals to S. pneumoniae TIGR4 by 
whole cell ELISA (OD 450-550), alongside IgG binding in  pooled sera (Malawi). (B) Linear regression 
of IgG binding in different individual BALF samples to TIGR4 by whole cell ELISA compared to binding 
to purified PspC by ELISA. (C) Linear regression of IgG binding in different individual lavage samples 
to TIGR4 by whole cell ELISA compared to binding to purified PhtE by ELISA. (D) Linear regression of 
IgG binding in individual lavage samples to TIGR4 by whole cell ELISA compared to the concentration 
of total IgG in each sample. (Error bars represent SD, P values represent F-test assessing difference 
of slope compared to zero).   ELISA titres are representative of two independent experiments. 
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3.1.13 Chapter Summary  
 
The pneumococcal antigen targets for IgG in adult human sera and IVIG are likely to reflect those 
acquired following natural exposure to S. pneumoniae. Data presented in this chapter indicate that 
there is a range of different S. pneumoniae antigens for IgG, including protein and capsular 
polysaccharide antigen. The whole cell ELISA results indicate that S. pneumoniae proteins were an 
important target for anti-pneumococcal IgG binding, as the titres in different adult sera correlated 
with IgG titres to different S. pneumoniae proteins but not anti-capsular IgG concentration. 
Additionally, competition ELISAs indicated that IgG binding to S. pneumoniae was not inhibited by 
pneumococcal capsular or cell wall polysaccharide, hence these antigens are not necessarily the 
major targets of naturally-acquired IgG binding to S. pneumoniae, when assessed by a whole cell 
ELISA assay.   
Luminex assays and Western blots were used to identify potential protein targets for IgG in human 
sera. The results indicated a small subset of S. pneumoniae protein antigens including PhtD, PspC, 
PspA and PsaA that are targets for IgG binding which appear to be conserved across geographical 
sources of pooled IgG, and between different strains of S. pneumoniae. The number of unidentified 
bands on Western blots indicates that antigen targets for IgG binding likely also include other 
proteins that were not assessed here. Different individual sera also had IgG responses to a similar 
range of protein antigens but with some variation, with certain individuals having low or absent 
responses to protein antigens that were otherwise dominant in pooled sera/IVIG.  
These data suggest that S. pneumoniae proteins may be targets for IgG binding. However, thus far 
the functional relevance of IgG to S. pneumoniae protein antigens remains unclear. Data presented 
in this chapter demonstrate IgG binding to purified S. pneumoniae proteins and lysates, or to S. 
pneumoniae by whole cell ELSIA. It has recently been demonstrated that whole cell ELISAs do not 
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necessarily provide an accurate assessment of antibody binding to the surface of S. pneumoniae  
(Cohen et al., 2013), and therefore are not necessarily a good measure of functional antibody 
responses.  
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4 Results (2): Functional targets of naturally-acquired IgG  
 
In the previous chapter protein antigens were shown to be an important target for naturally-
acquired IgG that recognises S. pneumoniae. However, the functional importance of anti-protein IgG 
is not known. IgG binding to the surface of S. pneumoniae is likely to be functional, promoting 
protective mechanisms including bacterial agglutination, opsonisation and fixation of complement. 
In this chapter the contribution of protein antigen targets for naturally-acquired IgG dependent 
immunity was assessed, using a range of in vitro functional assays. 
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4.1.1 IgG binding to S. pneumoniae and S. pneumoniaeΔcps 
 
To assess the relative contribution of the S. pneumoniae polysaccharide capsule or sub-capsular 
antigens as targets for naturally-acquired human IgG, flow-cytometry based surface binding assays 
to whole bacteria were performed. Binding to TIGR4 and an unencapsulated derivative of TIGR4 
(TIGR4Δcps) following incubation in 1% or 10% IVIG was assessed (Figure 4.1). Significant IgG bound 
to both strains with increased IgG binding to the surface of unencapsulated bacteria. IgG surface 
binding assays were repeated in 1% IVIG with the S. pneumoniae D39, ST3 and ST23F strains (Figure 
4.1), and their unencapsulated (Δcps) derivatives. Again there was increased binding of IgG to the 
surface of unencapsulated ST3 and ST23F S. pneumoniae but not the D39 strain. These results 
demonstrate that the pneumococcal capsular polysaccharide is not a very important antigen target 
for naturally-acquired IgG binding to the surface of these strains.  The presence of a capsule 
significantly decreased IgG binding for ¾ strains tested, suggesting sub-capsular antigens (proteins or 
CWPS) are the targets of naturally-acquired IgG, and the presence of a capsule can inhibit IgG 
binding to these targets.  
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Figure 4.1: Binding of IgG to the surface of S. pneumoniae.  
(A) Histogram of anti-human IgG-PE binding to S. pneumoniae TIGR4 and TIGR4Δcps following 
incubation in IVIG (Intratect) or PBS. (B) MFI of anti-human IgG-PE binding to S. pneumoniae TIGR4 
and TIGR4Δcps following incubation in 1% or 10% IVIG. (C-E) MFI of anti-human IgG-PE binding to S. 
pneumoniae D39, ST23F, ST3  and their unencapsulated derivatives following incubation in 1% IVIG.  
(P values represent Student’s unpaired T-test, error bars represent SD). Experiments presented in 
figures C-E were performed by Michal Barabas under my supervision, as part of a BSc project.    
Results are representative of two independent experiments. 
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4.1.2 IVIG binding to Streptococcus mitis  
 
To investigate the general effect the pneumococcal capsule had on binding of IgG to the bacterial 
surface a strain of S. mitis that was transformed to express a capsule from S. pneumoniae TIGR4 was 
utilised (S.mitisT4cps). Binding of IVIG to the surface of S.mitisT4cps was compared with binding to 
an unencapsulated strain of S. mitis. Instead of providing a target for IgG deposition, the binding of 
IgG to the surface of S.mitisT4cps was reduced following incubation in 1% IVIG, relative to 
unencapsulated S. mitis (Figure 4.2). These results further indicate that the S. pneumoniae capsule is 
not a major target for IgG binding to S. pneumoniae in IVIG, and encapsulation may instead prevent 
binding of naturally-acquired IgG to sub-capsular antigens. WT S. mitis like S. pneumoniae also 
produces a capsule-like structure(Rukke et al., 2012). WT encapsulated S. mitis also bound less IgG 
than its unencapsulated derivative following incubation in IVIG (Figure 4.2). This further suggests 
that encapsulation in general may mask targets for IgG deposition on the surface of bacteria.  
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Figure 4.2: IgG binding to S. mitis expressing a TIGR4 capsule 
MFI of anti-human IgG-PE binding to S. mitis, S. mitisΔcps and S.mitisT4cps, following incubation in 
1% IVIG (Intratect). (P value represents one way ANOVA and Tukey’s post-test to compare columns, 
error bars represent SD). This experiment was performed by Helina Marshall under my supervision, 
as part of a pre-PhD project.  Results are representative of two independent experiments. 
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4.1.3 Specific antibody absorbtion (depletion) of IVIG  
 
Assays of IgG binding to the surface of unencapsulated mutants of S. pneumoniae indicate that 
naturally-acquired IgG in IVIG can target non-capsular antigens. However these assays do not allow 
the relative contribution of IgG targeting the capsular polysaccharide or sub-capsular antigens to be 
assessed for encapsulated WT S. pneumoniae.  To assess the relative importance of IgG to the 
capsular polysaccharide for IgG binding to WT S. pneumoniae TIGR4, IVIG was depleted of antibodies 
to the type-4 capsular polysaccharide. This was achieved by absorption of IVIG with S. mitis 
expressing a type-4 capsule. IVIG absorbed against S. mitisT4cps displayed a 6-fold reduction in IgG 
binding titre to purified type-4 polysaccharide (Figure 4.3), with no effect on antibody binding to S. 
pneumoniae proteins when as assessed by Western blot or quantitatively by ELISA to purified PsaA 
or PhtE (Figure 4.3). 
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Figure 4.3: Absorbtion of anti-capsular IgG from IVIG.  
(A) ELISA titre of anti-serotype 4 IgG in IVIG pre-absorbed by incubation with S. mitis expressing a 
TIGR4 capsule or mock absorbed. (B) Western blot of S. pneumoniae TIGR4 lysate probed with 
absorbed or mock absorbed IVIG, developed with anti-human IgG. (C) ELISA titre of IgG binding to 
purified PsaA in absorbed and mock-absorbed IVIG. (D) ELISA titre of IgG binding to purified PhtE in 
absorbed and mock-absorbed IVIG. (P values represent Student’s unpaired T-test, error bars 
represent SD). 
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The effect of specific depletion of anti-capsular IgG on the ability of IVIG to bind to the bacterial 
surface was assessed by flow-cytometry. Specific depletion of anti-serotype 4 IgG from IVIG had no 
significant effect on IgG binding to the surface of S. pneumoniae TIGR4 following incubation in both 
1% and 10% IVIG (Figure 4.4). These data therefore indicate that naturally-acquired IgG in IVIG 
predominantly targets non-capsular antigens on the surface of intact S. pneumoniae. 
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Figure 4.4: Surface binding of absorbed IVIG.   
(A) Histogram of anti-human IgG-PE binding to S. pneumoniae TIGR4 following incubation in 1% IVIG 
depleted of anti-CPS IgG by in absorbtion against  S. mitis+TIGR4, or mock depleted IVIG. (B) MFI of 
anti-human IgG-PE binding to S. pneumoniae TIGR4 following incubation in 1% and 10% depleted or 
mock depleted IVIG. (P values represent Student’s unpaired T-test, error bars represent SD). 
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4.1.4 Protease shaving of S. pneumoniae 
 
Depletion of anti-capsular IgG from IVIG, and IVIG binding to unencapsulated mutants, 
demonstrated a role for IgG to non-capsular targets in determining binding of naturally-acquired IgG 
to the surface of S. pneumoniae.  To assess if these non-capsular targets could be proteins, S. 
pneumoniae was incubated with a protease (pronase) to digest surface-exposed proteins. Pronase 
treatment of S. pneumoniae has previously been used to confirm the surface localisation of 
pneumococcal proteins (Hammerschmidt et al., 1997). To ensure pronase treated S. pneumoniae 
didn’t re-express surface proteins upon division a strain of S. pneumoniae TIGR4 lacking PABA 
synthetase (TIGR4Δpab) was used, which is unable to replicate in sera (Chimalapati et al., 2011).  
There was no reduction in bacterial CFU following incubation of TIGR4Δpab with pronase, compared 
to PBS alone. The effect of pronase incubation on the binding of IVIG to the surface of S. 
pneumoniae was assessed by flow-cytometry. Pronase treatment of S. pneumoniae reduced the 
ability of IVIG to bind to the surface of S. pneumoniaeΔpab (Figure 4.5).  To confirm that pronase 
treatment didn’t affect the binding of IgG to the S. pneumoniae capsule the binding of anti-serotype 
4 PPS antisera to pronase treated and untreated S. pneumoniaeΔpab was assessed. Pronase 
treatment had no effect on IgG binding to the surface of S. pneumoniae Δpab following incubation in 
10% type-4 CPS antisera (Figure 4.5).  Incubation of WT S. pneumoniae and S. pneumoniaeΔpab in 
type-4 antisera also confirmed that the Δpab mutation did not affect IgG binding to the S. 
pneumoniae TIGR4 capsule (Figure 4.5).  These data indicate that some of the S. pneumoniae targets 
of IVIG binding to encapsulated S. pneumoniae, and therefore targets of naturally-acquired IgG are 
pneumococcal surface proteins, sensitive to digestion by pronase.  
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Figure 4.5: IgG binding to pronase-treated S. pneumoniae.  
(A) Histogram of anti-human IgG-PE binding to S. pneumoniae TIGR4Δpab pre-treated with 100µg/ml 
pronase or PBS, incubated in 1% IVIG (Intratect).(B) MFI of anti-human IgG-PE binding to S. 
pneumoniae TIGR4Δpab pre-treated with 100μg/ml pronase or PBS, incubated in 1% IVIG. (C) MFI of 
anti-rabbit IgG-PE binding to S. pneumoniae TIGR4 and TIGR4Δpab following incubation in 10% anti-
serotype 4 polyclonal rabbit sera. (D) MFI of anti-rabbit IgG-PE binding to S. pneumoniae TIGR4Δpab 
pre-treated with 100µg/ml pronase or PBS, incubated in 10% anti-serotype 4 polyclonal rabbit sera. 
(P values represent Student’s unpaired T-test, error bars represent SD). Results are representative of 
two independent experiments. 
  
TIGR4 TIGR4pab
0
10
20
30
40
50
60
70
80
90
0.0528P =
M
F
I 
P
o
o
l 
A
 b
in
d
in
g
 PBS  100g/ml pronase
0
10
20
30
40
50
60
70
80
90
1.0000P =
M
F
I 
P
o
o
lA
 b
in
d
in
g
A B 
C D 
Pronase 
treated 
PBS 
treated 
PBS 
FL2 
C
o
u
n
t 
PBS treated 100g/ml Pronase treated
0
50
100
150
0.0214P =
M
F
I 
IV
IG
 b
in
d
in
g
137 
 
4.1.5 Effect of IgG on in vitro growth of S. pneumoniae  
 
Surface binding assays utilising unencapsulated strains of S. pneumoniae indicated a potentially 
important role for opsonisation with IgG to sub-capsular protein antigens in IVIG.  To evaluate if 
naturally-acquired IgG to non-capsular targets could be functional the effect of IVIG on in vitro 
growth of WT and unencapsulated S. pneumoniae was investigated.  The addition of 10% IVIG to the 
growth medium (THY) impaired S. pneumoniae TIGR4 growth (Figure 4.6) as assessed by a change in 
OD580 over 8hrs. Repeating this assay with the TIGR4Δcps strain indicated that the inhibitory effect of 
IVIG was greater when the polysaccharide capsule was removed (Figure 4.6). The enhanced effect of 
IVIG on growth inhibition of unencapsulated S. pneumoniae was also demonstrated when repeating 
assays with unencapsulated derivatives of S. pneumoniae D39, ST3 and ST23F (Figure 4.6). This 
indicates that naturally-acquired IgG to non-capsular targets is capable of mediating the observed 
reduction in OD580
 following the addition of IVIG. Light microscopy of 8 hour cultures demonstrated 
that the addition of 10% IVIG to the growth medium facilitated bacterial agglutination (Figure 4.7). 
This phenotype was maintained for unencapsulated S. pneumoniae TIGR4 following growth in IVIG, 
indicating that antibodies to the capsular polysaccharide are not necessarily required for bacterial 
agglutination (Figure 4.7).  
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Figure 4.6: Effect of IVIG on S. pneumoniae growth.  
(A-D) 8 hour growth (OD580nm) of WT S. pneumoniae strains TIGR4, D39, ST23F, ST3 and their 
unencapsulated (Δcps) derivatives in THY supplemented with 10% IVIG (Intratect) or PBS. (Error bars 
represent SD). Experiments presented in figures B-D were performed by Michal Barabas under my 
supervision, as part of a BSc project. (Curves were compared by two-way ANOVA*= P<0.001 
compared to PBS controls). Results are representative of two independent experiments. 
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Figure 4.7: Microscopy of S. pneumoniae grown in the presence of IVIG.  
Light microscopy of S. pneumoniae TIGR4 and TIGR4Δcps after 8hrs growth in THY supplemented 
with 10% IVIG (Intratect) or PBS. 10μl of culture was air-dried on to glass slides and stained by rapid-
Romanowsky staining (Diff-quick). Results are representative of two independent experiments. 
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4.1.6 Effect of IgG on S. pneumoniae agglutination  
 
IgG recognition of S. pneumoniae may inhibit growth when measured by a change in OD via 
inhibition of surface protein function (e.g. cation uptake) or by promoting bacterial agglutination. 
Light microscopy of 8 hour cultures demonstrated that the addition of 10% IVIG to the growth 
medium did facilitate bacterial agglutination (Figure 4.7). This phenotype was maintained for 
unencapsulated S. pneumoniae TIGR4 following growth in IVIG, indicating that antibodies to the 
capsular polysaccharide are not necessarily required for this effect (Figure 4.7).To assess the targets 
of naturally-acquired IgG that may mediate agglutination independently of growth, a flow-cytometry 
based approach was used. Forward scatter (FSC) of light indicates the relative size of particles by 
flow-cytometry. An increase in particle size by FSC was therefore used as a measure of increased 
bacterial agglutination (Figure 4.8). The addition of increasing concentrations of IVIG to a suspension 
of either 1x106 CFU/ml FAM-SE labelled S. pneumoniae TIGR4 or TIGR4Δcps led to an increase in 
particle size for both strains, indicative of agglutination (Figure 4.8). This further suggests the target 
antigen of naturally-acquired IgG mediating agglutination is not necessarily the polysaccharide 
capsule and sub-capsular antigens can be functional targets.  
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Figure 4.8: IVIG mediated agglutination of S. pneumoniae.  
Mean forward scatter (flow-cytometry) of suspensions of S. pneumoniae TIGR4 and TIGR4Δcps pre-
incubated in increasing concentrations of IVIG (Intratect). (P values represent one-way ANOVA, error 
bars represent SD). Results are representative of two independent experiments. 
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4.1.7 IgG mediated phagocytosis and killing of S. pneumoniae  
 
Enhancing opsonophagocytosis is a primary mechanism by which IgG may be protective against S. 
pneumoniae. Therefore the functional targets of naturally-acquired IgG in vitro that could facilitate 
opsonophagocytosis of S. pneumoniae by macrophages and neutrophils were assessed. This was 
achieved by measuring the association of fluorescently labelled S. pneumoniae TIGR4 and TIGR4Δcps 
with phagocytes by flow-cytometry. Prior opsonisation of S. pneumoniae in 10% IVIG facilitated 
increased association of FAM-SE labelled S. pneumoniae with a murine macrophage cell line (RAW 
264.7) when co-incubated at an MOI of 10 (Figure 4.9). This effect compared to unopsonised 
bacteria was stronger against unencapsulated S. pneumoniae (Figure 4.9), indicating that naturally-
acquired IgG to non-capsular targets may be functional mediating phagocytosis of S. pneumoniae. 
Prior opsonisation in IVIG also increased the association of FAM-SE labelled S. pneumoniae TIGR4 
with human neutrophils (MOI 20), in a dose-dependent manner (Figure 4.9). Again the effect of 
increasing concentrations of IVIG was greater for the TIGR4Δcps strain, indicating IgG to sub-capsular 
targets is functional and mediates enhanced phagocytosis by both a RAW macrophage cell line and 
isolated human neutrophils. The lower association of encapsulated S. pneumoniae with phagocytes 
indicates that the polysaccharide capsule of S. pneumoniae may partially abrogate the opsonic 
effects of IgG binding to non-capsular targets following incubation in IVIG.   
The effect of opsonisation in IVIG on neutrophil killing of S. pneumoniae was also assessed. Isolated 
human neutrophils were incubated with S. pneumoniae (MOI 1/250) and bacterial survival assessed 
by counting CFU.  Prior opsonisation in IVIG enhanced the killing of both S. pneumoniae TIGR4 and 
TIGR4Δcps by human neutrophils in vitro, relative to unopsonised controls (Figure 4.9). This further 
supports the hypothesis that non-capsular antigens can be functional targets of naturally-acquired 
IgG in IVIG.   
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Figure 4.9: Effect of IVIG on S. pneumoniae phagocytosis and killing.  
(A) Histograms showing fluorescence intensity (FL-1) of RAW macrophages, detected by flow-
cytometry, following incubation with FAM-SE labelled S. pneumoniae TIGR4  and TIGR4Δcps, 
opsonised in 10% IVIG or PBS. (B) MFI (FL-1) of RAW macrophages incubated with FAM-SE S. 
pneumoniae TIGR4 and TIGR4Δcps opsonised in 10% IVIG or PBS. (C) MFI (FL-1) of human 
neutrophils incubated with FAM-SE labelled S. pneumoniae TIGR4 and TIGR4Δcps opsonised with 
increasing concentrations of IVIG. (D) Percentage survival of S. pneumoniae TIGR4 and TIGR4Δcps 
opsonised in 10% IVIG, incubated with neutrophils (MOI 1/250), compared to controls opsonised in 
PBS. (P values represent Student’s unpaired T-test (B,D) or one-way ANOVA (C), error bars represent 
SD). All results are representative of two independent experiments.  
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4.1.8 Chapter summary 
  
As previously discussed the pneumococcal targets in IVIG pooled from >1000 donors are likely to 
reflect the targets of naturally-acquired IgG within a population. IgG binding to unencapsulated S. 
pneumoniae indicated that naturally-acquired IgG in IVIG can opsonise S. pneumoniae by binding to 
non-capsular antigens on the surface of intact bacteria. Specific depletion of anti-capsular IgG in IVIG 
suggested that IgG to the S. pneumoniae capsular polysaccharide may be redundant for IgG binding 
to the surface of wild-type encapsulated S. pneumoniae TIGR4. Furthermore protease treatment of 
S. pneumoniae reduced IgG binding, indicating that surface proteins may be major targets of 
naturally-acquired IgG binding to S. pneumoniae.  
Assays of growth and agglutination using unencapsulated mutants of S. pneumoniae demonstrated 
that IgG recognition of protein antigens has a functional effect. Additionally, assays using TIGR4Δcps 
indicated that antibodies to these targets may be functional, enhancing both macrophage and 
neutrophil phagocytosis of S. pneumoniae and killing by neutrophils. The effect of opsonisation in 
IVIG was greater for unencapsulated strains of S. pneumoniae, both in terms of increased deposition 
of IgG on the bacterial surface, growth inhibition and enhanced phagocytosis and killing. This 
suggests that the bacterial effects of naturally-acquired IgG to S. pneumoniae are not necessarily 
mediated by anti-capsular antibody, but are mediated by anti-protein antibody, and that the S. 
pneumoniae capsule protects the bacteria from opsonisation by naturally-acquired IgG to non-
capsular antigens.   
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5 Results (3): In vivo effects of naturally-acquired IgG 
 
In vitro assays indicated that naturally-acquired IgG to S. pneumoniae may be protective facilitating 
agglutination of S. pneumoniae and enhancing phagocytosis.  To determine if naturally-acquired IgG 
could be protective against lung infection in vivo a mouse model of experimental S. pneumoniae 
challenge following IVIG treatment was used.  The effect of IVIG treatment on IN lung infection, 
experimental colonisation and IV challenge with S. pneumoniae TIGR4 was assessed. The S. 
pneumoniae TIGR4 strain was used for these experiments as it causes invasive, but not rapidly 
overwhelming infection in mice (Cohen et al., 2013), thereby allowing protection in different tissue 
compartments to be assessed. Cellular depletion strategies in vivo were used to assess the 
mechanisms by which naturally-acquired IgG mediated protection.  
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5.1.1 IgG distribution following IVIG treatment  
 
CD1 mice were passively vaccinated with human IgG (IVIG) via intraperitoneal inoculation 3hrs prior 
to challenge. To assess the distribution of IgG at different time points post-challenge the 
concentration of human IgG in sera, BALF and nasal washings was quantified by ELISA (Figure 5.1). 
3hrs following treatment human IgG was readily detectable in the sera of IVIG treated mice, but not 
the BALF or nasal washings (Figure 5.1 A,B). Following experimental colonisation of the nasopharynx 
with TIGR4 S. pneumoniae human IgG remained absent from nasal washes, 5 days post-inoculation 
(Figure 5.1 B). IP injection of IVIG followed by experimental lung infection 3hrs later resulted in 
detecdable levels of human IgG in BALF (Figure 5.1 C). There was a much greater accumulation of 
human IgG in the BALF 24hrs following infection with 1x107 CFU S. pneumoniae TIGR4 compared to 
2.5hrs after inoculation of 5x105 CFU (Figure 5.1). These data indicate that in this model human IgG 
was only detectable in the alveolar space post-infection following IVIG treatment. Bronchoalveolar 
lavages were performed 24hrs following IVIG adminisaration to assess if a longer time period post-
treatment would allow human IgG accumulation in BALF. 24hrs following treament human IgG 
remained absent from the BALF of IVIG treated mice without infection.  
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Figure 5.1: Distribution of human IgG in vivo following IVIG treatment.  
 
(A) Concentration of human IgG measured by ELISA, in sera of IVIG treated mice pre-challenge. (B) 
Human IgG concentration in nasal washings of IVIG treated mice pre and 5 days post IN colonisation 
with 1x107 CFU S. pneumoniae TIGR4. (C) Human IgG concentration in BALF 0, 2.5 (low dose) and 
24hrs (high dose) post IN challenge with S. pneumoniae TIGR4. (D) Human IgG concentration in BALF 
24hrs following IVIG treatment without challenge (Lines represent mean). Results are from one 
experiment at each time-point, except 24hrs which was performed twice.   
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To evaluate whether the absence of human IgG from the alveolar space in uninfected mice could be 
due to a species difference affecting the transit of human IgG across the murine alveolar epithelium, 
hyperimmune anti-S. pneumoniae mouse serum was passively transferred into mice by IP 
inoculation. A hyperimmune serum was obtained from mice 28 days after vaccination with the 
replication deficient TIGR4Δpab strain. 24hrs following passive vaccination with murine 
hyperimmune sera there was an increase in S. pneumoniae specific IgG compared to non-vaccinated 
controls was detected in BALF (Figure 5.2), suggesting that murine IgG can enter the alveolar space 
in the absence of inflammation. From these samples the relative concentration of S. pneumoniae 
specific IgG in the sera compared to BALF of passively vaccinated mice could be calculated. Using this 
ratio the concentration of human IgG that would be expected in BALF of mice 3hrs following IVIG 
treatment was estimated, based on the concentration in the sera (Figure 5.2).The BALF 
concentration of human IgG 24hrs following challenge in IVIG treated mice was significantly greater 
than the estimated concentration, based on the concentration of IgG in the sera at this time point 
post infection (Figure 5.2). This suggests that challenge with S. pneumoniae TIGR4 and associated 
inflammation may facilitate human IgG leak into the alveolar space.  To assess the potential 
contribution of alveolar permeability to IgG accumulation in the BALF following challenge with S. 
pneumoniae, albumin concentration in BALF from infected mice was measured as marker of 
epithelial permeability. Human IgG concentration in lavage samples of individual mice following 
challenge closely correlated with the albumin concentration in the same samples (Figure 5.2). These 
data suggest that in this murine model human IgG accumulates in the alveolar space following S. 
pneumoniae challenge In line with increased alveolar permeability.   
149 
 
0 10 20 30 40 50 60 70
0
500
1000
1500
P = 0.005
r2 = 0.8860
[ Human IgG] Lavage fluid (mg/ml)
[A
lb
u
m
in
] 
L
a
v
a
g
e
 f
lu
id
 (

g
/m
l)
  
      
                 
 
Figure 5.2: Distribution of IgG following passive transfer of murine immune sera.  
(A) Whole cell ELISA titre of anti-TIGR4 IgG in sera of mice 3hrs following IP administration of 
hyperimmune anti-pneumococcal sera. (B) ELISA titre of anti-TIGR4 IgG in BALF of mice 3hrs 
following IP administration of hyperimmune anti-pneumococcal sera. (C) Estimated concentration of 
human IgG in BALF based on the concentration of IgG in the sera and actual IgG concentration 
detected in BALF 24hrs post-challenge with S. pneumoniae TIGR4. (D) Linear regression of human 
IgG concentration in BALF and albumin concentration in BALF, measured by ELISA 24hrs following IN 
infection with S. pneumoniae TIGR4. (P value represents F-test assessing difference of slope 
compared to zero, error bars represent standard error). Results are from one experiment.  
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5.1.2 Protective effect of IVIG  
 
To assess at what level passively transferred human IgG (IVIG) may protect against S. pneumoniae 
infection, mice were challenged with different models of infection 3hrs post- IVIG treatment. Passive 
transfer of human IgG failed to protect against experimental colonisation with S. pneumoniae TIGR4; 
CFU in nasal washes were not reduced 5 days post-experimental colonisation in IVIG treated mice 
compared to controls (Figure 5.3). Similarly, IVIG treatment failed to reduce CFU in the lungs or BALF 
at an early time point (2.5hrs) following challenge with 5x105 CFU S. pneumoniae TIGR4 (Figure 5.3). 
This lack of protection in the nasopharynx and early in the lungs perhaps reflects the low distribution 
of human IgG at these body compartments and time points post-infection. At 24hrs following IN 
infection with 1x107 CFU prior IVIG treatment improved clearance of S. pneumoniae from the lung, 
and was powerfully protective against septicaemia compared to PBS treated controls (Figure 5.3). 
IVIG treatment had no effect on bacterial numbers in the BALF of mice 24hrs following challenge 
(Figure 5.3). The ability of human IgG to clear S. pneumoniae from the blood following challenge was 
assessed by IV challenge with S. pneumoniae TIGR4. 4hrs following IV challenge with 5x106CFU S. 
pneumoniae, 80% of mice treated with IVIG had cleared S. pneumoniae from the blood, whereas S. 
pneumoniae bacteraemia was detectable in all PBS treated controls (Figure 5.3).These data indicate 
that naturally-acquired human IgG can protect mice from lung infection with S. pneumoniae, 
reducing bacterial numbers in the lung and also strongly inhibits the development of bacteraemia. 
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Figure 5.3: Bacterial CFU in S. pneumoniae infected mice, following IVIG treatment. 
                                                                                                 
(A) CFU in nasal washes 5-days post IN colonisation with 1x107 CFU S. pneumoniae TIGR4 in mice 
treated with IVIG or PBS. (B) CFU in lungs and BALF 2.5hrs post IN challenge with 5x105 CFU S. 
pneumoniae TIGR4. (C) CFU in lungs, blood and BALF of PBS and IVIG treated mice 24hrs post IN 
challenge with 1x107CFU S. pneumoniae TIGR4. (D) CFU in blood 4hrs post IV challenge with 5x106 
CFU S. pneumoniae TIGR4 in IVIG or PBS treated mice. (P values represent Student’s unpaired T-test, 
lines represent mean). Results are from one experiment at except those presented in Figure C which 
were performed twice.   
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5.1.3 Inflammatory responses to infection in IVIG treated mice 
  
There are a number of mechanisms by which IVIG may mediate in vivo protective effects against S. 
pneumoniae lung infection. IVIG has been demonstrated to have immunomodulatory capacities 
which may mediate protection from infection separately to improved bacterial opsonisation 
(Hagiwara et al., 2008). However, in this model of infection IVIG treatment didn’t appear to 
significantly affect the inflammatory response to S. pneumoniae lung infection. Cell numbers in the 
BALF of IVIG treated mice were unchanged compared to PBS controls (Figure 5.4), as were levels of 
the pro-inflammatory cytokine TNF-α in lung tissue 24hrs post-infection with S. pneumoniae TIGR4 
(Figure 5.4). These data therefore suggest that the protective effects of IVIG in this model were 
probably not due to modulation of the inflammatory response within the lung. 
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Figure 5.4: Inflammatory responses to S. pneumoniae in IVIG treated mice. 
(A) Total cell counts in BALF 24hrs following IN challenge with 1x107 CFU S. pneumoniae TIGR4 in PBS 
and IVIG treated mice. (B) Concentration of TNF-α in BALF, measured by ELISA, 24hrs following 
challenge with 1x107 CFU S. pneumoniae TIGR4 in PBS and IVIG treated mice. (P values represent 
Student’s unpaired T-test, error bars represent SD). 
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5.1.4 Role of neutrophils in IVIG mediated protection  
 
Neutrophils were the main cell type in the alveolar space 24hrs following IN infection with S. 
pneumoniae TIGR4 (Figure 5.4). To determine if they were important for the protective effect of 
human IgG neutrophils were depleted prior to challenge in IVIG or PBS treated mice.  Administration 
of a monoclonal antibody against the neutrophil surface-marker Ly-6G, 24hrs prior to challenge, led 
to a 20-fold reduction in neutrophil numbers in the BALF 24hrs post-infection (Figure 5.5).  
Neutrophil depletion abolished the protective effect of IVIG treatment on S. pneumoniae CFU within 
the lung (Figure 5.5), suggesting an important role for neutrophils in protection from lung infection 
mediated by naturally-acquired human IgG. Interestingly neutrophil depletion also protected control 
mice from the development of bacteraemia following S. pneumoniae TIGR4 challenge (Figure 5.5), 
suggesting that neutrophils may contribute to the invasion of S. pneumoniae into the blood which in 
the absence of human IgG is not cleared in this model. 
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Figure 5.5: Effect of IVIG in vivo following neutrophil depletion.  
(A) Neutrophil numbers in BALF of mice treated with 1A8 anti-Ly6G neutrophil-depleting antibody or 
PBS, 24hrs after challenge with 1x107 CFU S. pneumoniae TIGR4. (B) CFU in lungs of neutrophil 
depleted mice treated with PBS or IVIG, 24hrs after challenge with 1x107 CFU S. pneumoniae TIGR4, 
compared to untreated controls. (C) CFU in blood of neutrophil depleted mice treated with PBS or 
IVIG, 24hrs after challenge with 1x107 CFU S. pneumoniae TIGR4. (D) CFU in BALF of neutrophil 
depleted mice treated with PBS or IVIG, 24hrs after challenge with 1x107 CFU S. pneumoniae TIGR4. 
(P values represent Student’s unpaired T-test (A) or one way ANOVAs with Tukey’s post-test to 
compare columns (B-D)). Results are representative of two independent experiments.  
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5.1.5 Mechanisms of clearance from blood 
 
Splenic macrophages play an important role in the clearance of bacteria from the blood (Kang et al., 
2004, Aichele et al., 2003). Therefore the role of these cells in the enhanced clearance of S. 
pneumoniae TIGR4 from the blood observed in mice treated with IVIG was investigated. IV 
administration of liposomal clodronate was used to specifically deplete splenic macrophages (van 
Rooijen and van Nieuwmegen, 1984), reducing the number of F4/80+ve macrophages in the spleen 
of CD1 mice by 50%, as assessed by flow-cytometry (Figure 5.6). Depletion of splenic macrophages 
by IV administration of liposomal clodronate impaired the ability of IVIG treated mice to clear S. 
pneumoniae TIGR4 from the blood following IV challenge with 5x105 CFU (Figure 5.6). IVIG treated 
mice that received liposomes containing PBS had no detectable bacteria in the blood; whereas 66% 
of IVIG treated mice that received liposomal clodronate had detectable bacteraemia. These data 
indicate that naturally-acquired IgG requires intact splenic macrophages for full clearance of S. 
pneumoniae from the blood. 
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Figure 5.6: Clearance of S. pneumoniae following clodronate depletion of macrophages. 
(A) Percentage of F4/80+ macrophages in the spleens of mice treated IV with liposomal clodronate 
or liposomal PBS. (B) CFU 4hrs following IV challenge with 5x105 S. pneumoniae TIGR4 in the blood of 
IVIG treated mice, treated with liposomal clodronate or liposomal PBS. (P values represent Student’s 
unpaired T-test, error bars represent SD). Results are representative of two independent 
experiments. 
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5.1.6 Effect of specific antibody depletion on protection 
 
Previous data (Figure 4.3) indicate that incubation of IVIG with S. mitis expressing a type-4 capsule 
(S.mitisT4cps) can deplete IVIG of anti-capsular antibody.  To assess if IVIG depleted of IgG specific 
for the serotype 4 capsular polysaccharide was still protective in vivo, mice were treated with 
depleted IVIG or PBS.  3hrs following administration of IVIG mice were challenged IN with 1x107 CFU 
S. pneumoniae TIGR4. The numbers of neutrophils or macrophages in the BALF of mice 24hrs 
following challenge were not significantly altered by anti-CPS ST4 depleted IVIG treatment (Figure 
5.7). IVIG depleted of anti-type-4 CPS IgG was still able to significantly enhance bacterial clearance 
from the blood 24hrs following IN challenge (Figure 5.7), and there was also a trend towards 
reduced S. pneumoniae CFU in the lungs post-infection (Figure 5.7). These data indicate that 
naturally-acquired IgG to the polysaccharide capsule is not required for the protective effect of IVIG, 
at least in the blood, and strongly supports the hypothesis that naturally-acquired IgG to non-
capsular targets is protective against S. pneumoniae infection.   
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Figure 5.7: IVIG depleted of anti-CPS IgG in vivo.   
(A)Total cell counts in BALF 24hrs following IN challenge with 1x107 CFU S. pneumoniae TIGR4 in 
mice treated with PBS or S.mitisT4cps absorbed IVIG. (B) CFU in blood24hrs following IN infection 
with 1x107 CFU S. pneumoniae TIGR4 in mice treated with PBS or absorbed IVIG.  CFU in lungs 24hrs 
following IN infection with 1x107 CFU S. pneumoniae TIGR4 in mice treated with PBS or absorbed 
IVIG. (P values represent Student’s unpaired T-test, error bars represent SD). Results are from one 
experiment. 
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5.1.7 Chapter summary 
 
Passive transfer of IVIG into mice allowed assessment of the protective effect of naturally-acquired 
human IgG against S. pneumoniae infection in vivo. In this model human IgG was not detectable in 
the alveolar space without infection. There may therefore be an additional role for pre-existing IgG 
in the alveolar space in the initial clearance of S. pneumoniae from the lung. IVIG treatment partially 
protected mice from S. pneumoniae lung infection and very strongly against bacteraemia, lung 
protection required neutrophils and blood protection macrophages. Since protection in this model 
appeared to be dependent upon phagocytes these data indicate that in vitro assays of phagocytosis 
(used in the previous chapter) are relevant for assessing the protective effects of IVIG. 
Importantly passive administration of IVIG depleted of IgG to the type-4 polysaccharide was still 
protective against S. pneumoniae TIGR4 infection, suggesting the protective effects of naturally-
acquired IgG may target non-capsular antigen. This is in agreement with data presented in chapter 4, 
demonstrating IVIG depleted of type-4 capsular polysaccharide still bound to the surface of S. 
pneumoniae TIGR4. Although these data do not confirm that the non-capsular antigens targeted by 
IVIG in vivo are pneumococcal surface proteins, the in vitro data presented in chapter 3 and 4 
strongly support that they are important targets for naturally-acquired anti-S. pneumoniae IgG.  
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6 Results (4): Acquired immunity to non-bacteraemic 
pneumonia 
 
Passive transfer of IVIG to mice pre-challenge with S. pneumoniae TIGR4 demonstrated that IgG has 
a role to play in protection from experimental lung infection. Previous data using murine models has 
established that antibody is the dominant mechanism preventing systemic infection after prior 
colonisation. However humoral immunity represents only one mechanism of naturally-acquired 
immunity that may be responsible for protection within the lung. An aim was therefore to develop a 
model of murine colonisation followed by challenge using a 19F strain of S. pneumoniae (EF3030) 
that causes lung infection without causing bacteraemia (Briles et al., 2003). This would allow 
interrogation of the immune mechanisms induced by colonisation that may be protective against 
subsequent lung infection independently of the mechanisms required for prevention of 
bacteraemia.   
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6.1.1 Assessment of EF3030 as model of non-bacteraemic pneumonia 
 
To assess if IN infection with S. pneumoniae EF3030 was an appropriate model of non-invasive S. 
pneumoniae pneumonia, mice were challenged IN with EF3030 or PBS in a volume of 50µl. Mice 
challenged with EF3030 had neutrophil infiltration into the alveolar space on histology (Figure 6.1), 
and a large increase in neutrophil numbers in BALF 24hrs post-infection (Figure 6.2). CFU counts 
confirmed that EF3030 was detectable in lung tissue and BALF samples (Figure 6.2), but importantly 
no bacteria were detectable in the blood 24hrs after challenge.  These data indicate that challenge 
with S. pneumoniae EF3030 recapitulates the import features of non-bacteraemic pneumonia, 
including cellular infiltration into the lungs and the absence of bacteria from the blood.     
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Figure 6.1: Lung histology following EF3030 challenge. 
Histological lung sections stained with Haematoxylin and Eosin, from mice 24hrs following IN 
challenge with (A) PBS or (B) 2x107 CFU of S. pneumoniae EF3030. (Arrow indicates cellular 
infiltration in to the alveolar space). Images are representative of the lungs from  two uninfected 
mice (Figure A)  and four mice infected with EF3030 (Figure B). 
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Figure 6.2: Non-invasive lung infection with S. pneumoniae EF3030.   
(A) CFU in lungs of C57/BL6 mice 24hrs following IN challenge with 2x107 CFU of S. pneumoniae 
EF3030 or PBS. (B) CFU in BALF of mice 24hrs following challenge with S. pneumoniae EF3030 or PBS. 
(C) CFU in blood of mice 24hrs following challenge with S. pneumoniae EF3030 or PBS. (D) Neutrophil 
numbers in BALF of mice 24hrs following IN challenge with S. pneumoniae EF3030 or PBS. (Lines 
represent mean). Results are from one experiment. 
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6.1.2 Nasopharyngeal colonisation with EF3030 
 
To assess if S. pneumoniae EF3030 could colonise the nasopharynx, C57/BL6 mice were 
experimentally colonised by IN inoculation of 1x107 CFU in 10μl of PBS, and culled at days 5, 13 and 
30 post-infection. EF3030 was detectable in nasal washes at 5 days and 13 days post-inoculation 
(Figure 6.3) and had been cleared by 30 days, demonstrating that EF3030 can colonise the nares of 
C57/BL6 mice for up to 13 days. Other models of murine colonisation with S. pneumoniae that 
induce an adaptive immune response have demonstrated colonisation for similar lengths of time 
(Cohen et al., 2011), suggesting that this model of colonisation with S. pneumoniae EF3030 is 
appropriate for assessing potentially protective immune responses.     
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Figure 6.3: S. pneumoniae in nares of mice post-colonisation.  
CFU in nasal washes of C57/BL6 mice at 5, 13, and 30 days following IN inoculation with 1x107 CFU S. 
pneumoniae EF3030 in 10μl PBS. (Lines represent mean).  Results are from one experiment at each 
time-point. 
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6.1.3 Protective effect of colonisation  
 
To assess if colonisation with S. pneumoniae EF3030 is protective against subsequent lung infection, 
mice were either experimentally colonised with EF3030 or sham colonised with PBS. 30 days 
following colonisation mice were challenged IN with EF3030 and culled at 4, 24 and 72hrs post-
infection. CFU were enumerated in the lungs and BALF of mice at each time point post-infection. 
4hrs following colonisation there was no difference in bacterial numbers in colonised or control mice 
(Figure 6.4). At 24hrs post-infection there was a significant reduction in bacterial numbers in the 
BALF and lungs of previously colonised mice (Figure 6.4). At 72hrs following S. pneumoniae challenge 
a significant reduction in bacterial burden remained in the lungs, but not BALF of colonised mice 
(Figure 6.4). Together these data demonstrate that colonisation with EF3030 is partially protective 
against subsequent S. pneumoniae lung infection, significantly reducing bacterial burden in BALF and 
lungs at 24hrs and lungs 72hrs post-infection.  
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Figure 6.4: CFU following lung infection in colonised mice.  
(A,B) CFU in BALF and lungs of mice colonised with EF3030 or PBS, 4hrs following challenge with 
2x107 CFU S. pneumoniae EF3030. (C,D) CFU in BALF and lungs of mice colonised with EF3030 or PBS, 
24hrs following challenge with 2x107 CFU S. pneumoniae. (E,F) ) CFU in BALF and lungs of mice 
colonised with EF3030 or PBS, 72hrs following challenge with S. pneumoniae. (P values represent 
Student’s unpaired T-test, lines represent mean). Results are from one experiment at each time-
point, except 24hrs which was repeated twice. 
PBS colonised EF3030 colonised
0
1
2
3
4
5
6
7
0.7330P =
L
o
g
1
0
 C
F
U
/m
l 
B
A
L
F
PBS colonised EF3030 colonised 
0
1
2
3
4
5
6
7
0.5724P =
L
o
g
1
0
 C
F
U
 L
u
n
g
s
4
h
rs
 
7
2
h
rs
 
2
4
h
rs
s
 
A B 
D 
 
C
 
F 
 
E 
 
169 
 
6.1.4 Antibody responses to colonisation  
 
In previous models of highly invasive lung-infection the development of antibodies following 
colonisation was essential for protection.  To explore the potential role for antibodies in the 
protection seen in this model, anti-pneumococcal antibody responses to colonisation were assessed. 
There was a significant increase in the binding titre of anti-EF3030 IgG in the sera of mice following 
colonisation (Figure 6.5) as assessed by whole cell ELISA. In colonised mice there was not a 
significant rise in IgG specific for the type-19F (EF3030) capsular polysaccharide as measured by 
ELISA (Figure 6.5). The concentration of IgM in sera recognising EF3030 by whole cell ELISA was also 
unchanged following colonisation (Figure 6.5). In these assays anti-EF3030 IgA was not detected in 
the sera or BALF of colonised or control mice by whole cell ELISA.  
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Figure 6.5: Serological responses to EF3030 colonisation.  
(A) Anti-EF3030 IgG in the sera (diluted 1:100) of mice 13 and 30 days post-colonisation with 1x107 
CFU S. pneumoniae EF3030 by whole cell ELISA compared to uncolonised controls, represented as 
OD405-630. (B) Anti-19F polysaccharide IgG in the sera (diluted 1:100) of mice 30 days post-
colonisation with S. pneumoniae EF3030 or PBS by ELISA represented as OD405-630. (C) Anti-EF3030 
IgM in the sera (diluted 1:150) of mice 30 days post-colonisation with S. pneumoniae EF3030 or PBS 
by whole cell ELISA represented as OD405-630. (P values represent Student’s unpaired T-test). Results 
are from one experiment at each time-point, ELISAs were repeated twice. 
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To assess if IgG responses could be responsible for the protection against infection within the lung, 
EF3030 specific and total murine IgG was measured in BALF following challenge. In the absence of 
infection EF3030 colonised mice had significantly greater EF3030-specific IgG detected in BALF 
(Figure 6.6). 4hrs post-challenge the concentration of EF3030-specific IgG remained significantly 
higher in colonised mice compared to non-colonised controls (Figure 6.6), and was significantly 
higher than in colonised mice pre-challenge (Figure 6.6). From 4 to 24hrs following infection the 
concentration of EF3030-specific IgG in the BALF fell (Figure 6.6). The concentration total murine IgG 
in the BALF was also measured by ELISA. In colonised mice there was an early increase in total IgG at 
4hrs that was not seen in uncolonised controls (Figure 6.6). By 24hrs post infection the total IgG 
concentration in the BALF of both groups was similar (Figure 6.6). Measurement of total IgG 
indicates that the reduction in pathogen specific IgG observed between 4 and 24hrs was not driven 
by global reduction in IgG concentration and may therefore be due to the adsorption of specific IgG 
onto S. pneumoniae. The increase in total IgG at 4hrs post-challenge may be responsible for the 
observed increase in EF3030-specific IgG in colonised mice at this time point. To assess if this 
increase in total IgG may be related to alveolar epithelial permeability albumin levels in the BALF 
were measured post-infection by ELISA. There was a strong correlation between the concentration 
of total IgG and albumin concentration in the BALF of colonised mice (Figure 6.6), indicating that IgG 
may accumulate in the BALF of mice in line with increased alveolar permeability following challenge.  
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Figure 6.6: Antibody dynamics in bronchoalveolar lavage fluid following challenge. 
(A) Anti-EF3030 IgG in BALF of mice colonised with EF3030 or PBS 0, 4 and 24hrs post- IN challenge 
with 2x107 CFU S. pneumoniae EF3030, by whole cell ELISA. (B) Total murine IgG in BALF of mice 
colonised with EF3030 or PBS 0, 4 and 24hrs post- IN challenge with 2x107 CFU S. pneumoniae 
EF3030, by whole cell ELISA. (C) Linear regression of total IgG concentration compared to albumin 
concentration in the BALF of EF3030 colonised mice 4hrs following EF3030 challenge. (P values 
represent one-way ANOVAs and Tukey’s post-test to compare columns, error bars represent SD). 
Results are from one experiment at each time-point, ELISAs were repeated twice. 
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6.1.5 Identification of S. pneumoniae target antigens 
 
Increased IgG levels in the BALF of colonised mice following challenge suggest a potential role for IgG 
in mediating the protection from lung infection observed in previously colonised mice. To investigate 
the potential targets of EF3030 specific IgG in colonised mice responses to purified pneumococcal 
polysaccharide (type 19F) and pneumococcal proteins were assessed. Very low levels of IgG to type 
19F CPS were detectable in the sera of sham colonised mice (Figure 6.5). Though there was a trend 
towards increased anti-CPS-specific IgG in the sera of EF3030 colonised mice, this was not 
significant, and levels of anti-CPS IgG remained low following colonisation (Figure 6.5). Responses to 
pneumococcal proteins following colonisation were initially assessed by Western blot. Probing 
lysates of EF3030 with sera from sham colonised or EF3030 colonised mice indicated the 
development of IgG to specific S. pneumoniae protein targets following colonisation with EF3030 
(Figure 6.7). Sera from sham colonised mice reacted with a single band at approximately 65KDa, 
whereas sera from different individual mice colonised with EF3030 gave a number of bands including 
at approximately 70, 55, 40, 35 and 25KDa (Figure 6.7). The pattern of responses in sera from 
colonised mice displayed some differences, with certain bands weaker or absent for sera from 
individual mice but present in others (Figure 6.7). To quantify antibody responses to different 
proteins and to identify some of the specific protein targets for post-colonisation IgG, the Luminex 
assay was used. Both sera and BALF from sham colonised mice displayed minimal IgG binding to all 
proteins (Figure 6.7). Sera and BALF from EF3030 colonised mice had significant IgG responses to the 
pneumococcal proteins PhtD, PsaA and PpmA (Figure 6.7).  
These data demonstrate that following colonisation with EF3030 mice develop IgG responses to a 
limited number of protein antigens, including the surface proteins PhtD, PsaA and PpmA. Western 
blotting indicated IgG responses to more than 3 proteins following EF3030 colonisation (Figure 6.7). 
These responses may be to proteins not included on the Luminex assay or to proteins that show 
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allelic variation between EF3030 and the strains from which the Luminex proteins were purified 
from (Table 2.5).  
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Figure 6.7: S. pneumoniae protein targets of IgG in colonised mice. 
 (A,B) Western blots of IgG binding to whole cell lysates of S. pneumoniae EF3030 probed with sera 
from individual mice colonised with PBS or EF3030 pre-infection. (C,D) Luminex assay of IgG binding 
to recombinant pneumococcal proteins in the sera (1:100) and BALF (1:1) of different individual mice 
colonised with PBS or EF3030 pre-infection, MFI represents binding of anti-mouse IgG-PE secondary 
antibody. (Columns represent mean of 5 mice per group, error bars represent SD). Results are from 
one experiment, Luminex assays were performed in duplicate.  
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6.1.6 Effect of colonisation on cellular responses in lungs of challenged mice 
 
To assess if colonisation also affected cellular responses to subsequent lung infection cell numbers in 
BALF were quantified by differential cell counting, under light microscopy. Colonisation had no effect 
on baseline numbers of neutrophils or macrophages in BALF prior to challenge (Figure 6.8). At 4hrs 
following lung challenge the numbers of neutrophils in the BALF of mice previously colonised with 
EF3030 was significantly higher than PBS colonised controls (Figure 6.8). By 24hrs post-challenge 
neutrophil numbers in colonised and control mice were similar and both significantly enhanced 
compared to 4hrs post-challenge (Figure 6.8). There were no significant differences in macrophage 
numbers at any time point post-challenge in previously colonised or control mice (Figure 6.8). These 
changes in cell numbers indicate that colonisation may affect the neutrophil response to subsequent 
challenge, with more neutrophils appearing in the alveolar space early (4hrs) post-challenge in 
colonised mice.   
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Figure 6.8: Cell numbers in bronchoalveolar lavage fluid of colonised mice following challenge. 
(A) Neutrophil numbers in BALF of mice colonised with PBS or EF3030 0, 4 and 24hrs following IN 
infection with 2x107 CFU S. pneumoniae EF3030. (B) Macrophage numbers in BALF of mice colonised 
with PBS or EF3030 0, 4 and 24hrs following IN infection with 2x107 CFU S. pneumoniae EF3030. (P 
value represent Student’s unpaired T-test, error bars represent SD). Results are from one 
experiment at each time point, except 24hrs which was repeated twice.  
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6.1.7 Effect of colonisation on cytokine responses in the lung    
 
A number of different cytokines may have a role to play in immunity to pneumococcal lung infection, 
and may therefore mediate the improved protection from lung infection demonstrated following 
nasopharyngeal colonisation of mice. As previously colonised mice displayed an enhanced neutrophil 
response to challenge, the concentration of the neutrophil chemoattractant KC, (the murine 
functional homologue of IL-8) was measured in lung tissue homogenates. 4hrs post-challenge there 
were significantly higher levels of KC in the lungs of EF3030 colonised mice compared to controls 
(Figure 6.9). By 24hrs following challenge the concentration of KC in lung tissue was lower than at 
4hrs for both groups and there was no significant difference in KC concentration between EF3030 
colonised mice and controls (Figure 6.9). The pro-inflammatory cytokine TNF-α has an important 
role in the initial immune response to S. pneumoniae lung infection and may affect the release of 
chemokines including KC from epithelial cells (Sun et al., 2007). Colonised mice demonstrated 
significantly higher levels of TNF-α in lung homogenates both at 4 and 24hrs following challenge with 
S. pneumoniae EF3030 compared to controls (Figure 6.9).  
Th17 responses and IL-17 in-particular have been demonstrated to be important for acquired 
immunity to S. pneumoniae within the nasopharynx (Zhang et al., 2009). IL-17 was therefore 
measured in the lungs of colonised and control mice following challenge with S. pneumoniae EF3030. 
4hrs post-infection IL-17 was detectable in lung homogenates of colonised mice but not in controls 
(Figure 6.10). Similarly IL-17 was only detectable in the lungs of colonised mice at 24hrs post-
infection (Figure 6.10). 3 days following challenge IL-17 was measureable in sham colonised mice, 
but remained significantly increased in EF3030 colonised mice (Figure 6.10). The cytokine IL-23 has a 
role in Th17 cell differentiation and initiation of IL-17 production (Ma et al., 2010). Levels of IL-23 in 
lung homogenates 4hrs following S. pneumoniae challenge were significantly increased in previously 
colonised mice, by 24hrs post-infection IL-23 concentrations in the lungs of both groups were similar 
(Figure 6.10).       
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Figure 6.9: KC and TNF-α responses in colonised mice following challenge. 
 (A,B) Concentration (pg/ml)  of TNF-α in the lung homogenates of mice colonised with EF3030 or 
PBS 4 and 24hrs following challenge with 2x107 CFU S. pneumoniae EF3030, measured by ELISA. (C,D) 
Concentration (pg/ml) of KC in the lung homogenates of mice colonised with EF3030 or PBS, 4 and 
24hrs following challenge with 2x107 CFU S. pneumoniae EF3030, measured by ELISA. (P values 
represent Student’s unpaired T-test). ELISA titres are representative of two independent 
experiments on the same samples. 
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Figure 6.10: IL-23 and IL-17 responses in colonised mice following challenge. 
(A,B) Concentration (pg/ml) of IL-23 in the lung homogenates of mice colonised with EF3030 or PBS, 
4 and 24hrs following challenge with 2x107 CFU S. pneumoniae EF3030, by ELISA. (C-E) Concentration 
(pg/ml) of IL-17 in the lung homogenates of mice colonised with EF3030 or PBS, 4, 24 and 72hrs 
following challenge with 2x107 CFU S. pneumoniae EF3030, measured by ELISA. (P values represent 
Student’s unpaired T-test). ELISA titres are representative of two independent experiments. 
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Differences in the regulatory cytokine IL-10 have previously been demonstrated as important in 
mediating susceptibility to experimental S. pneumoniae infection in mice (Neill et al., 2012). 
Therefore IL-10 concentration in lung homogenates at different time points post EF3030 infection 
was assessed. 4hrs post-infection there were significant increases in IL-10 in the lungs of mice 
previously colonised with EF3030, compared to PBS controls (Figure 6.11). However, at 24hrs post-
infection there was no difference in lung IL-10 concentrations between EF3030 colonised or control 
mice.  In colonised mice IL-10 levels remained significantly higher 3 days post S. pneumoniae 
infection, compared to controls (Figure 6.11). These data indicate that EF3030 colonisation appears 
to facilitate an early IL-10 response 4hrs following challenge, prior colonisation may also allow mice 
to maintain increased IL-10 responses for up to 72hrs post-challenge. These responses could be 
significant for the contribution to protection from S. pneumoniae EF3030 pneumonia, afforded by 
prior colonisation.   
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Figure 6.11: IL-10 responses in colonised mice following challenge.  
(A-C) Concentration of IL-10 in the lung homogenates of mice colonised with EF3030 or PBS, 4  24hrs 
and 72hrs following challenge with 2x107 CFU S. pneumoniae EF3030, measured by ELISA. (P values 
represent Student’s unpaired T-test). ELISA titres are representative of two independent 
experiments on the same samples. 
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Prior colonisation appears to have an effect on a number of different cytokine responses during 
subsequent challenge. Responses in previously colonised mice compared to uncolonised controls are 
summarised in Table 6.1, and include increases in TNF-α, KC, IL-23, IL-17 and IL-10. Enhanced in Th17 
type immune responses (IL-17 and IL-23) in the lung are of particular interest as they have been 
shown to be protective against S. pneumoniae in the nasopharynx following experimental 
colonisation. IL-17 was not detected in the lungs of colonised or control mice prior to EF3030 lung 
infection, suggesting that the observed responses are to subsequent infection rather than increased 
baseline cytokine levels following colonisation.    
 
 
Cytokine 4hrs 24hrs 72hrs 
KC ↑ → ND 
TNF-α ↑ ↑ ND 
IL-23 ↑  ND 
IL-17 ↑ ↑ ↑ 
IL-10 ↑ → ↑ 
 
 
Table 6.1: Summary of cytokine responses in lung tissue of previously colonised mice at different 
time points post IN infection with 2x107 CFU S. pneumoniae EF3030, relative to uncolonised controls 
(↑= increase,→ = no change, ND= not done).  
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6.1.8 Relevance of antibody, neutrophils, CD4 cells and IL-17 for protection  
 
A number of arms of the protective immune response to lung infection are enhanced by prior 
colonisation with S. pneumoniae EF3030. It is not clear thus far which of these may be important in 
mediating the protective effect of colonisation against subsequent lung infection. EF3030 
colonisation and challenge experiments were therefore repeated in mice that had undergone 
cellular or cytokine depletion strategies prior to challenge, or in μMT (B-cell deficient) mice.    
6.1.8.1 Absence of antibody 
 
Colonisation with S. pneumoniae EF3030 resulted in the development of a specific IgG response.  To 
assess if this response was required for protection from lung infection, μMT (B-cell deficient) mice 
were colonised with EF3030. Whole cell ELISAs on sera from colonised mice demonstrated the 
absence of a specific IgG response to colonisation in these mice (Figure 6.12). 24hrs following 
EF3030 challenge there was no difference in bacterial numbers in the BALF or lungs of previously 
colonised or sham colonised μMT mice (Figure 6.12). This suggests that anti-pneumococcal IgG 
responses are required for protection from lung infection with S. pneumoniae EF3030, following 
colonisation.  
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Figure 6.12: CFU in antibody deficient mice following challenge.  
(A,B,C) CFU in BALF, lungs and blood of μMT (B-cell deficient) mice colonised with EF3030 or PBS 
24hrs following challenge with 2x107 CFU S. pneumoniae. (D) Concentration of anti-EF3030 IgG in the 
sera of WT or μMT (B-cell deficient) mice colonised with 1x107 CFU EF3030 measured by whole cell 
ELISA.  (P values represent Student’s unpaired T-test). Results are from one experiment. 
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6.1.8.2 Absence of neutrophils 
 
Neutrophils were the most abundant cell type in the BALF following EF3030 challenge. Colonised 
mice also displayed significantly greater neutrophil numbers in the BALF at 4hrs post-infection. To 
assess if neutrophils were important in the observed protection from lung infection mice previously 
colonised with EF3030 or PBS were depleted of neutrophils prior to challenge. Administration of 
anti-Ly6G monoclonal antibody via IP inoculation 24hrs prior to challenge led to an 8-fold reduction 
in neutrophils in the BALF of mice 24hrs post S. pneumoniae infection, as assessed by differential cell 
counting under light microscopy (Figure 6.13). Neutrophil depletion abrogated the protective effect 
of colonisation, with no significant difference in bacterial numbers in the BALF and lungs of colonised 
compared to control mice (Figure 6.13). A few of these neutrophil depleted mice had S. pneumoniae 
EF3030 in the blood; however the vast majority remained free of detectable bacteraemia.  
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Figure 6.13: CFU in neutrophil depleted mice following challenge. 
(A-C) CFU in BALF, lungs and blood of colonised or control mice treated with neutrophil-depleting 
antibody (1A8, anti-Ly6G) 24hrs following challenge with 2x107 CFU S. pneumoniae. (D) Neutrophils 
in the BALF 24hrs following challenge with 2x107 CFU S. pneumoniae EF3030 in EF3030 colonised 
mice treated with 1A8 (anti-Ly6G) neutrophil depleting antibody or PBS 24hrs prior to infection. (P 
values represent Student’s unpaired T-test, lines represent mean, error bars represent SD (D)). 
Results are from one experiment.  
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6.1.8.3 Absence of CD4+ cells 
 
As previously discussed Th17 cells have been implicated in immunity to secondary pneumococcal 
colonisation. To assess if CD4+ T-cells were important in this model of protection from lung infection 
these cells were depleted prior to EF3030 challenge by administration of an anti-CD4 monoclonal 
antibody (GK 1.5), given as two does 48 and 24hrs prior to challenge. The efficacy of CD4+ T-cell 
depletion was assessed by flow-cytometry analysis of lung homogenates post-infection. Antibody 
depletion led to a 6 fold reduction in the number of CD4+ cells in the lung, compared to undepleted 
controls (Figure 6.14). This reduction could reflect antibody masking of CD4 cells rather than 
reduction in numbers of CD4+ cells, so depletion of CD4+ cells was confirmed by flow-cytometry to 
show a reduction in CD3+ CD8- cells (Figure 6.14).  
S. pneumoniae EF3030 CFU in the BALF and lungs of mice 24hrs following IN challenge were not 
significantly different in previously colonised or control mice following CD4+ T-cell depletion (Figure 
6.15), indicating that CD4+ cells are important in mediating protection from lung infection following 
EF3030 colonisation. CD4+ T-cell depletion also abrogated the IL-17 response to challenge 24hrs 
following challenge in colonised mice, indicating that CD4+ T-cells are likely the cellular source of IL-
17 in the lungs of colonised mice, at least at this time point following EF3030 challenge (Figure 6.15). 
The effects of CD4+ T-cell depletion on cytokine or cellular responses 4hrs following S. pneumoniae 
infection were not assessed.       
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Figure 6.14: CD4+ T-cells following depletion. 
 (A,B) Representative flow-cytometry dot-plots of splenocytes showing gating on CD3+ CD4+ 
splenocytes from mice treated with anti-CD4 depleting antibody (GK1.5) or PBS. (C,D) 
Representative flow-cytometry dot-plots of splenocytes showing gating on CD3+ CD8- splenocytes 
from mice treated with anti-CD4 depleting antibody (GK1.5) or PBS. (E) Total CD4+ cells in the lungs 
of mice treated with GK1.5 (anti-CD4) antibody. (F) Total CD3+ CD8- cells in the lungs of mice treated 
with GK1.5 (anti-CD4 antibody). (P values represent Student’s unpaired T-test, error bars represent 
SD). Results are from one experiment. 
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Figure 6.15: CFU in CD4+ T-cell depleted mice following challenge.  
(A-C) CFU 24hrs following challenge with 2x107 CFU S. pneumoniae EF3030 in BALF, lungs and blood 
of mice colonised with EF3030 or PBS treated IP with anti-CD4 antibody GK1.5 24 and 48hrs prior to 
infection. (D) Concentration of IL-17 in the lung homogenates of mice colonised with EF3030 or PBS, 
24hrs following challenge with 2x107 CFU EF3030, in mice treated IP with GK1.5 (CD4 depleting 
antibody) 24 and 48hrs prior to infection. (P values represent Student’s unpaired T-test, lines 
represent mean). Results are from one experiment. 
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6.1.8.4 Absence of IL-17 
 
The concentration of IL-17 was markedly reduced following antibody depletion of CD4+ cells, and 
depletion of CD4+ T-cells cells abrogated the protective effect of prior colonisation. To confirm If IL-
17 itself had a role in colonisation-induced protection from infection, mice were treated with an IL-
17 neutralising antibody (anti-IL-17A). Again there was no difference in bacterial numbers 24hrs 
post-infection in the BALF or lungs of EF3030 or sham colonised mice, following IL-17 neutralisation 
(Figure 6.16). This suggests that IL-17 is a key cytokine required for protection from EF3030 lung 
infection induced by prior colonisation in this murine model of non-invasive disease.  
            
 
Figure 6.16: CFU in IL-17 depleted mice following challenge.  
(A,B) CFU 24hrs following challenge with 2x107 CFU S. pneumoniae EF3030 in BALF and lungs of mice 
colonised with EF3030 or PBS treated IP with IL-17 neutralising antibody (anti-mouse IL-17A) 24hrs 
prior to infection. (P values represent Student’s unpaired T-test, lines represent mean). Results are 
from one experiment. 
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6.1.9 Chapter summary  
 
S. pneumoniae EF3030 is able to colonise the nares of C57/BL6 mice. Colonised mice developed a 
specific antibody response, associated with the development of IgG to protein antigens of S. 
pneumoniae.  Additionally colonised mice displayed altered cellular responses to S. pneumoniae lung 
infection, including an early influx of neutrophils into the alveolar space and enhanced cytokine 
responses. Challenge experiments indicated that these immune responses to colonisation protected 
against lung infection. Repeat challenge in B-cell deficient and neutrophil depleted mice indicated 
that the protective effect of colonisation required both antibodies and neutrophils, suggesting that 
enhanced phagocytosis of bacteria opsonised with specific antibody is the main mechanism by which 
colonisation protects against subsequent lung infection. However, enhanced IL-17 and IL-23 
responses in the lungs of colonised mice suggested a potential additional role for Th17 cell-mediated 
immunity in protection from lung infection following colonisation. Depletion of CD4+ cells confirmed 
that these cells were the likely source of IL-17 and important for the protective effect of colonisation 
against subsequent pneumonia. Furthermore, neutralisation of IL-17 confirmed that this cytokine 
was required for the protective effect of colonisation. These data suggest early T-cell responses in 
colonised mice may facilitate the early influx of neutrophils into the lung that can clear opsonised 
bacteria. 
Combined these data indicate that both humoral and cellular immune responses to nasal 
colonisation are required for subsequent protection in a mouse model of non-invasive pneumonia. 
Whilst these data confirm the importance of IL-17 and CD4+ cells for protection, they do not 
necessarily rule out important roles for other cytokines including IL-10 and TNF-α that were both 
elevated in the lungs of previously colonised mice after challenge with S. pneumoniae EF3030.  
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Summary of findings  
 
o The S. pneumoniae polysaccharide capsule is not a major target of naturally-acquired IgG 
binding to the surface of S. pneumoniae. 
o Naturally-acquired IgG targets proteins on the surface of S. pneumoniae.  
o The major S. pneumoniae protein targets appear conserved in pooled IgG from different 
populations, and between different S. pneumoniae strains.  
o IgG to non-capsular antigens facilitates agglutination, phagocytosis and killing of S. 
pneumoniae. 
o Naturally-acquired human IgG mediates protection from lung infection and bacteraemia in 
vivo. This requires neutrophils and macrophages respectively. 
o Experimental S. pneumoniae colonisation in mice protects against subsequent pneumonia, 
using a non-invasive model of infection with S. pneumoniae EF3030 (19F).  
o S. pneumoniae EF3030 colonisation enhances cytokine (KC, TNF-α, IL-10, IL-23, IL-17), 
cellular, and antibody (IgG) responses in the lung to subsequent pneumonia challenge. 
o Protection from lung infection with EF3030 following colonisation requires both humoral 
(IgG) and cellular (neutrophils, CD4+ T-cells) immune responses.   
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7 Discussion 
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7.1 S. pneumoniae targets of naturally-acquired IgG  
7.1.1 Anti-polysaccharide IgG  
 
Vaccine induced antibodies against the pneumococcal polysaccharide capsule clearly protect against 
S. pneumoniae, and can rapidly clear pneumococci from the blood (Alonso De Velasco et al., 1995). 
However, epidemiological evidence suggests anti-capsular antibodies may be redundant for the 
natural development of immunity to S. pneumoniae (Lipsitch et al., 2005), and the antigen targets 
for naturally-acquired IgG are not well understood. This thesis has investigated the naturally-
acquired antibody response to S. pneumoniae.  
Experimental colonisation of mice with S. pneumoniae EF3030 led to a rise in S. pneumoniae-specific 
IgG, but no detectable rise in IgG targeting the type 19F capsular polysaccharide, suggesting that 
following exposure in the nasopharynx the S. pneumoniae capsule is not a major target for the 
development of protective IgG. In other models of murine colonisation with S. pneumoniae D39 
(serotype 2), there was also no detectable rise in IgG targeting the type-2 polysaccharide in the sera 
of colonised mice (Cohen et al., 2012). Furthermore, colonisation of mice with unencapsulated 
mutants induced protective IgG responses to S. pneumoniae (Malley et al., 2001, Cohen et al., 2012). 
In contrast anti-capsular IgG (against a number of different S. pneumoniae serotypes including 19F) 
was detectable in both human sera and pooled human IVIG products. The differences in mouse and 
human antibody responses may reflect recurrent exposure of humans to S. pneumoniae compared 
to a single experimental colonisation event in mice. The duration of colonisation events in humans is 
also longer than the two week colonisation period in mouse models (Turner et al., 2012). However, 
whilst human sera do contain IgG to the polysaccharide capsule, it is not necessarily the major S. 
pneumoniae antigen target of naturally-acquired IgG in humans. Multiple data obtained using IVIG 
suggest that capsular antigen does not mediate acquired immunity. Purified capsular polysaccharide 
was unable to inhibit IVIG or pooled human sera binding to S. pneumoniae TIGR4 by whole cell ELISA 
and binding of IVIG to the surface of a number of different S. pneumoniae strains was increased, not 
196 
 
reduced by removal of the polysaccharide capsule. Additionally, depletion of IgG targeting the type-
4 polysaccharide capsule had no effect on IVIG binding to the surface of S. pneumoniae TIGR4 by 
flow-cytometry, and mice treated with depleted IVIG were still protected against experimental S. 
pneumoniae infection. Human sera also contained detectable IgG to S. pneumoniae CWPS. However, 
levels of CWPS-specific IgG in individual sera did not correlate with binding to S. pneumoniae, and 
purified CWPS was not able to inhibit IVIG binding to S. pneumoniae by whole cell ELISA, indicating it 
is not a major target of naturally-acquired IgG. These data are supported by previous  investigations 
that demonstrated antibodies raised against the pneumococcal CWPS antigen did not protect mice 
from lethal S. pneumoniae challenge (Szu et al., 1986).  
These data appear to contradict previous studies suggesting that opsonisation of S. pneumoniae may 
be exclusively dependent upon anti-polysaccharide IgG (Vitharsson et al., 1994, Vernacchio et al., 
2000). These conclusions were made from data comparing opsonic activity of sera pre and post-
polysaccharide vaccination, and not from assessing the naturally-acquired IgG targets in 
unvaccinated sera. Data presented here from both experimental colonisation and human sera/IVIG 
indicate that anti-capsular antibody may be dispensable for the protective effect of naturally-
acquired IgG. With this in mind, assessing titres of anti-capsular antibodies in unvaccinated 
individuals may not be a good correlate of protection. In patients receiving IVIG therapy increased 
serotype-specific anti-capsular antibody levels did not provide additional benefit (reduced incidence 
of respiratory infection), compared to increasing the total IgG concentration alone (Chua et al., 
2011).  
Specific antibody deficiency (SAD) is a clinical condition described in both adults and children 
associated with impaired antibody responses to polysaccharide vaccination, and increased incidence 
of respiratory tract infection (Boyle et al., 2006). The assumption in these patients is that the 
increased incidence of recurrent respiratory tract infections is due to the lack of development of 
protective anti-capsular IgG. Perhaps this assumption requires re-examination in the context of data 
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presented here which indicate that anti-capsular IgG may not be required for the development of 
protective humoral immunity to S. pneumoniae. In support of this notion it has recently been 
suggested that in patients with SAD, the concentration of antibodies to purified polysaccharide by 
ELISA does not necessarily correlate with the functional (opsonophagocytic) activity of patient sera 
(Gelfand et al., 2013). The concentration of antibodies to pneumococcal proteins in this patient 
population has not been assessed. SAD may be a marker for more general immune defects and 
these rather than anti-CPS antibody could underpin the susceptibility to respiratory tract infection. 
For example, in a recent controlled study of SAD it has been demonstrated that many children 
diagnosed with SAD may have other underlying immunological defects including phagocytic 
disorders, (Ruuskanen et al., 2013).        
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7.1.2 Anti-protein IgG 
 
Previous studies have demonstrated the acquisition of IgG to surface proteins following naturally-
acquired and experimental S. pneumoniae carriage (Lebon et al., 2011, Ferreira et al., 2013). 
Experimental colonisation of humans with S. pneumoniae 6B increased serum IgG to a number of 
pneumococcal proteins including PspC, PspA, PcsB and PiuA, that was detectable 2 weeks following 
inoculation (Ferreira et al., 2013). Hence colonisation results in anti-protein antibody responses, and 
this is likely to be why Western blotting and Luminex assays indicated that adult sera and IVIG 
contain IgG to a range of pneumococcal surface proteins.  Furthermore, data presented here 
demonstrate that colonisation of mice with S. pneumoniae EF3030 led to an increase in IgG against a 
limited number of specific S. pneumoniae protein antigens, including PhtD, PsaA and PpmA. Previous 
models of colonisation in mice with S. pneumoniae D39 also demonstrated increases in IgG to the 
pneumococcal proteins PspA, PsaA and PpmA but not to PhtD post-colonisation (Cohen et al., 2012). 
In comparison to individual human sera, mice colonised with S. pneumoniae EF3030 demonstrated 
antibody responses to relatively few protein targets. This perhaps reflects that humans are likely to 
have been colonised multiple times by different S. pneumoniae serotypes and therefore acquire 
significant antibody responses to a wider range of pneumococcal proteins. The effect on antibody 
responses of multiple colonisation events with different S. pneumoniae strains in mice has not been 
investigated.    
The relative functional importance of pneumococcal proteins as targets for naturally-acquired IgG to 
S. pneumoniae has previously been unclear and was investigated in this thesis. With the exception of 
serotype 1 S. pneumoniae whole cell ELISA titres in different sera correlated with the concentration 
of IgG to different protein targets, and not to anti-capsular IgG.  The structure of the type-1 
polysaccharide is distinct from other serotypes in that it is zwitterionic and can be presented on 
MHC class II (Mertens et al., 2009). Therefore the development of IgG to the type-1 capsule may be 
T-cell dependent. Protease treatment of pneumococcal lysates impaired their ability to compete out 
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IgG in pooled human sera binding to S. pneumoniae TIGR4, indicating that the whole cell ELISA 
measured IgG binding to protease-sensitive proteins of S. pneumoniae. Trypsin treatment of lysates 
did not fully restore whole cell ELISA titres of IgG binding to S. pneumoniae,  suggesting either that 
not all antigen targets for IgG are proteins or that trypsin treatment only partially denatured 
pneumococcal proteins, allowing some inhibition of IgG binding to be maintained. A limitation of 
whole cell ELISAs is that they are biased towards detecting antibodies to proteins as these are 
exposed by bacterial lysis (Cohen et al., 2013). However, flow-cytometry analysis to whole S. 
pneumoniae also indicated that IVIG binding to the surface of intact encapsulated S. pneumoniae 
was reduced by pre-incubation of S. pneumoniae with a protease (pronase). These data together 
therefore indicate that surface proteins are important pneumococcal antigen targets for naturally-
acquired IgG present in IVIG preparations 
Assessment of the potential target proteins for IgG by Luminex revealed well described vaccine 
candidates including PhtD, PspC and PspA as IgG targets in different IVIG preparations and adult 
sera.  Multiplex assays do not provide a comprehensive assessment of antibody responses against all 
proteins of S. pneumoniae. Instead they allow the strength of antibody responses to a pre-selected 
panel of antigens to be determined semi-quantitatively. This allows comparison of the pattern of 
responses to previously characterised important surface-protein antigens in different sources of 
sera. This approach does mean responses to potentially-important antigens not included on the 
panel are missed. Targets of naturally-acquired IgG identified in this thesis have previously been 
identified as strong IgG targets in human sera by screening an expression library of pneumococcal 
proteins (Giefing et al., 2008), generated by randomly fragmenting the genome and expressing 
proteins on the surface of E. coli. This screen also identified proteins absent from the Luminex panel 
(for example PcsB) as dominant targets of IgG binding in human sera. The Luminex assay should 
therefore be considered as providing a ‘snapshot’ of responses to a range of pneumococcal protein 
targets. Screening of expression libraries although not biased by pre-selection of protein antigens 
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also has limitations and may be biased by the ability of the expression system to display different 
proteins.  
It is possible that the Luminex assay does not provide an accurate quantification of antibody levels to 
each of the proteins included on the panel. However the ability of the Luminex assay to measure 
responses to PspC and PhtE was confirmed by ELISA, and the proteins PspA, PspC, and PhtD to which 
strong responses were detected by Luminex could also be detected as absent bands in Western blots 
of knockout strains probed with pooled IgG. Western blots of pneumococcal whole cell lysates in 
contrast to the multiplex assay allow a comprehensive assessment of antibody targets, but not 
necessarily the identification of antigens, except those for which mutant strains are available. 1-
dimensional (1-D) Western blotting also suffers from the problem of poor resolution, and proteins of 
a similar molecular weight may not always be distinguishable from each other as separate bands. 
Due to these limitations the assessment of antibody responses to S. pneumoniae lysates separated 
by 2-dimensional (2-D) electrophoresis may be warranted. This involves the separation of proteins 
first by their isoelectric point and then by size (Choi et al., 2012). The better separation achieved by 
2-D electrophoresis should allow responses to pneumococcal antigens in different sera and to 
different S. pneumoniae strains to be more completely compared. 2-D separation also facilitates the 
identification of antibody targets by mass-spectrometry. This would allow a comprehensive non-
biased identification of the range of immunogenic protein antigen targets for IgG in different sera.   
7.1.3 Surface-accessibility of S. pneumoniae protein antigens 
 
Multiplexed assays and immunoblotting demonstrated that S. pneumoniae proteins are targets of 
naturally-acquired IgG in IVIG preparations and adult sera. For IgG to be relevant for protective 
immunity it will have to bind the bacterial surface to facilitate functional effects including 
opsonophagocytosis and bacterial agglutination. Flow-cytometry based binding assays allow 
assessment of IgG binding to the surface of whole bacteria (Cohen et al., 2013). Binding of IVIG to 
unencapsulated mutants of S. pneumoniae demonstrated that removal of the polysaccharide 
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capsule enhanced IgG deposition for most strains, further indicating the target for the binding of 
naturally-acquired IgG to the bacterial surface are sub-capsular antigens such as proteins. The major 
targets of IgG binding to unencapsulated mutant of S. pneumoniae may well be different to the WT 
parent strain, as the presence of a polysaccharide capsule can mask immunogenic surface proteins 
(Abeyta et al., 2003, Gor et al., 2005). To overcome this problem the surface binding assay was 
repeated using protease treated encapsulated S. pneumoniae TIGR4. Protease treatment reduced 
the binding of IVIG to the bacterial surface, indicating that protease-sensitive proteins are targets for 
naturally-acquired IgG even in the presence of the type-4 capsule. My data suggests that whilst the 
capsule may reduce IgG binding to some surface proteins, they are still potential targets for 
opsonisation with IgG. Antibodies raised against a number of purified pneumococcal surface 
proteins, including PspA and PspC, were still able to bind to the surface of WT (encapsulated) S. 
pneumoniae (Ren et al., 2003, Ricci et al., 2011) supporting this observation. The presence of a 
capsule does not therefore necessarily prevent antibody binding to proteins that appear to be major 
targets of naturally-acquired IgG, and antibodies to S. pneumoniae surface proteins could thus be 
functional for protection.   
Protease treatment of S. pneumoniae as well as other Gram-positive bacteria including 
Streptococcus pyogenes has been used to screen for surface proteins that could be potential vaccine 
candidates (Olaya-Abril et al., 2012, Rodriguez-Ortega et al., 2006). In these studies the ‘shaved’ 
proteins have been separated by 2D gel electrophoresis and identified by mass spectrometry. This 
approach could be used to identify the surface proteins removed from S. pneumoniae by protease 
(pronase) treatment and allow a specific assessment of the targets of naturally-acquired IgG that are 
recognised on the surface of intact S. pneumoniae, and therefore are likely to be protective. 
Incubation with whole bacteria has also been used to deplete immune sera of antibodies to surface 
proteins, so allowing proteomic identification of antibody targets accessible on the surface of S. 
pneumoniae (Zhang et al., 2011). Hence incubation of S. pneumoniae in IVIG could be used to 
deplete antibodies to pneumococcal surface antigens, in order to investigate their function or 
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facilitate the comprehensive identification of surface-accessible protein targets of naturally-acquired 
IgG.    
7.1.4 Consistency of IgG responses to S. pneumoniae in different sera/IVIG 
 
Luminex data indicated that the protein targets of IgG binding in human sera and pooled 
immunoglobulin preparations appear conserved between populations. These assays demonstrated 
consistently high levels of anti- PhtD, PspA, PspC PsaA and Ply in geographically distinct sources of 
immunoglobulin, with weaker responses to PpmA, PhtE, Hyal, Sp0189, IgA1ase, and absent 
responses to several antigens including Eno, SlrA and NanA. Similarly, immunoblots demonstrated a 
similar pattern of bands with lysates of TIGR4 probed with pooled IgG from Europe, USA or Malawi. 
There is a surprising amount of genetic diversity between strains of S. pneumoniae, occurring on a 
number of levels. Firstly there is variation in gene content between different pneumococcal 
serotypes, and it has been suggested that as little as 50% of the pneumococcal genome may be 
‘core’ (conserved across all strains) (Hiller et al., 2007). Hence the accessory genome is very large 
and could readily contain important antigens that are specific only for a subset of strains such as 
PsrP and the pilus proteins (Munoz-Almagro et al., 2010, Basset et al., 2007b). Secondly, numerous 
single-nucleotide polymorphisms have been detected amongst even closely related strains (Pandya 
et al., 2011, Croucher et al., 2011). Finally, allelic variants of a number of surface proteins have been 
well described especially the choline binding proteins like PspA and PspC (Iannelli et al., 2002, 
Hollingshead et al., 2000). Because of the uneven global distribution of S. pneumoniae serotypes 
(Gordon et al., 2003, Hausdorff et al., 2000b) different populations will have been colonised with 
different strains, which are likely to express different allelic variants of the variable surface proteins 
and have novel antigens encoded by the accessory genome. Despite this, our data indicate that 
immunoglobulin preparations and sera pooled from geographically distinct populations contain IgG 
that recognised a remarkably consistent pattern of protein antigens. Interestingly, the pooled 
immunoglobulin and sera tested all contained high levels of IgG that recognised PspA and PspC 
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isolated from a serotype 4 (TIGR4) strain of S. pneumoniae (as measured by Luminex). Therefore 
despite allelic variation, IgG pooled from different populations is able to recognise PspA and PspC 
from one particular genetic background. Studies by other investigators have indicated that children 
develop antibody specific to the PspA type they have been exposed to (Melin et al., 2008). In the 
same study adult sera contained significant levels of antibody to both PspA families.  It could 
therefore be the case that as an individual’s cumulative exposure to different strains of S. 
pneumoniae increases, so does their level of cross-reactive antibody to structurally-variant proteins 
such as PspA. This may be down to allelic variants sharing similar immunogenic epitopes that can 
induce cross-reactive antibodies, as has been demonstrated for PspA (Darrieux et al., 2008). 
Alternatively in a population different individuals are likely to be colonised with strains expressing 
different allelic variants and therefore pooled sera and IVIG preparations will contain IgG that react 
to most of the common allelic variants.    
Pooled serum is by its nature not representative of every individual within a population. Instead it 
gives an ‘average’ response of those individuals that make up the pool. This is supported by the 
pattern of antibody targets in sera from different individuals to (as measured by Luminex) broadly 
reflecting those of pooled sera, with dominant responses to the same sub-set of pneumococcal 
antigens (PhtD, PspA, PspC and PsaA). Despite this, the relative response of each individual to a 
particular protein varied, with some individuals having lower responses to antigens to which most 
other sera had strong IgG responses. This variation is reflected both in Luminex assays of individual 
sera and Western blots against whole cell lysates probed with different individual sera, where for 
some individuals seemingly immunodominant bands were absent. Variation in responses to specific 
antigens in individual sera was seen both in volunteers from Malawi and the UK. This variation in 
individual responses to particular pneumococcal protein antigens may occur due to genetic variation 
of the host or due to differences in the strains that have colonised each individual (as discussed 
above). Different HLA alleles have been implicated in variant responses to protein antigens (Kruskall 
et al., 1992), and HLA variation may result in some individuals failing to mount antibody responses to 
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certain pneumococcal proteins. Host responses to pneumococcal proteins may also be affected by 
restriction in the range of peptides that can be presented by host MHC II (Brodsky et al., 1996), a 
requirement for the development of T-dependent IgG responses. Certain haplotypes of IL-4 and IL-
4Rα have been associated with lower antibody responses following pneumococcal polysaccharide 
vaccination (Wiertsema et al., 2007), and these polymorphisms may also affect individual’s antibody 
levels to specific pneumococcal proteins. Interestingly Western blotting against whole cell lysates 
indicated that sera from inbred mice all colonised with S. pneumoniae EF3030 displayed some 
variation in the intensity of IgG responses, acquired following colonisation. The reasons for this are 
unclear but could for example be as a result of varied expression of pneumococcal proteins; the 
potential impact of bacterial protein expression on the development of protective immunity is 
discussed later.  On-going experimental colonisation models in mice and humans may help elucidate 
the important factors influencing an individual’s immune response to different protein antigens 
following exposure to S. pneumoniae. 
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7.1.5 Consistency of IgG responses to different S. pneumoniae strains 
 
Individual sera demonstrated whole cell ELISA IgG titres against several S. pneumoniae strains. The 
similar pattern of immunogenic bands on immunoblots against the different S. pneumoniae 
serotypes indicated that the protein antigens recognised by IgG are generally conserved across 
different S. pneumoniae serotypes. This suggests that genetic variation of S. pneumoniae does not 
necessarily prevent the natural development of antibodies to common protein targets, and 
furthermore also suggests that perhaps with some exceptions dominant antigens are not usually 
part of the accessory genome. There was for example no appreciable antibody response observed in 
any of the sera or pooled IgG preparations tested to one of the pilus proteins (PilusA),  a protein 
present in only a minority of pneumococcal strains  (Basset et al., 2007b). Whilst this may reflect 
poor immunogenicity of this particular protein it may also indicate a relative lack of exposure to the 
human immune system (on a population level) compared to proteins common to all strains of S. 
pneumoniae.  
7.1.6 Antibody Isotypes and IgG sub-classes  
 
This thesis focussed on the role of naturally-acquired IgG in the context of protection from lung 
infection, based on the observation that purified IgG protects against S. pneumoniae when passively 
transferred to patients with immunoglobulin deficiency (Quinti et al., 2011).  IgG has previously been 
shown to be the main sub-class induced following experimental S. pneumoniae colonisation in mice 
(Cohen et al., 2011). Other antibody isotypes may possibly have a role to play in naturally-acquired 
immunity to pneumococcal lung infection, however in the murine model of colonisation there was 
no significant rise in anti-S. pneumoniae IgA or IgM detected by whole cell ELISA.  Small rises in anti-
S. pneumoniae IgA have previously been demonstrated in the lavage fluid of colonised mice (Cohen 
et al., 2011). These studies assessed IgA concentration in neat lavage fluid; whereas a dilution of 1:5 
was used here (due to limitations in quantity). Therefore small increases in IgA post-colonisation 
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may have been missed. Other murine models have also demonstrated a modest rise in anti-S. 
pneumoniae IgM in the sera of mice post-colonisation (Cohen et al., 2011) and a rise in specific anti-
capsular IgM (Cohen et al., 2011). However, no significant rise in anti-S. pneumoniae IgM post-
colonisation by whole cell ELISA was detected in this thesis.          
Each of the subclasses of human IgG (IgG 1-4) exhibit different effector functions. For example IgG1 
and IgG4 can activate the complement protein C1 more than IgG2 (Jefferis and Kumararatne, 1990). 
Different antigens may also  preferentially stimulate production of certain IgG sub-classes (Jefferis 
and Kumararatne, 1990).  Studies investigating subclass responses to vaccination have indicated that 
the concentration of IgG1 following vaccination most closely correlated with enhanced opsonic 
activity of human sera following immunisation with the 23-valent polysaccharide vaccine 
(Bardardottir et al., 1990). This thesis has not specifically examined the natural acquisition of anti-
pneumococcal IgG of different sub-classes, instead focussing on the functional targets of total IgG. 
The proportion of anti-pneumococcal IgG of different subclasses in IVIG represent those in human 
sera, acquired through natural exposure to S. pneumoniae.  Therefore using IVIG as a surrogate of 
naturally-acquired IgG is not biased by over or under-representation of certain subclasses. Further 
understanding of the specific IgG sub-class responses required for naturally-acquired immunity to S. 
pneumoniae may however be important for the development of prospective vaccines.     
7.1.7 Immunogenicity of S. pneumoniae proteins  
 
The dominant protein targets of IgG in humans appear consistent irrespective of location and 
population. The proteins identified as being major targets of naturally-acquired IgG fall into a 
number of different classes. They include choline binding proteins (PspA, PspC), lipoproteins (PsaA), 
and non-classical surface proteins (PhtD). The reason for the immunogenicity of certain proteins 
over others in the development of an antibody response is not clear. It could be related to their 
abundance on the bacterial cell surface, an inherent ability to activate innate immune receptors, or 
preferential trafficking to local lymph nodes. The site of development of immune response to 
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pneumococcal proteins is also not well understood. Adenoidal mononuclear cells appear to be 
capable of producing IgG to protein antigens upon stimulation in vitro (Zhang et al., 2006b). Capsular 
polysaccharide antigen is deposited in the nasal associated lymphoid tissue following colonisation, in 
a process that requires neutrophils and the virulence factor pneumolysin (Zhang et al., 2006b). T-cell 
help is required for the development of IgG to pneumococcal proteins and IgG levels to a number of 
pneumococcal proteins including PspA and PspC are reduced in the sera of children with HIV 
infection (Ditse et al., 2013). It is possible that protein presentation to T-cells on MHC II may 
determine the immunogenicity of certain pneumococcal proteins.  Following antigen exposure B-
cells differentiate into either memory plasma cells that secrete immunoglobulin, or into memory B-
cells which respond to subsequent antigenic stimulation (Yoshida et al., 2010). It is not entirely clear 
which population of cells is most important for the long term maintenance of serum antibody levels 
to pathogenic proteins (Amanna et al., 2007). Further understanding of the B-cell response to S. 
pneumoniae, including its site of development and the way in which B-cell memory persists may help 
to determine why antibodies to certain protein targets are maintained in adult sera.  
7.1.8  S. pneumoniae gene expression and IgG responses 
 
A number of studies have investigated the up-regulation of pneumococcal virulence genes during 
invasive disease (Mahdi et al., 2008, Orihuela et al., 2004). More recently the relative expression of 
genes between pneumococci isolated from the nasopharynx and lungs of challenged mice has been 
compared, and there is varied expression of certain pneumococcal proteins between these body 
compartments which may affect virulence (Ogunniyi et al., 2012). For example, 
maltose/maltodextrin-binding protein (MalX) was up-regulated in the lungs compared to 
nasopharynx.  It could be that genes up-regulated specifically during bacterial invasion into the lungs 
(or blood) may be important functionally as targets for protective IgG responses. Furthermore, 
antibodies induced following colonisation to proteins highly expressed in the nasopharynx may not 
be protective against lung infection if there is reduced expression of these proteins when the 
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bacteria enter the lungs. However, naturally-acquired IgG (acquired through colonisation) was 
protective against subsequent pneumococcal lung infection, both in a mouse model of colonisation 
or by passive transfer of human IVIG in to mice. Therefore despite variation in bacterial gene 
expression between these body compartments, antibodies induced following colonisation are still 
protective in the lung. Additionally, cell-mediated immunity acquired during colonisation still 
appears to be effective against subsequent pneumonia challenge, despite differences in expression 
of potentially immunogenic proteins of S. pneumoniae.   
As well as pneumococcal gene expression potentially affecting the development of antibody 
responses, IgG responses to specific protein antigens may affect the molecular ecology of S. 
pneumoniae. Sequencing of the PMEN1 isolate of S. pneumoniae over time has identified the genes 
encoding the surface proteins PspA and PspC as ‘recombination hotspots’, where horizontal gene 
transfer events occur at higher frequency (Croucher et al., 2011).  These gene transfer events may 
alter antigen expression and suggest that these surface proteins are under selective pressure. This 
selective pressure may be due to the development of naturally-acquired IgG to these proteins, high 
levels of IgG to PspC and PspA were detected in all sera samples assessed in this thesis.    
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7.2 Functional effects of naturally-acquired IgG  
 
7.2.1 Protective effects of IgG 
 
Passive transfer of IVIG protected mice from lung infection with S. pneumoniae TIGR4, reducing CFU 
in the lungs and clearing S. pneumoniae from the blood 24hrs post-challenge. Following EF3030 
colonisation mice were protected from re-challenge and had reduced CFU in the lungs and BALF 
24hrs post-challenge. This protective effect was lost in μMT (antibody deficient) mice. Together 
these data indicated an important role for IgG in naturally-acquired immunity to S. pneumoniae.  In 
vitro assays and cellular depletion experiment in vivo were used to assess the mechanisms by which 
antibodies could be protective against S. pneumoniae infection.   
7.2.2 IgG mediated bacterial agglutination  
 
Bacterial agglutination has been described as a mechanism by which antibodies may mediate 
protection. In 1915 it was noted that pneumococcal antisera when injected into rabbits with 
pneumococcal bacteraemia, induced clumping of S. pneumoniae in vivo and facilitated the clearance 
of bacteria from the blood (Bull, 1915b). More recently it has been demonstrated that anti-capsular 
antibody can mediate bacterial agglutination, which can promote complement dependent killing of 
S. pneumoniae (Dalia and Weiser, 2011). The targets of naturally-acquired IgG that may facilitate S. 
pneumoniae agglutination have not previously been investigated. Data in this thesis demonstrated 
that incubation in IVIG results in agglutination of both encapsulated and unencapsulated S. 
pneumoniae TIGR4. This indicates that naturally-acquired IgG can target non-capsular antigens to 
mediate bacterial agglutination. Addition of 10% IVIG to the culture medium inhibited growth of a 
number of S. pneumoniae strains and their unencapsulated derivatives, as assessed by a change in 
OD. As well as agglutination, naturally-acquired IgG may have additional effects on in vitro growth of 
S. pneumoniae, for example binding to and inhibiting the function of pneumococcal proteins 
involved in nutrient acquisition. 
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7.2.3 IgG mediated phagocytosis and killing  
 
Ingestion and killing of opsonised bacteria by phagocytes including macrophages and neutrophils is 
essential for host defence against S. pneumoniae (Standish and Weiser, 2009, Marriott and Dockrell, 
2007).  Serotype-specific IgG enhances phagocytosis of S. pneumoniae (Burton and Nahm, 2006) and 
improved opsonophagocytosis is a major readout for the effectiveness of current polysaccharide-
based vaccines (Song et al., 2013). Antibodies to S. pneumoniae surface proteins can also facilitate 
enhanced phagocytosis (Jomaa et al., 2005, Arulanandam et al., 2001). In this thesis opsonisation 
with IVIG increased the association of S. pneumoniae with both neutrophils and macrophages. The 
opsonising effect of IVIG was enhanced upon removal of the S. pneumoniae capsule, indicating that 
naturally-acquired IgG in IVIG may facilitate phagocytosis, targeting non-capsular antigens. 
Opsonisation in IVIG also improved the killing of both unencapsulated and WT S. pneumoniae by 
human neutrophils, further demonstrating that naturally-acquired IgG against non-capsular targets 
is functional. Phagocytic assays were performed in the absence of complement, therefore enhanced 
uptake of unencapsulated S. pneumoniae was independent of any effects of complement deposition, 
and directly due to opsonisation of IgG. Cellular depletion studies demonstrated that both 
neutrophils and macrophages were important for the protective effect of IgG in vivo, indicating in 
vitro assays of phagocyte function are relevant for assessing the potential protective effect of 
naturally-acquired IgG. 
7.2.4  IgG accumulation in the lungs post-challenge 
 
The low level of IgG in airway lining fluid prior to infection indicates that prevention of infection by 
IVIG is unlikely. Indeed in the model of passive IgG transfer and lung infection presented in this 
thesis, adoptive transfer of naturally-acquired human IgG failed to protect against early lung 
infection or colonisation. IgG may accumulate in the lungs by active transport (Kim et al., 2004), local 
production in response to antigen (Bice and Muggenburg, 1996), or passive leak (Renegar et al., 
2004). In mice treated with IVIG the accumulation of human IgG correlated with albumin 
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concentration in the BALF. IgG accumulation post-infection in the BALF of EF3030 colonised mice 
also correlated with albumin concentration, and enhanced accumulation of total IgG in the lavage 
fluid of EF3030 colonised mice was temporally associated with a neutrophil influx. Combined these 
data indicate that much of the IgG in the lung post-infection may be due to passive leak as a 
consequence of inflammation.  
The IVIG challenge model used in this thesis involved adoptive transfer of human IVIG into mice. 
Unlike when transferring murine IgG, human IgG was undetectable in the alveolar space in the 
absence of infection, demonstrating IgG accessibility to the lung in the absence of inflammation may 
be species dependent.  Therefore mouse models cannot be used to fully evaluate the role for human 
IgG in lung immunity to S. pneumoniae. For example, this model does not properly assess the 
relevance of IgG for bacterial interactions with alveolar macrophages prior to established lung 
infection, which may be important for early clearance of S. pneumoniae (Gordon et al., 2000). Pre-
existing IgG in the lungs of EF3030 colonised mice led to reduced CFU in the BALF 24hrs post-
challenge. In contrast, mice treated with IVIG had no human IgG detectable in the BALF prior to 
challenge and no reduction in CFU in BALF 24hrs post-challenge with S. pneumoniae TIGR4. The 
potential role of pre-existing IgG in protection from pneumococcal lung infection in humans is 
highlighted by the detection of anti-S. pneumoniae IgG in the lavage fluid of healthy volunteers. 
Though compared to sera low levels of IgG were detected in human BALF samples, obtaining these 
samples involves significant dilution of the epithelial lining fluid, and hence IgG concentration in neat 
epithelial lining fluid is likely substantial. Despite limitations with this model, passive transfer of 
human IgG to mice provided an important tool to study the mechanisms of protection post-infection 
with S. pneumoniae by naturally-acquired human IgG in vivo, using cellular depletion strategies that 
clearly could not be performed in humans.  
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7.2.5 Effect of IVIG on inflammatory responses to S. pneumoniae infection  
 
IVIG may have immunomodulatory effects and has been used in the treatment of a number of 
autoimmune and inflammatory conditions (Schwab and Nimmerjahn, 2013).  In a caecal-ligation and 
puncture (CLP) model of sepsis high dose IVIG (1000mg/kg) delivered intravenously to rats improved 
survival, and this was associated with reduced TNF-α levels in the sera 3hrs post-CLP and reduced IL-
6 6hrs post-CLP (Hagiwara et al., 2008). IVIG treatment also reduces inflammatory cell infiltration 
into the lungs 12hrs following CLP (Hagiwara et al., 2008). The effect of this IVIG therapy on bacterial 
numbers in the blood post-CLP was not assessed, and the effect on inflammation may have been 
related to IgG mediated clearance of bacteria following IVIG treatment. Cytokine concentrations in 
the sera of mice challenged with S. pneumoniae TIGR4 were not measured, however both TNF-α 
concentration in lung homogenates and neutrophil infiltration into the alveolar space were 
unaffected by IVIG treatment 24hrs post-infection. This indicates that changes in the inflammatory 
response were not necessarily responsible for the observed protective effect of adoptively 
transferred IVIG 24hrs post-lung infection. In this IVIG doses of approximately 500mg/kg were 
administered and delivered via the IP route, therefore the concentration of IgG achieved in the sera 
was approximately 1.5mg/ml. Normal doses for humans on IVIG replacement therapy are between 
400-600mg/kg IgG administered monthly (Gelfand et al., 2013).   
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7.3 Cell-mediated immunity  
7.3.1 Cellular effectors mediating naturally-acquired immunity 
 
The importance of neutrophils in host defence against bacterial respiratory infection is highlighted 
by the higher incidence of pneumonia in patients with neutropenia (Lanoix et al., 2012). Neutrophils 
were required for the protective effect of prior colonisation against EF3030 pneumonia. Previously 
colonised mice demonstrated a heightened early influx of neutrophils (4hrs post-challenge) 
compared to controls. Although differences in bacterial numbers in the lungs of mice were only 
observed by 24hrs post-infection, it is likely that this early neutrophil response contributed to the 
control of S. pneumoniae infection in colonised mice. In the nasopharynx, immunity to re-
colonisation has been demonstrated to depend on neutrophil influx into the nasal cavity following 
challenge (Zhang et al., 2009). Significant increases in KC (CXCL1-the murine functional homologue of 
human IL-8) were observed 4hrs following challenge in the lungs of colonised compared to control 
mice. KC has been well described as a neutrophil chemoattractant and it is possible that this increase 
in KC contributes to the early influx of neutrophils into the alveolar space of colonised mice. CXCL1(-
/-) mice infected with Klebsiella pneumoniae demonstrate a reduced neutrophil influx into the lungs, 
as well as reduced production of the inflammatory mediator leukotriene B4 (LTB4). In these studies 
exogenous LTB4 treatment restored neutrophil migration to the lungs (Batra et al., 2012). The 
potential role of LTB4 in the enhanced neutrophil responses to lung infection following experimental 
colonisation has not been assessed in this thesis. 
In addition to neutrophils the protective effect of prior colonisation on lung infection also required 
antibodies. It is therefore likely that neutrophils phagocytose EF3030 opsonised by specific antibody 
induced following colonisation. It has been demonstrated in the nasopharynx that neutrophils are 
important for the clearance of secondary but not primary S. pneumoniae colonisation, and 
neutrophils may be functional against secondary challenge due to the presence of opsonising 
antibody (Zhang et al., 2009). In  other models of murine colonisation with S. pneumoniae D39 
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opsonisation in sera from colonised mice improved S. pneumoniae uptake by human neutrophils in 
vitro, compared to sera from uncolonised controls (Cohen et al., 2011). 
Enhancement of neutrophil mediated phagocytosis is one mechanism by which naturally-acquired 
human IgG can prevent S. pneumoniae lung infection. Other mechanisms of neutrophil mediated 
protection against extracellular bacteria have also been described. Neutrophils may contribute to 
the killing of extracellular pathogens including S. pneumoniae by the formation of neutrophil 
extracellular traps (NETs) (Brinkmann et al., 2004, Yamada et al., 2011). These NETs consist of 
released chromatin and anti-microbial granule proteins. NET formation has been associated with 
IFN-γ production by neutrophils in response to S. pneumoniae infection (Yamada et al., 2011). 
However, S. pneumoniae expresses an endonuclease (endA) that may allow it to escape from NETs 
(Beiter et al., 2006). The contribution of NET formation to S. pneumoniae killing in vivo, and the 
potential relevance of antibody in this process remains unclear.  
Although neutrophils were required for the protective effect of naturally-acquired IgG, the data 
suggest they may also contribute to the pathogenesis of disease. Neutrophil depletion significantly 
reduced the number of bacteria in the blood of untreated mice following S. pneumoniae lung 
challenge, indicating that neutrophils may contribute to the development of bacteraemia. In other 
models of pulmonary S. pneumoniae infection mice depleted of neutrophils are protected from 
bacteraemia, and demonstrate enhanced survival following challenge with 5x103 CFU serotype 8 S. 
pneumoniae (Marks et al., 2007). Results presented here demonstrate that neutrophil depletion also 
significantly increases S. pneumoniae TIGR4 CFU in BALF 24hrs post-challenge. Therefore although 
neutrophil influx may facilitate bacterial invasion into the blood, neutrophils are required for the 
control of infection within the lung. Hence a regulated early influx of neutrophils may achieve 
clearance of S. pneumoniae from the lungs without contributing to bacteraemia. The enhanced 
susceptibility of male mice to pneumococcal disease may be in part due to neutrophil kinetics 
(Kadioglu et al., 2011a). Female mice demonstrate an earlier neutrophil influx post-infection, but 
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significantly reduced neutrophil numbers compared to male mice 24hrs following infection. Data in 
this thesis indicate the increased development of sepsis in male mice may be in part due to this 
enhanced late neutrophil influx and associated inflammation, perhaps by increasing pulmonary 
epithelial barrier breakdown.  
Macrophages appear to be important for the increased clearance of S. pneumoniae from the blood 
mediated by human IgG. Systemic clodronate treatment of mice was associated with depletion of 
splenic macrophages and impaired clearance of S. pneumoniae from the blood following IVIG 
treatment.  IVIG treatment may also reduce (though not completely clear) S. pneumoniae in the 
blood of splenectomised mice, via phagocytosis in the liver (Nakamura et al., 2013). The effect of 
clodronate treatment on cells of the liver was not assessed in this thesis, though Kupffer cells of the 
liver can be depleted by IV administration of liposomal clodronate (Meijer et al., 2000). However, 
the importance of the spleen in the clearance of blood-borne S. pneumoniae can be seen in the 
higher incidence of S. pneumoniae bacteraemia in patients with asplenia (Schutze et al., 2002).  In a 
model of sepsis with group B streptococci specific antibodies required the complement protein C3 to 
effectively clear S. pneumoniae from the blood (Wessels et al., 1995). It is likely that complement, in 
addition to macrophages is required for the protective effect of naturally-acquired IgG against 
sepsis, and IgG in human sera can facilitate C3b deposition on encapsulated and unencapsulated 
strains of S. pneumoniae (Hyams et al., 2010a). IgG could mediate protection from sepsis following 
lung infection by preventing invasion of bacteria into the blood from the lungs, rather than 
facilitating clearance of S. pneumoniae from the blood. However,  in  a study of IVIG treatment alone 
and in combination with ampicillin Intranasal administration of IVIG failed to prevent sepsis 
following lung infection with S. pneumoniae pn4241, whereas intravenous administration did (De 
Hennezel et al., 2001). Additionally, in data presented here human IgG treatment led to direct 
clearance from the blood following IV challenge with S. pneumoniae.  
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7.3.2 Cytokine responses to colonisation  
 
A number of cytokines were increased in the lungs of EF3030 colonised mice following challenge. Of 
particular interest was an increase in Th17-type cytokines (IL-23, IL-17). Th17-type responses are 
important for acquired immunity to S. pneumoniae colonisation in mouse models (Zhang et al., 
2009). In particular IL-17A responses in the nasopharynx are important for protection from re-
colonisation and IL-17A depletion abrogates the protective effect of prior colonisation (Zhang et al., 
2009). In models of invasive D39 pneumonia, prior colonisation lead to enhanced IL-17 and IL-22 
responses in the lavage fluid 18hrs post-challenge. However these responses appeared dispensable 
for protection against lung challenge with this highly invasive strain, in which lethality is largely due 
to the development of septicaemia.  
Protective immunity to non-invasive pneumonia challenge with EF3030 developed as a result of 
previous colonisation was abrogated by IL-17A depletion. IL-17A has a role in the recruitment of 
neutrophils and can induce the release of the neutrophil chemoattractant KC from other cell types 
including epithelial and endothelial cells (Swaidani et al., 2009). An early increase in IL-17 
concentration following EF3030 challenge was temporally associated with increased KC 
concentration in colonised mice. This suggests that IL-17 release post-infection may facilitate KC 
production, though it was not assessed if IL-17 was directly responsible for the enhanced KC 
response 4hrs post-challenge in the lungs of colonised mice. IL-23 contributes to the differentiation 
of naive CD4+ T-cells into Th17 cells (Silverpil et al., 2013). IL-23 is released from alveolar 
macrophages, mice lacking the IL-23 subunit alpha gene (IL-23p19) have impaired lung defence 
against the fungal pathogen Pneumocystis carinii, associated with reduced IL-17 and CD4+ T-cell 
responses to infection. IL-23 was increased in the lungs of EF3030 colonised mice at 4 but not 24hrs 
following S. pneumoniae challenge. This early increase in IL-23 perhaps reflects its role in the 
initiation of IL-17 responses that were maintained for up to 72hrs post-challenge in the lungs of 
colonised mice.  
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As well as Th17-type cytokine responses, previous EF3030 colonisation led to an increase in levels of 
TNF-α and IL-10 in the lungs of mice following infection.  TNF-α was also elevated 4hrs post-
challenge in models of S. pneumoniae D39 colonisation and challenge (Cohen et al., 2011). TNF-α is 
important for innate immunity to S. pneumoniae infection and TNF-α can stimulate the production 
of the neutrophil chemoattractant KC from murine lung cells (Sun et al., 2007). IL-10 is a regulatory 
cytokine produced by regulatory T-cells (Tregs). IL-10 production occurs in human adenoidal 
mononuclear cell in response to S. pneumoniae stimulation (Zhang et al., 2006a). IL-10 producing 
Tregs have been implicated in protection from primary S. pneumoniae lung infection, in particular 
protection from bacteraemia following challenge with S. pneumoniae D39 (Neill et al., 2012). This 
protection has been associated with reduced inflammation, preventing translocation of bacteria 
from the lungs to the blood. On the contrary other investigators have advocated that IL-10 may be 
negative for the outcome of primary pneumonia challenge in mice. Following lung-infection with S. 
pneumoniae ST3 IL-10 depletion reduced bacterial burden in the lungs of mice, which was associated 
with increased TNF-α production (van der Poll et al., 1996). The role of IL-10 may depend upon the 
pneumonia model used, including the invasiveness of the strain and the host genetic background. 
For example, CBA/Ca mice have a heightened susceptibility to infection due to reduced regulatory 
responses compared to BALB/c mice (Neill et al., 2012).   The significance of IL-10 in protection from 
lung infection induced by colonisation in this model is not clear; however the presence of IL-10 did 
not prevent a rise in TNF-α, or clearance of lung infection in colonised mice. Depletion of IL-10 in 
colonised mice would help to determine its functional relevance for protection in this model. Other 
cytokines that could have a role in protection from pneumococcal lung infection including IFN-γ 
were not measured in colonised mice following challenge. Assessing a wider range of cytokines 
(perhaps utilising a multiplex platform) would provide a more complete picture of the different 
responses to lung infection following prior colonisation.     
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7.3.3 T-cell responses acquired following colonisation  
 
In the model of non-bacteraemic pneumonia presented here CD4+ T-cells were required for the 
protective effect of prior colonisation. The absence of IL-17A in the lungs of challenged mice 
depleted of CD4+ cells indicates that these cells are the cellular source of the enhanced IL-17 
detected in the lungs of colonised mice. Previous studies of sub-lethal infection with S. pneumoniae 
ST1, followed 7 days later by challenge, have demonstrated (by intracellular cytokine staining) that 
CD4+ T-cells from the lungs of  protected mice produce high levels of IL-17A (Marques et al., 2012).   
γδ T-cells may be an important T-cell type required for IL-17 production in response to primary 
infection of the lungs (Ma et al., 2010). TCRδ(-/-) mice display significantly reduced IL-17 production 
4hrs  post-challenge with S. pneumoniae ST3, and reduced clearance of S. pneumoniae ST3 from the 
lungs 24hrs post-challenge (Ma et al., 2010). However, most gamma-delta T-cells lack CD4 
expression (Lockhart et al., 2006), and thus would not have been depleted by anti-CD4 antibody 
treatment. Therefore the cells responsible for IL-17 production in this model are either a subset of 
γδT-cells expressing CD4 or αβ T-cells. A process of antigen presentation by γδT-cells, to CD4+ αβT-
cells has been described (Collins et al., 1998). It is therefore possible that via this mechanism both 
cell types are required for the enhanced IL-17 production in response to lung infection in mice 
previously colonised with EF3030. 
In models of S. pneumoniae colonisation, protection from re-colonisation mediated by CD4+ IL-17+ 
cells occurs over the course of 5 days (Zhang et al., 2009). In contrast protection from re-infection in 
this model of pneumonia is seen as early as 24hrs post-challenge, but still required CD4+ T-cell 
responses. Although 24hrs seems very quick for the development of a protective T-cell response, T-
cells isolated from mice colonised with S. pneumoniae have demonstrated high levels of intracellular 
IL-17 after only 6hrs of stimulation with heat killed S. pneumoniae ex vivo (Zhang et al., 2009).   
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Experimental pneumococcal carriage in humans can lead to an increase the percentage of CD4+ cells 
expressing IL-17 in BALF samples, following stimulation with S. pneumoniae ex vivo (Wright et al., 
2013). Data from EF3030 colonised mice indicate that these Th17-type responses in humans may be 
relevant for protection from subsequent pneumonia. The higher incidence of pneumococcal disease 
in patients with HIV and associated reduction in CD4+ cell numbers further suggests an important 
role for T-cells in immunity to S. pneumoniae in humans (Hyams et al., 2010b, Dworkin et al., 2001). 
Impaired Th17 cell differentiation occurs in individuals with hyper-IgE syndrome, which is associated 
with an increased risk of bacterial lung infection (Milner et al., 2008). Patients with T-cell 
immunodeficiency may be at a higher risk of pneumonia due to a lack of naturally-acquired Th17-
type immunity to S. pneumoniae.   
Some S. pneumoniae antigens that can elicit of Th17-type immunity have been identified. Proteins of 
S. pneumoniae have been screened based on their ability to stimulate IL-17 secretion from the 
splenocytes of mice immunised intranasaly with a killed whole cell pneumococcal vaccine. Proteins 
identified in this manner include a ribosomal protein SP0862 and SP1534 a pyrophosphatase. 
Intranasal immunisation with these proteins is protective against nasal colonisation (Moffitt et al., 
2012). Separately, human CD4+ T-cells co-cultured with dendritic cells may produce IL-17 in 
response to stimulation with pneumococcal peptidoglycan, following secondary exposure in vitro 
(Olliver et al., 2013).  
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7.4 Schematic of naturally-acquired immunity to S. pneumoniae lung infection 
 
Data presented in this thesis demonstrate that exposure to S. pneumoniae in the nasopharynx 
results in the development of immunity that is protective against future lung infection. In-particular 
data implicate an important role for both Th17 and humoral immunity. However, as discussed, 
additional arms of the immune response that are potentially protective against lung infection are 
enhanced following nasopharyngeal colonisation with S. pneumoniae. Figure 7.1 summarises 
responses to colonisation that enhance or may enhance immunity to subsequent S. pneumoniae 
infection within the lung, and the potential interactions between each.  
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Schematic demonstrating the potential effects of nasopharyngeal colonisation on immunity to 
subsequent lung infection with S. pneumoniae.  Solid arrows indicate mechanisms of acquired 
immunity directly supported by data in this thesis, dashed arrows represent other potential 
mechanisms of acquired immunity and their possible interactions.   
Figure 7.1: Mechanisms of acquired immunity to S. pneumoniae lung infection.  
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7.5 Relevance for vaccine development 
 
Polysaccharide-based vaccines for S. pneumoniae suffer from a number of limitations including poor 
coverage and serotype replacement. Current purified polysaccharide vaccines used in adults are 
poorly protective against pneumonia (Dear et al., 2003), though the use of conjugate vaccines in 
adults may provide improved protection within the lung (Paradiso, 2012). Any new pneumococcal 
vaccines should have protection against pneumonia as an aim, since it represents the highest burden 
of disease caused by S. pneumoniae (O'Brien et al., 2009).    
Several vaccines based on conserved S. pneumoniae protein antigens are in development (Darrieux 
et al., 2013). These vaccines aim to induce protective antibodies to surface proteins of S. 
pneumoniae.  A number of protein based vaccines have demonstrated protection in animal models 
of disease, and  some including PhtD and PspA are immunogenic in adult humans (Darrieux et al., 
2013).  Based on data demonstrating that a Th17 based immunity is required for immunity to 
colonisation, vaccines aimed at stimulating cell-mediated immunity to S. pneumoniae are also in 
development (Moffitt et al., 2011). 
Data presented in this thesis demonstrate the need for both humoral and cell-mediated immunity in 
full protection from non-invasive pneumonia following colonisation. Any new vaccine that aims to 
provide protection from infection within lung may need to recapitulate both arms of this protective 
immune response. The proteins that induce protective antibody responses following colonisation in 
mice or humans include (but are not limited to) PhtD, PspA, PspC and PsaA. These appear distinct 
from the pneumococcal protein antigens that may stimulate cell-mediated immunity to S. 
pneumoniae (Moffitt et al., 2012). Vaccines against pneumonia may therefore be most effective if 
they contain combinations of antigens that stimulate both cell-mediated and humoral immunity. 
This could be either as a whole cell vaccine or as combination protein based vaccines.   
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A number of protein antigens that are in development as pneumococcal vaccines are also targets of 
naturally-acquired IgG in adult human sera. This raises the question of how effective vaccines 
inducing antibodies against these proteins may be, if such antibodies are already present and 
functional in normal sera. It may be that boosting antibodies to antigens that are also targets of 
naturally-acquired IgG may only be effective in subjects with reduced levels of naturally-acquired IgG 
to those antigens. Interestingly IgG to S. pneumoniae protein antigens including PspC, PhtD and PspA 
are reduced in sera from older individuals (>65) compared to younger controls (Simell et al., 2008); 
potentially this may be one reason why the elderly are at more risk of S. pneumoniae infection. It is 
therefore possible that boosting antibodies to these proteins may help reduce the increased risk of 
S. pneumoniae pneumonia in this population. 
The phagocytic function of human sera has been correlated with polysaccharide-specific IgG 
responses post-vaccination (Bardardottir et al., 1990). Current vaccination boosts phagocytosis by 
inducing capsule-specific IgG. If vaccines against common protein antigens of S. pneumoniae are to 
be successful they would have to boost the function of sera at least as much as current 
polysaccharide vaccines, but on the background of non-capsular (protein) antigens already being 
mediators of naturally-acquired protection. There is therefore the potential for the failure of 
functional improvement in antibody responses following vaccination with protein antigens, due to 
the presence of pre-existing antibody acquired through colonisation.  
Both data from EF3030 colonised mice and human sera indicate that colonisation has an immunising 
effect that protects against subsequent lung infection. One key aim of pneumococcal vaccination 
could be the elimination of carriage (Bogaert et al., 2004), so removing the reservoir for transmission 
of S. pneumoniae for the development of invasive disease (Bogaert et al., 2004). However, removal 
of carriage is likely to reduce the opportunity for the acquisition of natural immunity to S. 
pneumoniae, which can protect against invasive disease.  A recent rise in the adult incidence of 
whooping cough has been attributed to a lack of natural exposure to Bordatella pertussis during 
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childhood, as a consequence of vaccination (Lavine et al., 2011). It is possible that a similar increase 
in pneumococcal pneumonia could occur following a vaccine-induced reduction in pneumococcal 
carriage.  
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7.6 Future directions 
 
These data demonstrate the function for naturally-acquired IgG to pneumococcal protein antigens in 
human sera. However, a number of different factors are likely to influence an individual’s risk of 
pneumococcal pneumonia. Therefore in order to assess if levels of naturally-acquired IgG may be 
clinically relevant, a more thorough assessment of antibody levels to S. pneumoniae proteins in 
patient groups at risk of pneumonia is warranted. This should include detailed assessment of 
serological responses in the elderly. Any serological assessment of antibody responses in these 
patient groups should include assays of surface binding and phagocytosis to ensure potential 
differences can be correlated to function. Assessment of cellular immunity in patients at risk of S. 
pneumoniae infection may also we warranted. As discussed, a more comprehensive assessment of 
the targets of naturally-acquired IgG would be useful to fully understand the antibody targets that 
may be required for protection. This could involve assessment of antibody responses by 2D gel 
electrophoresis. Full understanding of the reasons for the immunogenicity of certain proteins 
following carriage also remains elusive, and understanding this would aid the development of new 
vaccines.       
In mice it appears that Th17-type responses are required for protection from S. pneumoniae 
pneumonia following colonisation. Identification and phenotyping of an IL-17 producing population 
of cells in the lungs of colonised mice (by flow-cytometry), may be important for understanding the 
precise cellular responses required for protection. The mechanism of enhanced neutrophil 
recruitment to the lungs of colonised mice, and the precise contribution of Th17 responses and KC 
require additional clarification. This could involve cellular depletion at early time points post-
infection. A more comprehensive assessment of cytokine responses to lung infection could be 
achieved using a multiplexed assay. Additionally, the role of other cytokines including IL-10 on the 
colonisation induced protection from non-invasive lung infection seen in this model requires further 
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investigation. Depletion of these cytokines in colonised mice prior to challenge could help elucidate 
their function.  
The need for both cell-mediated and humoral immunity for colonisation-induced protection from 
lung infection requires further assessment in the context of vaccine development. Protection 
following experimental vaccination of mice with antigens that elicit either cell-mediated or humoral 
immunity, alone and in combination would be informative. This vaccination approach in different 
models of lung infection would allow the rational design of vaccines aimed at protecting against 
different forms of pneumococcal disease.   
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7.6.1 Recommendations for future experiments 
 
1. Assessment of antibody levels to S. pneumoniae proteins in patient groups at risk of 
pneumonia.   
2. A comprehensive assessment of the S. pneumoniae protein targets of naturally-acquired 
human IgG by 2D gel electrophoresis and mass-spectrometry.   
3. Phenotyping of the IL-17 producing population of cells in the lungs of previously colonised 
mice by flow-cytometry. 
4. A more comprehensive assessment of cytokine responses enhanced by previous 
colonisation, using a multiplexed platform. 
5. Assessment of immune responses following CD4+ T-cell depletion at early time points (4hrs) 
post-challenge, in previously colonised mice. 
6. Investigation of the protective effect of experimental vaccination with antigens that elicit 
either cell-mediated or humoral immunity, in different murine models of S. pneumoniae 
infection.   
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